
<html lang="en"     class="pb-page"  data-request-id="f3def483-615b-438a-9956-4d64bf52d1b1"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-12;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.8b00405;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Multiplexed Targeting of Barrett’s Neoplasia with a Heterobivalent Ligand: Imaging Study on Mouse Xenograft in Vivo and Human Specimens ex Vivo" /></meta><meta name="dc.Creator" content="Jing  Chen" /></meta><meta name="dc.Creator" content="Juan  Zhou" /></meta><meta name="dc.Creator" content="Zhenghong  Gao" /></meta><meta name="dc.Creator" content="Xue  Li" /></meta><meta name="dc.Creator" content="Fa  Wang" /></meta><meta name="dc.Creator" content="Xiyu  Duan" /></meta><meta name="dc.Creator" content="Gaoming  Li" /></meta><meta name="dc.Creator" content="Bishnu P.  Joshi" /></meta><meta name="dc.Creator" content="Rork  Kuick" /></meta><meta name="dc.Creator" content="Henry D.  Appelman" /></meta><meta name="dc.Creator" content="Thomas D.  Wang" /></meta><meta name="dc.Description" content="Esophageal adenocarcinoma (EAC) is a molecularly heterogeneous disease that is rising rapidly in incidence and has poor prognosis. We developed a heterobivalent peptide to target detection of early..." /></meta><meta name="Description" content="Esophageal adenocarcinoma (EAC) is a molecularly heterogeneous disease that is rising rapidly in incidence and has poor prognosis. We developed a heterobivalent peptide to target detection of early..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 5, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00405" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00405" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00405" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00405" /></link>
        
    
    

<title>Multiplexed Targeting of Barrett’s Neoplasia with a Heterobivalent Ligand: Imaging Study on Mouse Xenograft in Vivo and Human Specimens ex Vivo | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00405" /></meta><meta property="og:title" content="Multiplexed Targeting of Barrett’s Neoplasia with a Heterobivalent Ligand: Imaging Study on Mouse Xenograft in Vivo and Human Specimens ex Vivo" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0009.jpeg" /></meta><meta property="og:description" content="Esophageal adenocarcinoma (EAC) is a molecularly heterogeneous disease that is rising rapidly in incidence and has poor prognosis. We developed a heterobivalent peptide to target detection of early Barrett’s neoplasia by combining monomer heptapeptides specific for either EGFR or ErbB2 in a heterodimer configuration. The structure of a triethylene glycol linker was optimized to maximize binding interactions to the surface receptors on cells. The Cy5.5-labeled heterodimer QRH*–KSP*–E3–Cy5.5 demonstrated specific binding to each target and showed 3-fold greater fluorescence intensity and 2-fold higher affinity compared with those of either monomer alone. Peak uptake in xenograft tumors was observed at 2 h postinjection with systemic clearance by ∼24 h in vivo. Furthermore, ligand binding was evaluated on human esophageal specimens ex vivo, and 88% sensitivity and 87% specificity were found for the detection of either high-grade dysplasia (HGD) or EAC. This peptide heterodimer shows promise for targeted detection of early Barrett’s neoplasia in clinical study." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00405"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00405">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00405&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00405&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00405&amp;href=/doi/10.1021/acs.jmedchem.8b00405" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 5323-5331</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00384" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00549" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Multiplexed Targeting of Barrett’s Neoplasia with a Heterobivalent Ligand: Imaging Study on Mouse Xenograft in Vivo and Human Specimens ex Vivo</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Jing Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jing Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Chen">Jing Chen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8863-2843" title="Orcid link">http://orcid.org/0000-0001-8863-2843</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Juan Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Juan Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Juan++Zhou">Juan Zhou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhenghong Gao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhenghong Gao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhenghong++Gao">Zhenghong Gao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xue Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xue Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xue++Li">Xue Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fa Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fa Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fa++Wang">Fa Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiyu Duan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiyu Duan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiyu++Duan">Xiyu Duan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gaoming Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gaoming Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gaoming++Li">Gaoming Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bishnu P. Joshi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bishnu P. Joshi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bishnu+P.++Joshi">Bishnu P. Joshi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rork Kuick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rork Kuick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rork++Kuick">Rork Kuick</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Henry D. Appelman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Henry D. Appelman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Henry+D.++Appelman">Henry D. Appelman</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Thomas D. Wang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas D. Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Gastroenterology, Department of Internal Medicine,  Department of Biomedical Engineering,  Department of Mechanical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Tel.: (734) 936-1228. Fax: (734) 647-7950. E-mail: <a href="/cdn-cgi/l/email-protection#691d010604081a1e08291c04000a01470c0d1c"><span class="__cf_email__" data-cfemail="13677b7c7e7260647253667e7a707b3d767766">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+D.++Wang">Thomas D. Wang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9182-9620" title="Orcid link">http://orcid.org/0000-0001-9182-9620</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00405&amp;href=/doi/10.1021%2Facs.jmedchem.8b00405" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 5323–5331</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 5, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>12 March 2018</li><li><span class="item_label"><b>Published</b> online</span>5 June 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 June 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00405" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00405</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5323%26pageCount%3D9%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJing%2BChen%252C%2BJuan%2BZhou%252C%2BZhenghong%2BGao%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D12%26contentID%3Dacs.jmedchem.8b00405%26title%3DMultiplexed%2BTargeting%2Bof%2BBarrett%25E2%2580%2599s%2BNeoplasia%2Bwith%2Ba%2BHeterobivalent%2BLigand%253A%2BImaging%2BStudy%2Bon%2BMouse%2BXenograft%2Bin%2BVivo%2Band%2BHuman%2BSpecimens%2Bex%2BVivo%26numPages%3D9%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5331%26publicationDate%3DJune%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00405"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1166</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00405" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Multiplexed Targeting of Barrett’s Neoplasia with a Heterobivalent Ligand: Imaging Study on Mouse Xenograft in Vivo and Human Specimens ex Vivo&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Juan&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Zhenghong&quot;,&quot;last_name&quot;:&quot;Gao&quot;},{&quot;first_name&quot;:&quot;Xue&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Fa&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Xiyu&quot;,&quot;last_name&quot;:&quot;Duan&quot;},{&quot;first_name&quot;:&quot;Gaoming&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Bishnu&quot;,&quot;last_name&quot;:&quot;P. Joshi&quot;},{&quot;first_name&quot;:&quot;Rork&quot;,&quot;last_name&quot;:&quot;Kuick&quot;},{&quot;first_name&quot;:&quot;Henry&quot;,&quot;last_name&quot;:&quot;D. Appelman&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;D. Wang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;5323-5331&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00405&quot;},&quot;abstract&quot;:&quot;Esophageal adenocarcinoma (EAC) is a molecularly heterogeneous disease that is rising rapidly in incidence and has poor prognosis. We developed a heterobivalent peptide to target detection of early Barrett’s neoplasia by combining monomer heptapeptides specific for either EGFR or ErbB2 in a heterodimer configuration. The structure of a triethylene glycol linker was optimized to maximize binding interactions to the surface receptors on cells. The Cy5.5-labeled heterodimer QRH*–KSP*–E3–Cy5.5 demonstrated specific binding to each target and showed 3-fold greater fluorescence intensity and 2-fold higher affinity compared with those of either monomer alone. Peak uptake in xenograft tumors was observed at 2 h postinjection with systemic clearance by ∼24 h in vivo. Furthermore, ligand binding was evaluated on human esophageal specimens ex vivo, and 88% sensitivity and 87% specificity were found for the detection of either high-grade dysplasia (HGD) or EAC. This peptide heterodimer shows promise for targeted detectio&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00405&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00405" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00405&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00405" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00405&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00405" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00405&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00405&amp;href=/doi/10.1021/acs.jmedchem.8b00405" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00405" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00405" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00405%26sid%3Dliteratum%253Aachs%26pmid%3D29870260%26genre%3Darticle%26aulast%3DChen%26date%3D2018%26atitle%3DMultiplexed%2BTargeting%2Bof%2BBarrett%25E2%2580%2599s%2BNeoplasia%2Bwith%2Ba%2BHeterobivalent%2BLigand%253A%2BImaging%2BStudy%2Bon%2BMouse%2BXenograft%2Bin%2BVivo%2Band%2BHuman%2BSpecimens%2Bex%2BVivo%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D12%26spage%3D5323%26epage%3D5331%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=291912" title="Fluorescence">Fluorescence</a>,</li><li><a href="/action/doSearch?ConceptID=290975" title="Biopolymers">Biopolymers</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/jmcmar.2018.61.issue-12/20180628/jmcmar.2018.61.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Esophageal adenocarcinoma (EAC) is a molecularly heterogeneous disease that is rising rapidly in incidence and has poor prognosis. We developed a heterobivalent peptide to target detection of early Barrett’s neoplasia by combining monomer heptapeptides specific for either EGFR or ErbB2 in a heterodimer configuration. The structure of a triethylene glycol linker was optimized to maximize binding interactions to the surface receptors on cells. The Cy5.5-labeled heterodimer QRH*–KSP*–E3–Cy5.5 demonstrated specific binding to each target and showed 3-fold greater fluorescence intensity and 2-fold higher affinity compared with those of either monomer alone. Peak uptake in xenograft tumors was observed at 2 h postinjection with systemic clearance by ∼24 h in vivo. Furthermore, ligand binding was evaluated on human esophageal specimens ex vivo, and 88% sensitivity and 87% specificity were found for the detection of either high-grade dysplasia (HGD) or EAC. This peptide heterodimer shows promise for targeted detection of early Barrett’s neoplasia in clinical study.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22445" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22445" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Esophageal adenocarcinoma (EAC) is a deadly cancer that is rising in incidence rapidly and is associated with a poor prognosis and low 5 year survival.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Barrett’s esophagus (BE) represents a metaplastic transformation of squamous (SQ) epithelium into specialized columnar epithelium in response to long-standing acid and bile reflux.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> BE is known to transform stepwise through low-grade dysplasia (LGD) to high-grade dysplasia (HGD) before developing into EAC. HGD is a premalignant condition that provides a window of opportunity for intervention with either curative resection or ablation therapy.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Therefore, new methods for accurate detection of HGD and early EAC is needed.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Conventional surveillance using white-light illumination with random four-quadrant biopsies has been found to have limited effectiveness for localizing dysplasia that is flat in appearance, focal in extent, and patchy in distribution.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Chemoprevention with nonsteroidal anti-inflammatory drugs, such as COX-2 inhibitors, has been limited by unacceptable side effects.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">The ability to identify expression of molecular targets can be used to diagnose, stage, and classify tumors and to monitor response to therapy. Gene expression of EAC is heterogeneous,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and strategies that focus on a single target are limited. Epidermal-growth-factor receptor (EGFR) and ErbB2 have been found to be high-frequency-gene-amplified and overexpressed in HGD and early EAC.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> These receptor tyrosine kinases have been validated as cancer biomarkers and function to stimulate epithelial-cell growth, proliferation, and differentiation.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Emerging evidence supports early expression in the progression of BE to EAC, when intervention can improve patient outcomes.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> In addition, targets located on the cell surface are well suited for development of either diagnosis or therapy. Minimal overlap in expression has been found in studies of surgically resected HGD and EAC specimens.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> These observations motivate a need for a combined approach that detects multiple targets concurrently.</div><div class="NLM_p last">Multivalent ligands generate synergistic effects that can increase their affinity, avidity, selectivity, and potency by binding multiple targets concurrently.<a onclick="showRef(event, 'ref13 ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16 ref17">(13−17)</a> These properties can enhance in vivo diagnostic-imaging performance by improving target-to-background ratios (T/B) and detecting targets at lower levels of expression.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Also, this strategy can be effective for therapy by connecting different cell signaling pathways.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The ability to interact with multiple targets simultaneously may reduce acquired resistance that arises with the use of a single target.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> This heterobivalent targeting strategy was first tested as a proof-of-principle study on receptors of human melanocortin-4 and δ-opioid in vitro<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and other G-protein-coupled receptors (GPCR).<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a> Peptides specific for α<sub>v</sub>β<sub>3</sub> integrin and gastrin-releasing peptide receptor (GRPR) have been arranged in a heterodimeric configuration and radiolabeled with <sup>18</sup>F for PET imaging.<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25−27)</a> Recently, the heterodimeric peptide <sup>68</sup>Ga–BBN–RGD was evaluated for prostate-cancer diagnosis and clinically translated.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> A number of bispecific antibodies have been developed for multivalent targeting;<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> however, effectiveness may be limited by poor tumor uptake, immunogenicity, and high manufacture costs.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> We have previously identified and validated heptapeptide monomers specific for EGFR and ErbB2.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> In this study, we arrange heptapeptide monomers in a heterodimer configuration, and present the first heterodimeric peptide that targets EGFR and ErbB2. This bivalent probe was screened using variable-length linkers to optimize binding efficiency and was labeled with a near-infrared dye. Further validation was conducted in an OE33-tumor-bearing mouse model in vivo and with antibodies for binding to HGD and EAC found in human esophageal specimens.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64385" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64385" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Heterodimeric-Peptide Configuration</h3><div class="NLM_p">The heptapeptide sequences QRHKPRE (green in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) and KSPNPRF (purple) were synthesized to bind specifically to EGFR and ErbB2, respectively.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> The fluorophore Cy5.5 (red) was attached to the C-termini via a GGGSK linker (blue), resulting in QRH*–Cy5.5 and KSP*–Cy5.5 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Cy5.5 was chosen because of its good photostability and high quantum yield in the near-infrared (NIR) spectrum.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The linker separates the peptide and fluorophore to prevent steric hindrance. Purities of >95%, as determined by analytical HPLC, were achieved for both monomers, and experimental mass-to-charge ratios (<i>m</i>/<i>z</i>) of 1794.98 and 1900.04 were measured by mass spectrometry, which agree with the expected values (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S1A,B</a>). The monomers were combined in a heterodimer configuration by introducing a linker with either a variable PEG spacer, ranging in size from 17 to 74 atoms, or a hydrophobic 6-aminohexonic acid linker in the α- and ξ-amino groups of the second lysine attached to Cy5.5 (red, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The linker length was varied to determine the optimal spacing between monomers in order to maximize binding interactions to EGFR and ErbB2.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of the peptide heterodimer. Chemical structures for heptapeptide monomers QRHKPRE (QRH*) and KSPNPRF (KSP*) are shown along with the arrangement of heterodimer configuration with the variable-length linkers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The fluorescence spectra of the Cy5.5-labeled peptide monomers and optimized heterodimer revealed peak fluorescence absorbance and emission at λ = 680 and 708 nm, respectively (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S2A,B</a>). Through confocal microscopy, the strength of binding of each candidate heterodimer with different-length linkers to the surfaces of SKBr3 cells is shown (arrows in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A–E). These cells are well-known to express EGFR and ErbB2.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The mean intensity for each heterodimer was quantified (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>F). The heterodimer QRH*–KSP*–E3–Cy5.5 with the triethylene glycol linker (E3) showed the highest signal and was found to have good hydrophilicity as well. The signal decreased dramatically with longer linkers because of either increased flexibility or internal entropy. Aminohexonic acid linkers could also be used to provide comparable binding affinities; however, their decreased hydrophilicity as compared with that of the PEG linkers may be more challenging for clinical translation. A Western blot of the cells is shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>G.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Optimization of the peptide heterodimer. (A–E) Confocal-microscopy images of fluorescence from the binding of the candidate heterodimers with linkers (A) E2, (B) Hex, (C) E3, (D) E6, and (E) E10 to the surfaces of SKBr3 cells (arrows). (F) Quantified results showing that the E3 linker provides the highest mean fluorescence intensity. <i>P</i>-values were determined using unpaired <i>t</i> tests. Measurements are an average of 10 randomly chosen cells from 4 images collected independently. (G) Western blot showing EGFR and ErbB2 expression in SKBr3 and QhTERT cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We also evaluated heterodimer binding using structural models for EGFR (1IVO) and ErbB2 (2A91) and found that the triethylene glycol linker (E3) provides spacing for the heterodimer QRH*–KSP*–E3–Cy5.5 to bind to domain 2 of EGFR and domain 3 of ErbB2 (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S3A–C</a>). The model suggests that a linker length of ∼60 Å is needed for the heterodimer to conform to the spacing between these binding domains. We then synthesized QRH*–KSP*–E3–Cy5.5 with >95% purity, as determined by analytical HPLC, and measured an experimental mass-to-charge ratio (<i>m</i>/<i>z</i>) of 2974.69 by mass spectrometry, which agreed with the expected value (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S1C</a>). The spectra revealed no change in peak values after the peptide monomers were arranged in this heterodimeric configuration.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Stability</h3><div class="NLM_p last">The stability of the peptide heterodimer in PBS containing 0.1% BSA at pH 7.4 and 37 °C was monitored by HPLC for 0.5, 2, 6, and 12 h (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S4A</a>). No noticeable degradation was observed. We also monitored enzymatic stability by incubating the heterodimer at a concentration of 30 μM in mouse serum at 37 °C for 0.5, 1.0, 1.5, and 2 h of incubation (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S4B</a>). We observed the formation of a new peak that may arise from degradation, and at 2 h, the area of the newly formed peak was about 20%.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Validation with Confocal Microscopy</h3><div class="NLM_p last">Through confocal microscopy, strong binding by the peptide heterodimer (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S5A</a>, red) to the surface (arrow) of OE33 human esophageal-adenocarcinoma cells was observed. By comparison, we visualized much less fluorescence intensity with either monomer (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S5B,C</a>). Minimal binding was observed for all peptides to QhTERT human nondysplastic Barrett’s esophagus cells (control), which do not express either EGFR or ErbB2 (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S5D–F</a>). Quantified results show a greater signal for the heterodimer compared with those of the individual monomers combined (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S5G</a>). The Western blot is shown in <a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S5H</a>. These results support the effective use of peptide heterodimers at much lower concentrations than those of the monomers.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> siRNA Knockdown</h3><div class="NLM_p">siRNA-knockdown experiments were performed to validate the specific binding of the heterodimer to either EGFR or ErbB2 using SKBr3 cells. Confocal microscopy showed that QRH*–KSP*–E3–Cy5.5 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A, red) binds strongly to the surfaces (arrow) of cells transfected with siCL, the nontargeting siRNA (control). Reduced fluorescence intensity was seen with knockdown cells transfected with siEGFR, the targeting siRNA (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). Similar results were found with the heterodimer and monomer for ErbB2 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C,D). The fluorescence intensities were quantified, and the differences were found to be significant (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>E). The Western blot for the control and knockdown SKBr3 cells is shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>F.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Characterization of the peptide heterodimer. (A–D) siRNA knockdown experiments of QRH*–KSP*–E3–Cy5.5 (red) showing significantly greater binding to the surfaces (arrows) of (A) siCL (control) SkBr3 cells than to (B) siEGFR (knockdown) cells and significantly greater binding to the surfaces of (C) siCL cells than to (D) siErbB2 (knockdown) cells. (E) Quantified results showing significantly greater intensity for siCL-cell binding versus siEGFR-cell binding and significantly greater intensity for siCL-cell binding versus siErbB2-cell binding (<i>P</i> = 3.6 × 10<sup>–4</sup> and <i>P</i> = 7.8 × 10<sup>–3</sup>, respectively, by unpaired <i>t</i> tests). The mean values were calculated from five cells chosen randomly from three images collected independently. (F) Western blots showing EGFR and ErbB2 expression in the control and knockdown cells. (G) Apparent dissociation constant (binding affinity) of QRH*–KSP*–E3–Cy5.5, <i>k</i><sub>d</sub> = 23 nM, versus those of QRH*–Cy5.5 and KSP*–Cy5.5, <i>k</i><sub>d</sub> = 98 and 54 nM, respectively. (H) Apparent association-time constant of QRH*–KSP*–E3–Cy5.5, <i>k</i> = 0.22 min<sup>–1</sup> (4.5 min), versus those of QRH*–Cy5.5 and KSP*–Cy5.5, <i>k</i> = 0.21 min<sup>–1</sup> (4.8 min) and 0.35 min<sup>–1</sup> (2.9 min), respectively. Results for each measurement are representative of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Binding Properties</h3><div class="NLM_p last">The binding parameters of the peptide heterodimer were measured using flow cytometry with OE33 cells, and an apparent dissociation constant of <i>k</i><sub>d</sub> = 23 nM was measured (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>G). This result is much improved compared with those of the peptide monomers, QRH*–Cy5.5 or KSP*–Cy5.5, which were <i>k</i><sub>d</sub> = 98 and 54 nM, respectively. The apparent association-time constant of <i>k</i> = 0.22 min<sup>–1</sup> (4.5 min) was measured for the heterodimer, whereas those of the monomers, QRH*–Cy5.5 and KSP*–Cy5.5, were <i>k</i> = 0.21 min<sup>–1</sup> (4.7 min) and 0.35 min<sup>–1</sup> (2.8 min), respectively (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>H).</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Colocalization</h3><div class="NLM_p last">Colocalization experiments were performed to further validate specific binding of the peptide heterodimer to either EGFR or ErbB2. Confocal microscopy shows that QRH*–KSP*–E3–Cy5.5 (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S6A</a>, red) binds strongly to the surfaces (arrow) of SKBr3 cells. Binding by AF568-labeled anti-EGFR (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S6B,C</a>, yellow) and AF488-labeled anti-ErbB2 (green) to the surfaces (arrows) of the same cells are shown for comparison. We measured Pearson’s correlation coefficients of ρ = 0.77 and 0.65 between the heterodimer and the anti-EGFR and anti-ErbB2 antibodies, respectively (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S6D,E</a>). The DAPI image shows the locations of the cell nuclei (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S6F</a>).</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Internalization</h3><div class="NLM_p last">We collected confocal images over time to demonstrate heterodimer internalization. From 1 to 4 min, QRH*–KSP*–E3–Cy5.5 accumulates on the surfaces of SKBr3 cells (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S7A–C</a>). At 8 min, internalization begins and reaches near completion at 40 min (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S7D–G</a>). DAPI images show the locations of cell nuclei (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S7H–N</a>). The spatial distribution of the ligand can be appreciated on merged images (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S7O–U</a>). Ligand-mediated endocytosis can result in signal amplification and supports the use of this in mediating targeted therapy.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Effect on Cell Signaling</h3><div class="NLM_p">The effect of heterodimer binding on downstream signaling was evaluated in SKBr3 cells. The Western blot shows no change in phosphorylation for either EGFR (p-EGFR) or ErbB2 (p-ErbB2) with the addition of up to 20 μM QRH*–KSP*–E3–Cy5.5 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Similarly, no downstream changes were observed in AKT (p-AKT) or ERK (p-ERK). By comparison, strong phosphorylation activity for AKT (p-AKT) and ERK (p-ERK) was observed with the addition of EGF, which was used as a positive control. Also, the addition of lapatinib, a tyrosine-kinase inhibitor known to disrupt ErbB2 signaling in solid tumors, resulted in reduced expression of p-ErbB2, p-AKT, and p-ERK.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. No effect of the peptide heterodimer on cell signaling. We evaluated the effects of QRH*–KSP*–E3–Cy5.5 binding on downstream cell signaling in SKBr3 cells. In the Western blot, we observed no changes in phosphorylation of EGFR (p-EGFR), ErbB2 (p-ErbB2), or of downstream AKT (p-AKT) and ERK (p-ERK) when the cells were incubated with the heterodimer at 1, 5, and 20 μM. By comparison, the addition of EGF, an endogenous ligand for EGFR, showed increased expression of p-AKT and p-ERK. The addition of 100 nM lapatinib, a tyrosine-kinase inhibitor known to interrupt EGFR and ErbB2 signaling in solid tumors, resulted in reduced expression of p-EGFR, p-ErbB2, and p-AKT. Cells treated with 1% DMSO and untreated cells showed no suppression of EGFR- and ErbB2-mediated signaling. β-tubulin was used as a loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Pharmacokinetics</h3><div class="NLM_p">The heterodimer (300 μM, 150 μL) was injected via the tail vein to evaluate its in vivo uptake by OE33 xenograft tumors. Fluorescence images were collected before peptide injection to assess baseline and then at various time points up to 24 h, when the probe had cleared <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). A set of images was also collected with a Cy5.5-labeled control peptide (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Peak intensity was observed at 2 h postinjection, and the mean result for the targeted peptide was significantly greater than that for the control (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C,D). We also performed blocking studies by injecting unlabeled QRH*, KSP*, and both monomers together prior to measuring the fluorescence intensity from the tumor (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>E, arrow) at 2 h postinjection. A significant reduction in signal was observed for each condition (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>F).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pharmacokinetics of the peptide heterodimer. (A) Representative whole-body NIR-fluorescence images showing uptake of the targeted peptide heterodimer QRH*–KSP*–E3–Cy5.5 in a xenograft tumor (arrow) over time. (B) Representative whole-body NIR-fluorescence images with (GGGAGGG)<sub>2</sub>KK–Cy5.5, the control. (C) Quantitative analysis showing peak mean signal from <i>n</i> = 6 tumors at 2 h following iv injection. Mean (±SD) T/B ratios of 2.39 ± 0.52 and 1.43 ± 0.28 were measured at the tumors for the targeted (<i>n</i> = 6) and control (<i>n</i> = 6) peptides, respectively. The signal returns to baseline by ∼24 h. (D) Mean fluorescence intensities from individual tumors at 2 h with the targeted and control peptides, <i>P</i> = 2.9 × 10<sup>–3</sup> by an unpaired <i>t</i> test. (E) Representative whole-body NIR-fluorescence images with unlabeled QRH*, KSP*, and both (QRH* and KSP*) monomer peptides iv-injected prior to the heterodimer for blocking. (F) Quantified results showing significant reduction in mean intensity from the tumor (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Biodistribution</h3><div class="NLM_p">Heterodimer biodistribution was evaluated in nude mice bearing OE33 xenograft tumors following systemic injection (300 μM, 150 μL of PBS) of either the targeted peptide QRH*–KSP*–E3–Cy5.5 (<i>n</i> = 6) or the control (GGGAGGG)<sub>2</sub>KK–Cy5.5 (<i>n</i> = 6). The mice were sacrificed 2 h later, and heterodimer uptake was found to be significantly higher in tumors than in other organs, including 5-fold higher than in muscle (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). High uptake was also visualized in kidneys, supporting renal clearance. Significantly lower intensity was observed in tumors when the control peptide was used (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Quantified results showed a significantly greater mean value in tumors for the heterodimer versus that for the control (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C). Overexpression of EGFR and ErbB2 was validated in sections of OE33 xenograft tumors ex vivo with immunohistochemistry (IHC, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S8</a>), and no evidence of acute toxicity was found with histology (H&E, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">Figure S9</a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Biodistribution of the peptide heterodimer. (A,B) Representative fluorescence images from excised mouse organs at ∼2 h postinjection of (A) targeted peptide heterodimer QRH*–KSP*–E3–Cy5.5 and (B) control peptide (GGGAGGG)<sub>2</sub>KK–Cy5.5. (C) Fluorescent signals quantified from individual organs (<i>n</i> = 6) for each peptide. The mean fluorescence intensity for the targeted one was significantly greater than that for the control (5.28 ± 1.14 versus 2.24 ± 0.82, <i>P</i> = 5.5 × 10<sup>–4</sup> by an unpaired <i>t</i> test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Validation with Human Esophageal Specimens</h3><div class="NLM_p">Using confocal microscopy, specific heterodimer binding was validated with human specimens of Barrett’s neoplasia ex vivo. We observed minimal fluorescence intensity with SQ and BE and increased signal with HGD and EAC (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A–D). The same set of specimens was also stained with AF568-labeled anti-EGFR antibody (yellow) and AF488-labeled anti-ErbB2 antibody (green). Colocalization of heterodimer and antibody binding can be appreciated on the merged images. Fluorescence intensities were measured from a set of three boxes with dimensions of 20 × 20 μm<sup>2</sup> placed within random crypts of heterodimer and antibody images (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). At higher magnification, cell-surface binding (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B, arrows) can be appreciated. Colocalization of binding was evaluated between the heterodimer QRH*–KSP*–E3–Cy5.5 (red) and the anti-EGFR-AF568 (yellow) and anti-ErbB2-AF488 (green) antibodies, and Pearson’s correlation coefficients of ρ = 0.60 and 0.75, respectively, were measured.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Specific binding of the peptide heterodimer to Barrett’s neoplasia: representative confocal-microscopy images of human esophageal specimens ex vivo with minimal QRH*–KSP*–E3–Cy5.5 (red) staining in (A) squamous (SQ) and (B) Barrett’s esophagus (BE) cells and increased intensity in (C) high-grade dysplasia (HGD) and (D) esophageal adenocarcinoma (EAC) cells. Similar results were found with the AF568-labeled anti-EGFR antibody (yellow) and the AF488-labeled anti-ErbB2 antibody (green). Merged images show colocalization of peptide and antibody binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Colocalization of the peptide heterodimer and antibody binding to Barrett’s neoplasia. (A) Confocal-microscopy images of serial sections of HGD in human esophageal specimens following staining with QRH*–KSP*–E3–Cy5.5 (red), anti-EGFR antibody labeled with AF568 (yellow), and anti-ErbB2 antibody labeled with AF488 (green). Fluorescence intensity was quantified from the mean of a set of three boxes with dimensions of 20 × 20 μm<sup>2</sup> placed over random crypts. Colocalization of binding can be appreciated on the merged image. (B) High-magnification images from the dashed boxes. On the merged image, Pearson’s correlation coefficients of ρ = 0.60 and 0.75 were measured for EGFR and ErbB2, respectively. (C) Significantly greater mean QRH*–KSP*–E3–Cy5.5-fluorescence intensities from HGD and EAC cells compared with those from BE and SQ cells, from <i>n</i> = 31, 8, 23, and 12 SQ, BE, HGD, and EAC specimens, respectively. The <i>P</i>-value for the differences are calculated by Tukey’s multiple comparisons. Similar results were found for anti-EGFR-AF568 and anti-ErbB2-AF488. (D) ROC curve showing 88% sensitivity, 87% specificity, and an AUC of 0.95 with QRH*–KSP*–E3–Cy5.5; 74% sensitivity, 69% specificity, and an AUC of 0.79 with anti-EGRF-AF568; and 85% sensitivity, 79% specificity, and an AUC of 0.91 with anti-ErbB2-AF488.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We measured the mean (±SD) fluorescence intensity for the heterodimer from <i>n</i> = 31, 8, 23, and 12 human SQ, BE, HGD, and EAC specimens, respectively (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C). The result for HGD was significantly higher than those for BE and SQ. Similar findings were found with the anti-EGFR and anti-ErbB2 antibodies. From receiver–operator-characteristic (ROC) curves, we found 88% sensitivity and 87% specificity for the heterodimer in detecting Barrett’s neoplasia (HGD and EAC) at a T/B ratio of 5.9 when compared with pathology (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>D). The sensitivity and specificity for the heterodimer were higher than those for either antibody.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08552" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08552" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Progression of BE to EAC is characterized by high molecular heterogeneity, which has limited the usefulness of conventional ligands that recognize a single target. Here, we demonstrate the development of a peptide heterodimer that binds either EGFR or ErbB2 or both concurrently with improved performance, made by matching the linker length in the heterodimer to the mean distance between the extracellular binding domains of the targets. We found that QRH*–KSP*–E3–Cy5.5, with triethylene glycol (PEG3) consisting of 30 atoms as the linker, produced 3-fold greater fluorescence intensity from binding to OE33 cells than that of either monomer alone. Through immunofluorescence, this heterobivalent probe provided higher sensitivity and specificity for the detection of Barrett’s neoplasia in human esophageal specimens than those of the known monoclonal antibodies for the targets. The in vivo imaging results in OE33 xenograft tumors showed peak uptake in ∼2 h and systemic clearance within ∼24 h, providing pharmacokinetic parameters that are compatible with diagnostic imaging. No evidence of acute toxicity was found on pathology. This combination strategy for target binding is promising for developing novel diagnostic and therapeutic agents for clinical use to manage this heterogeneous disease.</div><div class="NLM_p">Bispecific ligands are promising for their potential to improve in vivo binding performance. By covalently linking two unique peptide sequences, multivalent ligand–target interactions were generated to improve binding affinity by >2-fold. This synergy is reflected by the mean fluorescence intensity for heterodimer binding to OE33 cells being greater than the sum of those for the two individual monomers, allowing the targets to be detected at lower levels of expression. With the heterodimer, we achieved 88% sensitivity and 87% specificity for detection of either HGD or EAC, a result that was better than those of the monoclonal antibodies for the targets. Higher sensitivity results from the detection of two independent targets, and greater specificity arises from dual binding to a larger, combined target epitope in comparison with the monomer.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> A high T/B ratio is achieved using Cy5.5 to emit NIR fluorescence, which is little affected by hemoglobin absorption, tissue scattering, and background autofluorescence<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and provides maximum tumor-imaging depth.</div><div class="NLM_p last">To our knowledge, this is the first bivalent heterodimer demonstrated for targeting Barrett’s neoplasia. Peptides offer a number of advantages over bulky antibodies for in vivo targeting.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Their small size and low molecular weight facilitate greater vascular permeability, enhanced tissue diffusion, and deeper tumor penetration. Peptides have less potential for immunogenicity than antibodies, allowing for repetitive use.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In the future, this dual-targeting agent will undergo rigorous pharmacology and toxicology studies and will be synthesized under Good Manufacturing Practice (GMP) conditions for FDA approval to be used in human clinical studies with fluorescence endoscopy. This combination approach greatly simplifies the process for FDA review in comparison with that for two ligands separately. Development of bivalent peptides can be performed at a substantially lower cost than that for other protein-based agents used separately in combination therapy. Established peptide-synthesis processes are easy to scale up for mass manufacture, with reproducible results.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> By recognizing two different cell-surface targets that are validated EAC biomarkers, enhanced diagnostic and therapeutic effects can be achieved as compared with ligands that bind only one target.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51643" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51643" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Cells and Media</h3><div class="NLM_p last">All cells were maintained at 37 °C and 5% CO<sub>2</sub> and were supplemented with 10% FBS and 1% penicillin/streptomycin. Penicillin/streptomycin was omitted for the siRNA knockdown studies, and FBS was omitted from the keratinocyte-SFM media. Human SKBr3 breast-cancer cells were obtained from the American Type Culture Collection (ATCC) and cultured in McCoy’s 5A media. Human OE33 and QhTERT esophageal cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 media and keratinocyte-SFM media (Gibco), respectively. Cells were passaged using 0.25% EDTA containing trypsin (Mediatech), and a hemocytometer was used to count cell numbers. Peptide-synthesis reagents (<i>N</i><sup>α</sup>-Fmoc-protected amino acids, HBTU, and HOBt) were purchased from either Anaspec or AAPPTec. The side-chain protecting groups used the following amino acids: Arg(<i>N</i><sup>ω</sup>-Pbf), Asn(<i>N</i><sup>γ</sup>-Trt), Glu(<i>O</i>-<i>t</i>Bu), His(<i>N</i><sup>im</sup>-Trt), Ser(<i>t</i>Bu), Lys(<i>N</i><sup>ε</sup>-Alloc), Lys(<i>N</i><sup>ε</sup>-Ivdde). Fmoc-AEA, Fmoc-AEEA, Fmoc-AE3A, Fmoc-AE6A, Fmoc-AE10A, and 6-aminohexanoic acid were purchased from AAPPTec. These reagents were analytical-grade with >99% purity and were used without further purification. Rink-amide-MBHA resin with an initial loading of 0.2 mmol/g was acquired from Protein Technologies, Inc. Cy5.5–NHS ester was acquired from Lumiprobe. Analytical-grade solvents for peptide synthesis and HPLC were purchased from Fisher Scientific and were used without further purification unless otherwise stated.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Peptide Monomers and Heterodimer</h3><div class="NLM_p">Peptide monomers and heterodimers were synthesized and labeled with Cy5.5 using standard Fmoc solid-phase chemical synthesis with rink-amide-MBHA resin in a PS3 automatic synthesizer (Protein Technologies Inc.). Fmoc-protected <span class="smallcaps smallerCapital">l</span>-amino acids were applied with standard HBTU/HOBt activation. The C-terminus lysine was incorporated as Fmoc–Lys(Alloc)–OH for fluorophore labeling. Upon completion of peptide assembly, the resin was transferred to a reaction vessel for manual labeling with dye. The Alloc side-chain protecting group was removed with a palladium catalyst. The resin was washed with dimethylformamide (DMF) and dichloromethane (DCM) for 1 min 3×. The protected, resin-bound peptide was reacted with Cy5.5–NHS ester and <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA) for 12 h. The completion of the reaction was monitored with a qualitative ninhydrin test. A cleavage cocktail reagent of TFA/TIS/H<sub>2</sub>O (95:2.5:2.5, v/v/v) was mixed with the resin and stirred for 2 h in dark conditions at 25 °C. The crude peptides were isolated from the resin by filtration and evaporated with N<sub>2</sub> gas, after which they were precipitated with chilled diethyl ether and stored at −20 °C for 12 h. The precipitated peptides were centrifuged, washed 2× with ether, dried, dissolved in water, and lyophilized to produce a dark-green powder. The crude peptides were purified by prep-HPLC with a C18 column (Waters Inc.) using a water (0.1% TFA)–acetonitrile (0.1% TFA) gradient. Peptide purity was tested using an analytical C18 column. Further characterization was confirmed by either ESI (Waters Inc.) or Q-TOF (Agilent Technologies) mass spectrometry.</div><div class="NLM_p last">The absorbance spectra of the Cy5.5-labeled peptides were characterized with a spectrophotometer (NanoDrop 2000, Thermo Scientific). Fluorescence emission from a 1 μM peptide solution diluted in PBS was collected with a fiber-coupled spectrophotometer (Ocean Optics) using a diode-pumped solid-state laser (Technica Laser Inc.) with λ<sub>ex</sub> = 671 nm. The spectra were plotted with Origin 8.5 software (OriginLab Corporation).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Peptide-Heterodimer Validation with Confocal Microscopy</h3><div class="NLM_p last">Cells were cultured to ∼70% confluence on glass coverslips, washed with PBS, and incubated with 2% BSA in PBS for 30 min to block nonspecific binding. Cy5.5-labeled peptides (1 μM) were added and incubated for 30 min at 4 °C. The cells were then washed 3× with PBS, fixed with ice-cold 4% paraformaldehyde (PFA) for 10 min, washed with PBS 1×, and then mounted on glass slides with ProLong Gold reagent containing DAPI (Invitrogen). For antibody staining, cells were incubated with either anti-EGFR (1:500, #2232S) or anti-ErbB2 (1:500, #29D8) primary antibody from Cell Signaling Inc. overnight at 4 °C after fixation, and then they were washed with PBS 3× and processed with secondary-antibody staining. Either goat anti-rabbit-IgG (H+L) antibody labeled with Alexa-Fluor 488 (1:1000, #A-11008, Invitrogen) or goat anti-mouse-IgG (H+L) antibody labeled with Alexa-Fluor 568 (1:1000, #ab175473, Abcam) was added and incubated for 1 h at room temperature (RT). The cells were washed with PBS 3× and mounted onto glass coverslips. Confocal fluorescence images were collected using DAPI-, AF488-, AF568-, and Cy5.5-filter sets. Fluorescence intensities from three independent images were quantified using custom Matlab (Mathworks) software.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Western Blot</h3><div class="NLM_p last">Western blots were performed by lysing cells in Pierce RIPA lysis buffer containing Halt protease-inhibitor cocktail (#87786, Thermo Scientific) for 30 min on ice. The lysates were centrifuged at 10 000 rpm for 10 min at 4 °C. A BSA-protein-assay kit (#23227, Thermo Scientific) was used to quantify the protein concentration in the supernatant. Aliquots of protein (10 μL) were used for electrophoresis on NuPAGE 4–12% Bis-Tris Gels (#17031471, Invitrogen) followed by electrophoretic transfer onto membranes (#ISEQ00010, Merck Millipore Ltd.). The membranes were incubated with primary rabbit anti-EGFR monoclonal antibody (1:1000, #2232S) and rabbit anti-ErbB2 monoclonal antibody (1:1000, #2165S) from Cell Signaling Inc. Mouse anti-β-tubulin monoclonal antibody (1:500, #32-2600, Invitrogen) was used as the loading control. For visualization, horseradish-peroxidase (HRP)-conjugated secondary antibodies consisting of goat anti-rabbit-IgG (H+L)–HRP (1:5000, #65-6120) and goat anti-mouse-IgG (H+L)–HRP (1:5000, #62-6520) from Thermo Scientific were used, after which an ECL kit (#RPN2106, GE Healthcare) was used per the manufacturer’s instructions.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Heterodimer Stability</h3><div class="NLM_p last">The stability of the heterodimer was evaluated in 0.01 mol/L PBS containing 0.1% bovine serum albumin (BSA, pH 7.4) at 37 °C. Degradation was monitored by HPLC at 0.5, 2, 6, and 12 h. Enzymatic stability was also evaluated by incubating the heterodimer (30 μM) in mouse serum at 37 °C. The samples were centrifuged at 14 000 rpm, and 20 μL aliquots of the supernatant were analyzed by HPLC at 0.5, 1.0, 1.5, and 2 h of incubation.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> siRNA Knockdown</h3><div class="NLM_p last">We performed separate knockdowns of EGFR and ErbB2 expression in SKBr3 cells to validate specific peptide binding. ON-TARGETplus human EGFR siRNA (#L-003114-00-0005), ON-TARGETplus human ErbB2 siRNA (#L-003126-00-0005), and an ON-TARGET plus nontargeting pool (#D-001810-10-05) were used. siRNA (5 μΜ, 5 μL) was transfected into SKBr3 cells using DharmaFECT transfection reagents (Thermo Scientific). Briefly, cells were seeded in six-well culture plates at 30% confluence in McCoy’s 5A media supplemented with 10% FBS without antibiotics. The cells were transfected with siRNA at a final concentration of 5 μM using oligofectamine (Thermo Scientific). Knockdown of either EGFR or ErbB2 was confirmed by Western blot.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Binding Properties</h3><div class="NLM_p">We measured the apparent dissociation constant, <i>k</i><sub>d</sub>, of the peptide heterodimer to OE33 cells to assess binding affinity. The heterodimer was serially diluted in PBS at concentrations of 0, 10, 25, 50, 100, and 200 nM, which were incubated with ∼10<sup>5</sup> OE33 cells at 4 °C for 1 h, after which the cells were washed with cold PBS. The mean fluorescence intensities were measured with flow cytometry (BD LSRII, BD Biosciences). The equilibrium dissociation constant, <i>k</i><sub>d</sub> = 1/<i>k</i><sub>a</sub>, was calculated with a least-squares fit of the data to the nonlinear equation <span class="NLM_inline-formula"><img class="imgWithoutFigViewer inline-formula-styles" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_m001.gif" alt="" id="_i24" /></img></span>. <i>I</i><sub>0</sub> and <i>I</i><sub>max</sub> are the initial and maximum fluorescence intensities, corresponding to no peptide and at saturation, respectively, and [X] represents the concentration of bound peptide. Prism 5.0 software (Graphpad Inc.) was used to calculate <i>k</i><sub>d</sub> and <i>k</i><sub>a</sub>.</div><div class="NLM_p last">We measured the apparent association-time constant, <i>k</i>, to OE33 cells to assess binding kinetics. OE33 cells were grown to ∼80% confluence in 10 cm dishes, and detached with PBS-based cell-dissociation buffer (Invitrogen). Cells (∼10<sup>5</sup>) were incubated with the heterodimer (1 μM) at 4 °C for different time periods ranging from 0 to 60 min. The cells were centrifuged, washed with cold PBS, and fixed with 4% PFA. Flow cytometry was performed, and the median fluorescence intensity (<i>y</i>) was compared with that of OE33 cells without the addition of peptide at various time points (<i>t</i>) using Flowjo software. The rate constant, <i>k</i>, was calculated by fitting the data to the first-order kinetics model, <span class="NLM_inline-formula"><img class="imgWithoutFigViewer inline-formula-styles" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_m002.gif" alt="" id="_i25" /></img></span>, where <i>I</i><sub>max</sub> is the maximum value, using Prism 5.0 software.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Colocalization</h3><div class="NLM_p last">We evaluated colocalization of the binding of the peptide heterodimer to SKBr3 cells with that of the anti-EGFR antibody and with that of the anti-ErbB2 antibody. The heterodimer at a 1 μM concentration was incubated with cells for 1 h at 4 °C. The cells were washed and fixed with 4% PFA for 10 min and then incubated with either primary mouse anti-EGFR and secondary AF568-labeled antibodies or primary rabbit anti-ErbB2 and secondary AF488-labeled antibodies.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Effect on Cell Signaling</h3><div class="NLM_p last">SKBr3 cells were seeded in six-well flat-bottom plates. For EGFR activation, serum-free medium was used to culture the cells for 16 h. EGF (#E9644, Sigma) was reconstituted to 1 mg/mL using 10 mM acetic acid, diluted with 0.1% BSA, and added to SKBr3 cells at a concentration of 100 ng/mL. Lapatinib (CDS022971, Sigma) was diluted to 100 nM in DMSO and PBS from a 1 mg/mL stock solution and then added to the cells incubated with the heterodimer at concentrations of 1, 5, and 20 μM in separate wells. The cells were washed, harvested by RIPA buffer containing protease inhibitors (#11836170001, Roche), and evaluated by Western blot. Anti-EGFR antibody (#2232S), anti-HER2 antibody (#2165), anti-phospho-EGFR sampler kit (#9922s), anti-phospho-HER2/ErbB2 (Tyr1248) antibody (#2247), anti-AKT antibody (#4691P), anti-ERK1/2 antibody (#4695P), anti-phospho-AKT antibody (pS473; #4060P), and anti-phospho-ERK1/2 antibody (#4370P) were used per the manufacturer’s instructions (Cell Signaling, Inc.).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Pharmacokinetics</h3><div class="NLM_p">All experimental procedures were performed in accordance with relevant guidelines and regulations of the University of Michigan, and all animal studies were conducted with approval by the University Committee on the Use and Care of Animals (UCUCA). Animals were housed per the guidelines of the Unit for Laboratory Animal Medicine (ULAM).</div><div class="NLM_p">Female athymic nude mice (002019 Foxn1, Jackson Laboratories) were obtained at 4–5 weeks of age, housed with four animals per cage, and fed sterilized pellet chow and water. Mice were anesthetized in an isoflurane chamber, and OE33 xenograft tumors were generated by subcutaneous injection of ∼5 × 10<sup>7</sup> tumor cells suspended in 100 μL of sterile PBS into the hind-limb flank. Mice were studied at ∼3–4 weeks postinoculation when the tumor volume reached ∼0.5–0.8 cm in size.</div><div class="NLM_p last">We collected fluorescence images in vivo using the Xenogen IVIS 200 small-animal system. The fluorescence intensity was measured and normalized. Mice were anaesthetized using isoflurane, and each was administered a 300 μM concentration of either the targeted or control peptide diluted in 150 μL of PBS via the tail vein. Images were collected prior to peptide injection to assess baseline autofluorescence and at various time points postinjection. Fluorescence images were excited at λ<sub>ex</sub> = 675 nm, and emission was collected at λ<sub>em</sub> = 740 nm with 5 s exposure (<i>f</i>/stop = 8).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Competition</h3><div class="NLM_p last">In vivo heterodimer specificity was assessed by competition with a 3000 μM concentration of the unlabeled peptide monomer or a mixture of the two monomers diluted in 50 μL of PBS injected 20 min beforehand in tumor-bearing mice (<i>n</i> = 3 per group). Images were collected 2 h after heterodimer injection of when peak uptake was expected. The ratios of fluorescence intensity in the tumors were calculated using regions of interest.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Biodistribution</h3><div class="NLM_p last">We evaluated peptide biodistribution in nude mice bearing OE33 xenograft tumors. Mice (<i>n</i> = 6 per group) were injected with either the heterodimer or control at a concentration of 300 μM (150 μL in PBS) and were euthanized 2 h later. Organs were harvested, separated, and imaged ex vivo using the Xenogen IVIS 200 small-animal-imaging system. Fluorescence intensity from each organ was quantified using regions of interest (ROI).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Validation with Human Esophageal Specimens</h3><div class="NLM_p last">Formalin-fixed, paraffin-embedded (FFPE) specimens of human esophagus were obtained from the archived-tissue bank in the Department of Pathology. The tissues were cut into 10 μm sections, deparaffinized, and rehydrated using standard conditions. Two-step acidic and protease-based antigen retrieval was performed. The sections were blocked with protein serum for 10 min at RT, rinsed with PBS, and then incubated with the heterodimer (0.5 μM) for 10 min in dark conditions at RT. The sections were then washed for 3 min with PBS 3× and further incubated sequentially with a 1:200 dilution of EGFR monoclonal antibody (H11, #MA5–13070, Invitrogen) and 1:500 goat anti-mouse-IgG (H+L) AF-568-labeled secondary antibody (#A-11004, Thermo Fisher Scientific) or with a 1:500 dilution of ErbB2 primary antibody (#29D8, rabbit monoclonal antibody #2165S, Cell Signaling Inc.) and 1:1000 goat anti-rabbit-IgG (H+L) AF-488-labeled secondary antibody (#A11008, Life Technologies Corporation). Each antibody was incubated for 1 h at RT. Sections were washed with TBST 3× and mounted with Prolong Gold reagent containing DAPI (Invitrogen) using #1 cover glass (1.5 μm thickness). Confocal fluorescence microscopy was performed using DAPI-, AF488-, AF568-, and Cy5.5-filter sets. Image quantification was performed by placing three boxes with dimensions of 20 × 20 μm<sup>2</sup> completely within cells found in the epithelium. Mean fluorescence intensities were measured using custom Matlab software. Regions of saturated intensities were avoided.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Statistical Analysis</h3><div class="NLM_p last">We fit the fluorescence intensities from the human esophageal specimens according to four histological classifications, squamous (SQ), Barrett’s esophagus (BE), high-grade dysplasia (HGD), and esophageal adenocarcinoma (EAC), and used a unpaired <i>t</i> test and one-way ANOVA. Colocalization of peptide and antibody binding was evaluated using Pearson’s correlation coefficient.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00405" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21416" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21416" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00405" class="ext-link">10.1021/acs.jmedchem.8b00405</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Mass spectrometry analysis, spectral properties, peptide binding on structural models, heterodimer stability, comparison of binding between heterodimer and monomers, colocalization of peptide and antibody binding, heterodimer internalization, immunohistochemistry (IHC), histology (H&E), HPLC spectra, and chemical properties of peptide monomers and heterodimers (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf">jm8b00405_si_001.pdf (3.18 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00405" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81833" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81833" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas D. Wang</span> - <span class="hlFld-Affiliation affiliation">Division
of Gastroenterology, Department of Internal Medicine, 
    Department of Biomedical Engineering, 
    Department of Mechanical
Engineering, 
    , , , , , University of Michigan, Ann Arbor, Michigan 48109, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9182-9620" title="Orcid link">http://orcid.org/0000-0001-9182-9620</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2d594542404c5e5a4c6d5840444e4503484958"><span class="__cf_email__" data-cfemail="7d091512101c0e0a1c3d0810141e1553181908">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Chen</span> - <span class="hlFld-Affiliation affiliation">Division
of Gastroenterology, Department of Internal Medicine, , , , , University of Michigan, Ann Arbor, Michigan 48109, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8863-2843" title="Orcid link">http://orcid.org/0000-0001-8863-2843</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juan Zhou</span> - <span class="hlFld-Affiliation affiliation">Division
of Gastroenterology, Department of Internal Medicine, , , , , University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenghong Gao</span> - <span class="hlFld-Affiliation affiliation">Division
of Gastroenterology, Department of Internal Medicine, , , , , University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xue Li</span> - <span class="hlFld-Affiliation affiliation">Division
of Gastroenterology, Department of Internal Medicine, , , , , University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fa Wang</span> - <span class="hlFld-Affiliation affiliation">Division
of Gastroenterology, Department of Internal Medicine, , , , , University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiyu Duan</span> - <span class="hlFld-Affiliation affiliation">Department of Biomedical Engineering, , , , , University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gaoming Li</span> - <span class="hlFld-Affiliation affiliation">Department of Biomedical Engineering, , , , , University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bishnu P. Joshi</span> - <span class="hlFld-Affiliation affiliation">Division
of Gastroenterology, Department of Internal Medicine, , , , , University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rork Kuick</span> - <span class="hlFld-Affiliation affiliation">Cancer Center, , , , , University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Henry D. Appelman</span> - <span class="hlFld-Affiliation affiliation">Department of Pathology, , , , , University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>J.C. and T.D.W. conceived and designed the experiments; J.C., J.Z., X.L., F.W., and Z.G. performed the experiments; J.C., Z.G., X.D., and G.L. contributed to image-analysis tools; H.D.A. reviewed pathology; R.K. performed statistical analysis; and J.C. and T.D.W. wrote the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27732" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27732" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Funding was provided in part by NIH U54 CA163059 and U01 CA189291 (to T.D.W.) and P30 CA046592 (to R.K.).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AFI</td><td class="NLM_def"><p class="first last">autofluorescence imaging</p></td></tr><tr><td class="NLM_term">BE</td><td class="NLM_def"><p class="first last">Barrett’s esophagus</p></td></tr><tr><td class="NLM_term">EAC</td><td class="NLM_def"><p class="first last">esophageal adenocarcinoma</p></td></tr><tr><td class="NLM_term">EGF</td><td class="NLM_def"><p class="first last">epidermal growth factor</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal-growth-factor receptor</p></td></tr><tr><td class="NLM_term">EMR</td><td class="NLM_def"><p class="first last">endoscopic mucosal resection</p></td></tr><tr><td class="NLM_term">ErbB2</td><td class="NLM_def"><p class="first last">epidermal-growth-factor receptor 2</p></td></tr><tr><td class="NLM_term">FFPE</td><td class="NLM_def"><p class="first last">formalin-fixed, paraffin-embedded</p></td></tr><tr><td class="NLM_term">HGD</td><td class="NLM_def"><p class="first last">high-grade dysplasia</p></td></tr><tr><td class="NLM_term">NBI</td><td class="NLM_def"><p class="first last">narrow-band imaging</p></td></tr><tr><td class="NLM_term">NIR</td><td class="NLM_def"><p class="first last">near-infrared</p></td></tr><tr><td class="NLM_term">RFA</td><td class="NLM_def"><p class="first last">radio-frequency ablation</p></td></tr><tr><td class="NLM_term">ROI</td><td class="NLM_def"><p class="first last">regions of interest</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">T/B</td><td class="NLM_def"><p class="first last">target-to-background ratio</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01176" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01176" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 40 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torre, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Global cancer incidence and mortality rates and trends—an update</span>. <i>Cancer Epidemiol., Biomarkers Prev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1158/1055-9965.EPI-15-0578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1158%2F1055-9965.EPI-15-0578" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=16-27&author=L.+A.+Torreauthor=R.+L.+Siegelauthor=E.+M.+Wardauthor=A.+Jemal&title=Global+cancer+incidence+and+mortality+rates+and+trends%E2%80%94an+update&doi=10.1158%2F1055-9965.EPI-15-0578"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1158%2F1055-9965.EPI-15-0578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1055-9965.EPI-15-0578%26sid%3Dliteratum%253Aachs%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DWard%26aufirst%3DE.%2BM.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520cancer%2520incidence%2520and%2520mortality%2520rates%2520and%2520trends%25E2%2580%2594an%2520update%26jtitle%3DCancer%2520Epidemiol.%252C%2520Biomarkers%2520Prev.%26date%3D2016%26volume%3D25%26spage%3D16%26epage%3D27%26doi%3D10.1158%2F1055-9965.EPI-15-0578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spechler, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, R. F.</span></span> <span> </span><span class="NLM_article-title">Barrett’s esophagus</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">836</span>– <span class="NLM_lpage">845</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1314704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1056%2FNEJMra1314704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=25162890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12jtLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=836-845&author=S.+J.+Spechlerauthor=R.+F.+Souza&title=Barrett%E2%80%99s+esophagus&doi=10.1056%2FNEJMra1314704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Barrett's esophagus</span></div><div class="casAuthors">Spechler, Stuart J.; Souza, Rhonda F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">836-845, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGronTSVJJPJlbVg90H21EOLACvtfcHk0lisxRC-AgIBfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12jtLbN&md5=124a4595410a69ef7c81fcf27ce7b193</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1314704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1314704%26sid%3Dliteratum%253Aachs%26aulast%3DSpechler%26aufirst%3DS.%2BJ.%26aulast%3DSouza%26aufirst%3DR.%2BF.%26atitle%3DBarrett%25E2%2580%2599s%2520esophagus%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D836%26epage%3D845%26doi%3D10.1056%2FNEJMra1314704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levine, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggitt, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blount, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, B. J.</span></span> <span> </span><span class="NLM_article-title">An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’s esophagus</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/0016-5085(93)90008-Z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1016%2F0016-5085%2893%2990008-Z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=1993&pages=40-50&author=D.+S.+Levineauthor=R.+C.+Haggittauthor=P.+L.+Blountauthor=P.+S.+Rabinovitchauthor=V.+W.+Ruschauthor=B.+J.+Reid&title=An+endoscopic+biopsy+protocol+can+differentiate+high-grade+dysplasia+from+early+adenocarcinoma+in+Barrett%E2%80%99s+esophagus&doi=10.1016%2F0016-5085%2893%2990008-Z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2F0016-5085%2893%2990008-Z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0016-5085%252893%252990008-Z%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DD.%2BS.%26aulast%3DHaggitt%26aufirst%3DR.%2BC.%26aulast%3DBlount%26aufirst%3DP.%2BL.%26aulast%3DRabinovitch%26aufirst%3DP.%2BS.%26aulast%3DRusch%26aufirst%3DV.%2BW.%26aulast%3DReid%26aufirst%3DB.%2BJ.%26atitle%3DAn%2520endoscopic%2520biopsy%2520protocol%2520can%2520differentiate%2520high-grade%2520dysplasia%2520from%2520early%2520adenocarcinoma%2520in%2520Barrett%25E2%2580%2599s%2520esophagus%26jtitle%3DGastroenterology%26date%3D1993%26volume%3D105%26spage%3D40%26epage%3D50%26doi%3D10.1016%2F0016-5085%2893%2990008-Z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lekakos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karidis, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitroulis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsigris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouraklis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiteas, N.</span></span> <span> </span><span class="NLM_article-title">Barrett’s esophagus with high-grade dysplasia: focus on current treatment options</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">4174</span>, <span class="refDoi"> DOI: 10.3748/wjg.v17.i37.4174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.3748%2Fwjg.v17.i37.4174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=22072848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A280%3ADC%252BC3MbotlOltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=4174&author=L.+Lekakosauthor=N.+P.+Karidisauthor=D.+Dimitroulisauthor=C.+Tsigrisauthor=G.+Kouraklisauthor=N.+Nikiteas&title=Barrett%E2%80%99s+esophagus+with+high-grade+dysplasia%3A+focus+on+current+treatment+options&doi=10.3748%2Fwjg.v17.i37.4174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Barrett's esophagus with high-grade dysplasia: focus on current treatment options</span></div><div class="casAuthors">Lekakos Leonidas; Karidis Nikolaos P; Dimitroulis Dimitrios; Tsigris Christos; Kouraklis Gregory; Nikiteas Nikolaos</div><div class="citationInfo"><span class="NLM_cas:title">World journal of gastroenterology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">4174-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">High-grade dysplasia (HGD) in Barrett's esophagus (BE) is the critical step before invasive esophageal adenocarcinoma.  Although its natural history remains unclear, an aggressive therapeutic approach is usually indicated.  Esophagectomy represents the only treatment able to reliably eradicate the neoplastic epithelium.  In healthy patients with reasonable life expectancy, vagal-sparing esophagectomy, with associated low mortality and low early and late postoperative morbidity, is considered the treatment of choice for BE with HGD.  Patients unfit for surgery should be managed in a less aggressive manner, using endoscopic ablation or endoscopic mucosal resection of the entire BE segment, followed by lifelong surveillance.  Patients eligible for surgery who present with a long BE segment, multifocal dysplastic lesions, severe reflux symptoms, a large fixed hiatal hernia or dysphagia comprise a challenging group with regard to the appropriate treatment, either surgical or endoscopic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNbjar9RT4pDMsgLhIoICsfW6udTcc2eakOP3jAqP927ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbotlOltA%253D%253D&md5=cf552aa08a496f6c2c91cd8dd25795c8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v17.i37.4174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v17.i37.4174%26sid%3Dliteratum%253Aachs%26aulast%3DLekakos%26aufirst%3DL.%26aulast%3DKaridis%26aufirst%3DN.%2BP.%26aulast%3DDimitroulis%26aufirst%3DD.%26aulast%3DTsigris%26aufirst%3DC.%26aulast%3DKouraklis%26aufirst%3DG.%26aulast%3DNikiteas%26aufirst%3DN.%26atitle%3DBarrett%25E2%2580%2599s%2520esophagus%2520with%2520high-grade%2520dysplasia%253A%2520focus%2520on%2520current%2520treatment%2520options%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2011%26volume%3D17%26spage%3D4174%26doi%3D10.3748%2Fwjg.v17.i37.4174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaheen, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerson, L. B.</span></span> <span> </span><span class="NLM_article-title">ACG clinical guideline: diagnosis and management of Barrett’s esophagus</span>. <i>Am. J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/ajg.2015.322</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1038%2Fajg.2015.322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=26526079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Cmt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=30-50&author=N.+J.+Shaheenauthor=G.+W.+Falkauthor=P.+G.+Iyerauthor=L.+B.+Gerson&title=ACG+clinical+guideline%3A+diagnosis+and+management+of+Barrett%E2%80%99s+esophagus&doi=10.1038%2Fajg.2015.322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus</span></div><div class="casAuthors">Shaheen, Nicholas J.; Falk, Gary W.; Iyer, Prasad G.; Gerson, Lauren B.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-50</span>CODEN:
                <span class="NLM_cas:coden">AJGAAR</span>;
        ISSN:<span class="NLM_cas:issn">0002-9270</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Barrett's esophagus (BE) is among the most common conditions encountered by the gastroenterologist.  In this document, the American College of Gastroenterol. updates its guidance for the best practices in caring for these patients.  These guidelines continue to endorse screening of high-risk patients for BE; however, routine screening is limited to men with reflux symptoms and multiple other risk factors.  Acknowledging recent data on the low risk of malignant progression in patients with nondysplastic BE, endoscopic surveillance intervals are attenuated in this population; patients with nondysplastic BE should undergo endoscopic surveillance no more frequently than every 3-5 years.  Neither routine use of biomarker panels nor advanced endoscopic imaging techniques (beyond high-definition endoscopy) is recommended at this time.  Endoscopic ablative therapy is recommended for patients with BE and high-grade dysplasia, as well as T1a esophageal adenocarcinoma.  Based on recent level 1 evidence, endoscopic ablative therapy is also recommended for patients with BE and low-grade dysplasia, although endoscopic surveillance continues to be an acceptable alternative.  Given the relatively common recurrence of BE after ablation, we suggest postablation endoscopic surveillance intervals.  Although many of the recommendations provided are based on weak evidence or expert opinion, this document provides a pragmatic framework for the care of the patient with BE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTxL2_G9NEVrVg90H21EOLACvtfcHk0lh28GSzftJ7Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Cmt7Y%253D&md5=e3117fc652ebd9988d8c5a64b36c2424</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fajg.2015.322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fajg.2015.322%26sid%3Dliteratum%253Aachs%26aulast%3DShaheen%26aufirst%3DN.%2BJ.%26aulast%3DFalk%26aufirst%3DG.%2BW.%26aulast%3DIyer%26aufirst%3DP.%2BG.%26aulast%3DGerson%26aufirst%3DL.%2BB.%26atitle%3DACG%2520clinical%2520guideline%253A%2520diagnosis%2520and%2520management%2520of%2520Barrett%25E2%2580%2599s%2520esophagus%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2016%26volume%3D111%26spage%3D30%26epage%3D50%26doi%3D10.1038%2Fajg.2015.322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, J. A.</span></span> <span> </span><span class="NLM_article-title">Chemoprevention of esophageal adenocarcinoma</span>. <i>Ther. Adv. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1177/1756283X08093568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1177%2F1756283X08093568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=21180511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FmvVOnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2008&pages=7-18&author=J.+A.+Abrams&title=Chemoprevention+of+esophageal+adenocarcinoma&doi=10.1177%2F1756283X08093568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoprevention of esophageal adenocarcinoma</span></div><div class="casAuthors">Abrams Julian A</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic advances in gastroenterology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-18</span>
        ISSN:<span class="NLM_cas:issn">1756-283X</span>.
    </div><div class="casAbstract">The incidence of esophageal adenocarcinoma (EAC) is rising rapidly in Western countries, and effective chemoprevention for this malignancy is lacking.  Endoscopic surveillance of patients with Barrett's esophagus is currently employed to diagnose EAC at earlier stages, but this strategy has several limitations.  Non-steroidal anti-inflammatory drugs and proton pump inhibitors are the most promising agents for prevention of EAC, and a randomized controlled trial of aspirin and esomeprazole is ongoing.  Other agents under investigation include green tea, berries, and antioxidants.  Cost-effectiveness analyses have shown that chemopreventive agents need to be highly effective at preventing EAC in order to have benefit beyond endoscopic surveillance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4gQmIkMU1A-2mnZh2OgS0fW6udTcc2eZL-pQmOLKJd7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FmvVOnsA%253D%253D&md5=cbb911f99ec887331baf8477256efcca</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1177%2F1756283X08093568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1756283X08093568%26sid%3Dliteratum%253Aachs%26aulast%3DAbrams%26aufirst%3DJ.%2BA.%26atitle%3DChemoprevention%2520of%2520esophageal%2520adenocarcinoma%26jtitle%3DTher.%2520Adv.%2520Gastroenterol.%26date%3D2008%26volume%3D1%26spage%3D7%26epage%3D18%26doi%3D10.1177%2F1756283X08093568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dulak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lieshout, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saksena, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baca, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">4383</span>– <span class="NLM_lpage">4393</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1158%2F0008-5472.CAN-11-3893" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=4383-4393&author=A.+M.+Dulakauthor=S.+E.+Schumacherauthor=J.+van+Lieshoutauthor=Y.+Imamuraauthor=C.+Foxauthor=B.+Shimauthor=A.+H.+Ramosauthor=G.+Saksenaauthor=S.+C.+Bacaauthor=J.+Baselga&title=Gastrointestinal+adenocarcinomas+of+the+esophagus%2C+stomach%2C+and+colon+exhibit+distinct+patterns+of+genome+instability+and+oncogenesis&doi=10.1158%2F0008-5472.CAN-11-3893"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3893%26sid%3Dliteratum%253Aachs%26aulast%3DDulak%26aufirst%3DA.%2BM.%26aulast%3DSchumacher%26aufirst%3DS.%2BE.%26aulast%3Dvan%2BLieshout%26aufirst%3DJ.%26aulast%3DImamura%26aufirst%3DY.%26aulast%3DFox%26aufirst%3DC.%26aulast%3DShim%26aufirst%3DB.%26aulast%3DRamos%26aufirst%3DA.%2BH.%26aulast%3DSaksena%26aufirst%3DG.%26aulast%3DBaca%26aufirst%3DS.%2BC.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DGastrointestinal%2520adenocarcinomas%2520of%2520the%2520esophagus%252C%2520stomach%252C%2520and%2520colon%2520exhibit%2520distinct%2520patterns%2520of%2520genome%2520instability%2520and%2520oncogenesis%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D4383%26epage%3D4393%26doi%3D10.1158%2F0008-5472.CAN-11-3893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAdam, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danikas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tselepis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, G.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett’s esophagus (BE)</span>. <i>Am. J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1038/ajg.2010.433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1038%2Fajg.2010.433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=21157443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVKitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2011&pages=46-56&author=J.+Croninauthor=E.+McAdamauthor=A.+Danikasauthor=C.+Tselepisauthor=P.+Griffithsauthor=J.+Baxterauthor=L.+Thomasauthor=J.+Mansonauthor=G.+Jenkins&title=Epidermal+growth+factor+receptor+%28EGFR%29+is+overexpressed+in+high-grade+dysplasia+and+adenocarcinoma+of+the+esophagus+and+may+represent+a+biomarker+of+histological+progression+in+Barrett%E2%80%99s+esophagus+%28BE%29&doi=10.1038%2Fajg.2010.433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in High-Grade Dysplasia and Adenocarcinoma of the Esophagus and May Represent a Biomarker of Histological Progression in Barrett's Esophagus (BE)</span></div><div class="casAuthors">Cronin, James; McAdam, Elizabeth; Danikas, Antonios; Tselepis, Chris; Griffiths, Paul; Baxter, John; Thomas, Linzi; Manson, James; Jenkins, Gareth</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-56</span>CODEN:
                <span class="NLM_cas:coden">AJGAAR</span>;
        ISSN:<span class="NLM_cas:issn">0002-9270</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Objectives: The assessment of cancer risk in patients with Barrett's esophagus (BE) is currently fraught with difficulty.  The current gold std. method of assessing cancer risk is histol. assessment, with the appearance of high-grade dysplasia (HGD) as the key event monitored.  Sampling error during endoscopy limits the usefulness of this approach, and there has been much recent interest in supplementing histol. assessment with mol. markers, which may aid in patient stratification.  Methods: No mol. marker has been yet validated to accurately correlate with esophageal histol. progression.  Here, we assessed the suitability of several membranous proteins as biomarkers by correlating their abundance with histol. progression.  In all, 107 patient samples, from 100 patients, were arranged on a tissue microarray (TMA) and represented the various stages of histol. progression in BE.  This TMA was probed with antibodies for eight receptor proteins (mostly membranous).  Results: Epidermal growth factor receptor (EGFR) staining was found to be the most promising biomarker identified with clear increases in staining accompanying histol. progression.  Further, immunohistochem. was performed using the full-tissue sections from BE, HGD, and adenocarcinoma tissues, which confirmed the stepwise increase in EGFR abundance.  Using a robust H-score anal., EGFR abundance was shown to increase 13-fold in the adenocarcinoma tissues compared to the BE tissues.  EGFR was "overexpressed" in 35% of HGD specimens and 80% of adenocarcinoma specimens when using the H-score of the BE patients (plus 3 s.d.) as the threshold to define overexpression.  EGFR staining was also noted to be higher in BE tissues adjacent to HGD/adenocarcinoma.  Western blotting, although showing more EGFR protein in the adenocarcinomas compared to the BE tissue, was highly variable.  EGFR overexpression was accompanied by aneuploidy (gain) of chromosome 7, plus amplification of the EGFR locus.  Finally, the bile acid deoxycholic acid (DCA) (at neutral and acidic pH) and acid alone was capable of upregulating EGFR mRNA in vitro, and in the case of neutral pH DCA, this was NF-κB dependent.  Conclusions: EGFR is overexpressed during the histol. progression in BE tissues and hence may be useful as a biomarker of histol. progression.  Furthermore, as EGFR is a membranous protein expressed on the luminal surface of the esophageal mucosa, it may also be a useful target for biopsy guidance during endoscopy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1ixl-JgkXuLVg90H21EOLACvtfcHk0lh28GSzftJ7Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVKitQ%253D%253D&md5=0b11a2f2b16a57005f64dc04736915f7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fajg.2010.433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fajg.2010.433%26sid%3Dliteratum%253Aachs%26aulast%3DCronin%26aufirst%3DJ.%26aulast%3DMcAdam%26aufirst%3DE.%26aulast%3DDanikas%26aufirst%3DA.%26aulast%3DTselepis%26aufirst%3DC.%26aulast%3DGriffiths%26aufirst%3DP.%26aulast%3DBaxter%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3DManson%26aufirst%3DJ.%26aulast%3DJenkins%26aufirst%3DG.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520is%2520overexpressed%2520in%2520high-grade%2520dysplasia%2520and%2520adenocarcinoma%2520of%2520the%2520esophagus%2520and%2520may%2520represent%2520a%2520biomarker%2520of%2520histological%2520progression%2520in%2520Barrett%25E2%2580%2599s%2520esophagus%2520%2528BE%2529%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2011%26volume%3D106%26spage%3D46%26epage%3D56%26doi%3D10.1038%2Fajg.2010.433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratzke, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddaus, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrin, L. J.</span></span> <span> </span><span class="NLM_article-title">ERBB2 amplifications in esophageal adenocarcinoma</span>. <i>Ann. Thorac. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1790</span>– <span class="NLM_lpage">1800</span>, <span class="refDoi"> DOI: 10.1016/j.athoracsur.2004.05.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1016%2Fj.athoracsur.2004.05.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=15511476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A280%3ADC%252BD2crks1Sitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=1790-1800&author=P.+S.+Dahlbergauthor=B.+A.+Jacobsonauthor=G.+Dahalauthor=J.+M.+Finkauthor=R.+A.+Kratzkeauthor=M.+A.+Maddausauthor=L.+J.+Ferrin&title=ERBB2+amplifications+in+esophageal+adenocarcinoma&doi=10.1016%2Fj.athoracsur.2004.05.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB2 amplifications in esophageal adenocarcinoma</span></div><div class="casAuthors">Dahlberg Peter S; Jacobson Blake A; Dahal Ganesh; Fink James M; Kratzke Robert A; Maddaus Michael A; Ferrin Lance J</div><div class="citationInfo"><span class="NLM_cas:title">The Annals of thoracic surgery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1790-800</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, Her-2-neu) gene amplification and overexpression has been reported in several types of cancer.  The purpose of this study was to (1) determine the frequency of ERBB2 amplification (in comparison to other proto-oncogenes) in tumors from patients with esophageal adenocarcinoma, (2) characterize structural details of an ERBB2 amplicon in the esophageal adenocarcinoma cell line OE19 (contains a 100-fold ERBB2 amplification), and (3) test whether growth of the OE19 cell line is sensitive to the ERBB2 inhibitor trastuzumab (Herceptin; Genetech, Inc, San Francisco, CA).  METHODS:  First, we determined the frequency, by Southern blotting techniques, of amplification of ERBB2 and 13 other proto-oncogenes in a panel of 25 esophageal adenocarcinoma tumors.  Then, in a second panel of 10 tumor specimens, expression levels of the ERBB2 gene and of several other genes that flank ERBB2 on chromosome 17 were determined by microarray analysis.  Next we characterized the ERBB2 amplicon in the esophageal adenocarcinoma cell line OE19 using cytogenetic methods and a Rec-A protein assisted restriction endonuclease mapping technique.  Finally, an in vitro growth inhibition assay was used to measure the sensitivity of OE19 and OE33 cells to treatment with trastuzumab (humanized antibody to ERBB2).  RESULTS:  ERBB2 was the most frequently amplified proto-oncogene among 25 esophageal adenocarcinoma tumors tested (greater than 10-fold amplification in 3 of 25 (12%) tumors tested).  The OE19 cell line contains a 100-fold amplification of the ERBB2 gene, and highly expresses its messenger ribonucleic acid.  Transcripts from genes that flank ERBB2 including GRB7, a protein linked to metastasis in esophageal cancer, also showed high levels of expression.  In OE19 cells, the ERBB2 amplicon was localized to a homogeneously staining region of chromosome 14.  Southern blots from the Rec-A protein assisted restriction endonuclease cleavage mapping experiments in OE19 showed a strong band of 210 kilobases in size, demonstrating that the main amplicon was a tandem repeat.  In the in vitro growth inhibition assay, trastuzumab inhibited the OE19 and OE33 cells growth by 49% and 20%, respectively, at a saturating concentration of 20 microg/mL.  CONCLUSIONS:  ERBB2 is the most frequently amplified proto-oncogene in esophageal adenocarcinoma among the genes that we tested.  In the OE19 esophageal adenocarcinoma cell line, the ERBB2 amplicon is translocated onto chromosome 14, is amplified 100-fold at the deoxyribonucleic acid level, and is highly overexpressed at the messenger ribonucleic acid level.  Finally, the growth of this cell line was inhibited by incubation with trastuzumab.  These results demonstrate that a substantial number of esophageal adenocarcinomas have amplified copies of the ERBB2 gene, and that they may be responsive to ERBB2 targeted therapies such as trastuzumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfmkLzcsXZvdyzdcP07UmufW6udTcc2eaMcLSTkgJtsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crks1Sitg%253D%253D&md5=32fb182bab6d577d127691f1de55e868</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.athoracsur.2004.05.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.athoracsur.2004.05.037%26sid%3Dliteratum%253Aachs%26aulast%3DDahlberg%26aufirst%3DP.%2BS.%26aulast%3DJacobson%26aufirst%3DB.%2BA.%26aulast%3DDahal%26aufirst%3DG.%26aulast%3DFink%26aufirst%3DJ.%2BM.%26aulast%3DKratzke%26aufirst%3DR.%2BA.%26aulast%3DMaddaus%26aufirst%3DM.%2BA.%26aulast%3DFerrin%26aufirst%3DL.%2BJ.%26atitle%3DERBB2%2520amplifications%2520in%2520esophageal%2520adenocarcinoma%26jtitle%3DAnn.%2520Thorac.%2520Surg.%26date%3D2004%26volume%3D78%26spage%3D1790%26epage%3D1800%26doi%3D10.1016%2Fj.athoracsur.2004.05.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Citri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span> <span> </span><span class="NLM_article-title">EGF–ERBB signalling: towards the systems level</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1038/nrm1962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1038%2Fnrm1962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=16829981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1OhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=505-516&author=A.+Citriauthor=Y.+Yarden&title=EGF%E2%80%93ERBB+signalling%3A+towards+the+systems+level&doi=10.1038%2Fnrm1962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">EGF-ERBB signaling: towards the systems level</span></div><div class="casAuthors">Citri, Ami; Yarden, Yosef</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">505-516</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Signaling through the ErbB/HER receptors is intricately involved in human cancer and already serves as a target for several cancer drugs.  Because of its inherent complexity, it is useful to envision ErbB signaling as a bow-tie-configured, evolvable network, which shares modularity, redundancy, and control circuits with robust biol. and engineered systems.  Because network fragility is an inevitable trade-off of robustness, systems-level understanding is expected to generate therapeutic opportunities to intercept aberrant network activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSSvt-HLGFXLVg90H21EOLACvtfcHk0liG4u2QbgkAag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1OhsLc%253D&md5=0d41fd52d0498765a16b422d66398037</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrm1962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1962%26sid%3Dliteratum%253Aachs%26aulast%3DCitri%26aufirst%3DA.%26aulast%3DYarden%26aufirst%3DY.%26atitle%3DEGF%25E2%2580%2593ERBB%2520signalling%253A%2520towards%2520the%2520systems%2520level%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2006%26volume%3D7%26spage%3D505%26epage%3D516%26doi%3D10.1038%2Fnrm1962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, A.
L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’donovan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provenzano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McManus, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovat, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, R. C.</span></span> <span> </span><span class="NLM_article-title">Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>230</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1002/path.4044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1002%2Fpath.4044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=22733579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVektb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=230&publication_year=2013&pages=118-128&author=A.%0AL.+Patersonauthor=M.+O%E2%80%99donovanauthor=E.+Provenzanoauthor=L.+J.+Murrayauthor=H.+G.+Colemanauthor=B.+T.+Johnsonauthor=D.+T.+McManusauthor=M.+Novelliauthor=L.+B.+Lovatauthor=R.+C.+Fitzgerald&title=Characterization+of+the+timing+and+prevalence+of+receptor+tyrosine+kinase+expression+changes+in+oesophageal+carcinogenesis&doi=10.1002%2Fpath.4044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis</span></div><div class="casAuthors">Paterson, Anna L.; O'Donovan, Maria; Provenzano, Elena; Murray, Liam J.; Coleman, Helen G.; Johnson, Brian T.; McManus, Damian T.; Novelli, Marco; Lovat, Laurence B.; Fitzgerald, Rebecca C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">230</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">118-128</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Despite being common in epithelial malignancies, the timing of receptor tyrosine kinase (RTK) up-regulation is poorly understood and therefore hampers the identification of the receptor to target for effective treatment.  We aimed to det. if RTK expression changes were early events in carcinogenesis.  Oesophageal adenocarcinoma and its pre-invasive lesion, Barrett's esophagus, were used for immunohistochem. anal. of the RTK panel, EGFR, ErbB2, ErbB3, Met, and FGFR2, by utilizing a cohort of patients with invasive disease (n = 367) and two cohorts with pre-invasive disease, one cross-sectional (n = 110) and one longitudinal in time (n = 91).  The results demonstrated that 51% of esophageal adenocarcinomas overexpressed at least one of the RTK panel, with 21% of these overexpressing multiple receptors.  Up-regulation of RTK expression was an early event corresponding with low-grade dysplasia development (25% in areas without dysplasia vs. 63% in low-grade dysplasia, p < 0.001).  There was a trend for an increase in the prevalence of concomitant overexpression of multiple receptors as intestinal metaplasia progressed to low-grade dysplasia, 7% vs. 10%; and from low-grade dysplasia to high-grade dysplasia, 10% vs. 19% (p = 0.06 and 0.24, resp.).  The timing of receptor up-regulation varied; FGFR, ErbB2, and Met overexpression occurred as dysplasia first developed, while EGFR overexpression was predominately seen in invasive disease and ErbB3 overexpression was uniformly rare.  We provide evidence for a frequent and early role for multiple different RTKs in esophageal carcinogenesis.  Given the early timing of receptor deregulation, inhibiting RTKs in pre-invasive disease may also represent a novel and effective chemopreventive strategy.  Copyright © 2012 Pathol. Society of Great Britain and Ireland.  Published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7OUn3UOb2ubVg90H21EOLACvtfcHk0ljZpYu4l1eUAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVektb8%253D&md5=c8f98db6cc760c49eae45eb546462c3f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fpath.4044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.4044%26sid%3Dliteratum%253Aachs%26aulast%3DPaterson%26aufirst%3DA.%2BL.%26aulast%3DO%25E2%2580%2599donovan%26aufirst%3DM.%26aulast%3DProvenzano%26aufirst%3DE.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26aulast%3DColeman%26aufirst%3DH.%2BG.%26aulast%3DJohnson%26aufirst%3DB.%2BT.%26aulast%3DMcManus%26aufirst%3DD.%2BT.%26aulast%3DNovelli%26aufirst%3DM.%26aulast%3DLovat%26aufirst%3DL.%2BB.%26aulast%3DFitzgerald%26aufirst%3DR.%2BC.%26atitle%3DCharacterization%2520of%2520the%2520timing%2520and%2520prevalence%2520of%2520receptor%2520tyrosine%2520kinase%2520expression%2520changes%2520in%2520oesophageal%2520carcinogenesis%26jtitle%3DJ.%2520Pathol.%26date%3D2013%26volume%3D230%26spage%3D118%26epage%3D128%26doi%3D10.1002%2Fpath.4044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schipper, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normolle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannettoni, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orringer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, D. G.</span></span> <span> </span><span class="NLM_article-title">Gene amplification in esophageal adenocarcinomas and Barrett’s with high-grade dysplasia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4819</span>– <span class="NLM_lpage">4825</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=14581353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVGjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=4819-4825&author=C.+T.+Millerauthor=J.+R.+Moyauthor=L.+Linauthor=M.+Schipperauthor=D.+Normolleauthor=D.+E.+Brennerauthor=M.+D.+Iannettoniauthor=M.+B.+Orringerauthor=D.+G.+Beer&title=Gene+amplification+in+esophageal+adenocarcinomas+and+Barrett%E2%80%99s+with+high-grade+dysplasia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Gene Amplification in Esophageal Adenocarcinomas and Barrett's with High-Grade Dysplasia</span></div><div class="casAuthors">Miller, Charles T.; Moy, Justin R.; Lin, Lin; Schipper, Matthew; Normolle, Daniel; Brenner, Dean E.; Iannettoni, Mark D.; Orringer, Mark B.; Beer, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4819-4825</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The purpose of this study was to det. the frequency and overall contribution of specific gene amplification events in the formation of Barrett's adenocarcinomas.  The relationship of gene amplification to clin.-pathol. variables and its potential usefulness as a marker for early cancer detection were also examd.  The authors used quant. PCR and Southern blot anal. to screen 87 cases of Barrett's adenocarcinoma for the presence or absence of 13 distinct gene amplification events.  Gene amplification was then examd. for correlation with other amplification events and clin. variables (survival, stage, nodal involvement, tumor invasion, smoking history, and gender).  Addnl., 22 specimens of Barrett's with high-grade dysplasia (HGD) were examd. for the presence of gene amplification.  One or more amplification events were present in 50 of 87 (57%) adenocarcinomas.  The ERBB2 gene was amplified in 19 of 87 (21.8%), CCNE1 in 11 of 87 (12.6%), GATA4 in 9 of 87 (10.3%), KRAS in 9 of 87 (10.3%), EGFR in 7 of 87 (8.0%), CCND1 in 6 of 87 (6.8%), HNF3α in 5 of 87 (5.7%), PIK3CA in 5 of 87 (5.7%), C-MYC in 4 of 87 (4.6%), DYRK2 in 2 of 87 (2.3%), and AIB1, AKT1, and IGF1R were amplified in 0 of 87 (0%) of the tumors.  CCND1 amplification was found to correlate neg. with survival (P < 0.05).  In addn., the ERBB2 amplicon pos. correlated (P < 0.05) with GATA4 amplification.  Increased copy no. of the ERBB2 (1 of 22), GATA4 (1 of 22), KRAS (2 of 22), C-MYC (1 of 22), CCNE1 (2 of 22), and CCND1 (2 of 22) genes was also obsd. in one or more Barrett's adenocarcinomas with HGD.  The high frequency of gene amplification in esophageal adenocarcinomas and HGD indicates the important role of these events in esophageal adenocarcinoma development.  Addnl., these results underscore the possible usefulness of early detection approaches and chemotherapeutic strategies (ErbB2 and cyclin D1) targeted against amplified gene products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLaCLtPpj7_bVg90H21EOLACvtfcHk0ljZpYu4l1eUAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVGjtr0%253D&md5=1490e308399c9bbb6b2e047d188d2a51</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DC.%2BT.%26aulast%3DMoy%26aufirst%3DJ.%2BR.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DSchipper%26aufirst%3DM.%26aulast%3DNormolle%26aufirst%3DD.%26aulast%3DBrenner%26aufirst%3DD.%2BE.%26aulast%3DIannettoni%26aufirst%3DM.%2BD.%26aulast%3DOrringer%26aufirst%3DM.%2BB.%26aulast%3DBeer%26aufirst%3DD.%2BG.%26atitle%3DGene%2520amplification%2520in%2520esophageal%2520adenocarcinomas%2520and%2520Barrett%25E2%2580%2599s%2520with%2520high-grade%2520dysplasia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D4819%26epage%3D4825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesides, G. M.</span></span> <span> </span><span class="NLM_article-title">A trivalent system from vancomycin·d-Ala-d-Ala with higher affinity than avidin biotin</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">711</span>, <span class="refDoi"> DOI: 10.1126/science.280.5364.708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1126%2Fscience.280.5364.708" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=1998&pages=708-711&author=J.+Raoauthor=J.+Lahiriauthor=L.+Isaacsauthor=R.+M.+Weisauthor=G.+M.+Whitesides&title=A+trivalent+system+from+vancomycin%C2%B7d-Ala-d-Ala+with+higher+affinity+than+avidin+biotin&doi=10.1126%2Fscience.280.5364.708"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.280.5364.708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.280.5364.708%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DJ.%26aulast%3DLahiri%26aufirst%3DJ.%26aulast%3DIsaacs%26aufirst%3DL.%26aulast%3DWeis%26aufirst%3DR.%2BM.%26aulast%3DWhitesides%26aufirst%3DG.%2BM.%26atitle%3DA%2520trivalent%2520system%2520from%2520vancomycin%25C2%25B7d-Ala-d-Ala%2520with%2520higher%2520affinity%2520than%2520avidin%2520biotin%26jtitle%3DScience%26date%3D1998%26volume%3D280%26spage%3D708%26epage%3D711%26doi%3D10.1126%2Fscience.280.5364.708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Handl, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mash, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, R. J.</span></span> <span> </span><span class="NLM_article-title">Hitting multiple targets with multimeric ligands</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1517/14728222.8.6.565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1517%2F14728222.8.6.565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=15584863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1eisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2004&pages=565-586&author=H.+L.+Handlauthor=J.+Vagnerauthor=H.+Hanauthor=E.+Mashauthor=V.+J.+Hrubyauthor=R.+J.+Gillies&title=Hitting+multiple+targets+with+multimeric+ligands&doi=10.1517%2F14728222.8.6.565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Hitting multiple targets with multimeric ligands</span></div><div class="casAuthors">Handl, Heather L.; Vagner, Josef; Han, Haiyong; Mash, Eugene; Hruby, Victor J.; Gillies, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">565-586</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Multimeric ligands consist of multiple monomeric ligands attached to a single backbone mol., creating a multimer that can bind to multiple receptors or targets simultaneously.  Numerous examples of multimeric binding exist within nature.  Due to the multiple and simultaneous binding events, multimeric ligands bind with an increased affinity compared to their corresponding monomers.  Multimeric ligands may provide opportunities in the field of drug discovery by providing enhanced selectivity and affinity of binding interactions, thus providing mol.-based targeted therapies.  However, gaps in our knowledge currently exist regarding the quant. measures for important design characteristics, such as flexibility, length and orientation of the inter-ligand linkers, receptor d. and ligand sequence.  In this review, multimeric ligand binding in two sep. phases is examd.  The prerecruitment phase describes the binding of one ligand of a multimer to its corresponding receptor, an event similar to monomeric ligand binding.  This results in transient increases in the local concn. of the other ligands, leading to apparent cooperativity.  The postrecruitment phase only occurs once all receptors have been aligned and bound by their corresponding ligand.  This phase is analogous to DNA-DNA interactions in that the stability of the complex is derived from phys. orientation.  Multiple factors influence the kinetics and thermodn. of multimeric binding, and these are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7NOkX9Q-NcLVg90H21EOLACvtfcHk0ljZpYu4l1eUAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1eisg%253D%253D&md5=8aad8ea5debf2373eb5d59f5bab63dc5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1517%2F14728222.8.6.565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.8.6.565%26sid%3Dliteratum%253Aachs%26aulast%3DHandl%26aufirst%3DH.%2BL.%26aulast%3DVagner%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DMash%26aufirst%3DE.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26atitle%3DHitting%2520multiple%2520targets%2520with%2520multimeric%2520ligands%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2004%26volume%3D8%26spage%3D565%26epage%3D586%26doi%3D10.1517%2F14728222.8.6.565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Landers, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebay, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purdie, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scells, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samaratunga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavin, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, R. A.</span></span> <span> </span><span class="NLM_article-title">Use of multiple biomarkers for a molecular diagnosis of prostate cancer</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">950</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1002/ijc.20760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1002%2Fijc.20760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=15609297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsFWjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2005&pages=950-956&author=K.+A.+Landersauthor=M.+J.+Burgerauthor=M.+A.+Tebayauthor=D.+M.+Purdieauthor=B.+Scellsauthor=H.+Samaratungaauthor=M.+F.+Lavinauthor=R.+A.+Gardiner&title=Use+of+multiple+biomarkers+for+a+molecular+diagnosis+of+prostate+cancer&doi=10.1002%2Fijc.20760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Use of multiple biomarkers for a molecular diagnosis of prostate cancer</span></div><div class="casAuthors">Landers, Kelly A.; Burger, Michelle J.; Tebay, Michelle A.; Purdie, David M.; Scells, Betty; Samaratunga, Hemamali; Lavin, Martin F.; Gardiner, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">950-956</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The identification of biomarkers capable of providing a reliable mol. diagnostic test for prostate cancer (PCa) is highly desirable clin.  The authors describe here 4 biomarkers, UDP-N-Acetyl-α-D-galactosamine transferase (GalNAc-T3; not previously assocd. with PCa), PSMA, Hepsin and DD3/PCA3, which, in combination, distinguish prostate cancer from benign prostate hyperplasia (BPH).  GalNAc-T3 was identified as overexpressed in PCa tissues by microarray anal., confirmed by quant. real-time PCR and shown immunohistochem. to be localized to prostate epithelial cells with higher expression in malignant cells.  Real-time quant. PCR anal. across 21 PCa and 34 BPH tissues showed 4.6-fold overexpression of GalNAc-T3.  The noncoding mRNA (DD3/PCA3) was overexpressed 140-fold in the cancer samples compared to BPH tissues.  Hepsin was overexpressed 21-fold, whereas the overexpression for PSMA was 66-fold.  When the gene expression data for these 4 biomarkers was combined in a logistic regression model, a predictive index was obtained that distinguished 100% of the PCa samples from all of the BPH samples.  Therefore, combining these genes in a real-time PCR assay represents a powerful new approach to diagnosing PCa by mol. profiling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocvyIEXQFnHLVg90H21EOLACvtfcHk0lhSXNp83UL5Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsFWjsrg%253D&md5=57d7dcc04c857bfdbecd6755b7165586</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fijc.20760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.20760%26sid%3Dliteratum%253Aachs%26aulast%3DLanders%26aufirst%3DK.%2BA.%26aulast%3DBurger%26aufirst%3DM.%2BJ.%26aulast%3DTebay%26aufirst%3DM.%2BA.%26aulast%3DPurdie%26aufirst%3DD.%2BM.%26aulast%3DScells%26aufirst%3DB.%26aulast%3DSamaratunga%26aufirst%3DH.%26aulast%3DLavin%26aufirst%3DM.%2BF.%26aulast%3DGardiner%26aufirst%3DR.%2BA.%26atitle%3DUse%2520of%2520multiple%2520biomarkers%2520for%2520a%2520molecular%2520diagnosis%2520of%2520prostate%2520cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2005%26volume%3D114%26spage%3D950%26epage%3D956%26doi%3D10.1002%2Fijc.20760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shallal, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minn, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisok, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mease, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomper, M. G.</span></span> <span> </span><span class="NLM_article-title">Heterobivalent agents targeting PSMA and integrin-αvβ3</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.1021/bc4005377</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc4005377" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsVSguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=393-405&author=H.+M.+Shallalauthor=I.+Minnauthor=S.+R.+Banerjeeauthor=A.+Lisokauthor=R.+C.+Measeauthor=M.+G.+Pomper&title=Heterobivalent+agents+targeting+PSMA+and+integrin-%CE%B1v%CE%B23&doi=10.1021%2Fbc4005377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Heterobivalent Agents Targeting PSMA and Integrin-αvβ3</span></div><div class="casAuthors">Shallal, Hassan M.; Minn, Il; Banerjee, Sangeeta R.; Lisok, Ala; Mease, Ronnie C.; Pomper, Martin G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">393-405</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Differential expression of surface proteins on normal vs malignant cells provides the rationale for the development of receptor-, antigen-, and transporter-based, cancer-selective imaging and therapeutic agents.  However, tumors are heterogeneous, and do not always express what can be considered reliable, tumor-selective markers.  That suggests development of more flexible targeting platforms that incorporate multiple moieties enabling concurrent targeting to a variety of putative markers.  We report the synthesis, biochem., in vitro, and preliminary in vivo evaluation of a new heterobivalent (HtBv) imaging agent targeting both the prostate-specific membrane antigen (PSMA) and integrin-αvβ3 surface markers, each of which can be overexpressed in certain tumor epithelium and/or neovasculature.  The HtBv agent was functionalized with either 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) or the com. available IRDye800CW.  DOTA-conjugated HtBv probe 9 bound to PSMA or αvβ3 with affinities similar to those of monovalent (Mnv) compds. designed to bind to their targets independently.  In situ energy minimization expts. support a model describing the conformations adapted by 9 that enable it to bind both targets.  IRDye800-conjugated HtBv probe 10 demonstrated target-specific binding to either PSMA or integrin-αvβ3 overexpressing xenografts.  HtBv agents 9 and 10 may enable dual-targeted imaging of malignant cells and tissues in an effort to address heterogeneity that confounds many cancer-targeted imaging agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFuI-0LWEK6rVg90H21EOLACvtfcHk0lhSXNp83UL5Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsVSguw%253D%253D&md5=8102ca98c2564749c6c3cd356a1d1ebf</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fbc4005377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc4005377%26sid%3Dliteratum%253Aachs%26aulast%3DShallal%26aufirst%3DH.%2BM.%26aulast%3DMinn%26aufirst%3DI.%26aulast%3DBanerjee%26aufirst%3DS.%2BR.%26aulast%3DLisok%26aufirst%3DA.%26aulast%3DMease%26aufirst%3DR.%2BC.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26atitle%3DHeterobivalent%2520agents%2520targeting%2520PSMA%2520and%2520integrin-%25CE%25B1v%25CE%25B23%26jtitle%3DBioconjugate%2520Chem.%26date%3D2014%26volume%3D25%26spage%3D393%26epage%3D405%26doi%3D10.1021%2Fbc4005377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauder-Wüst, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhut, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">659</span>– <span class="NLM_lpage">668</span>, <span class="refDoi"> DOI: 10.1002/pros.22784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1002%2Fpros.22784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=24464532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVGgsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=659-668&author=M.+Ederauthor=M.+Sch%C3%A4ferauthor=U.+Bauder-W%C3%BCstauthor=U.+Haberkornauthor=M.+Eisenhutauthor=K.+Kopka&title=Preclinical+evaluation+of+a+bispecific+low-molecular+heterodimer+targeting+both+PSMA+and+GRPR+for+improved+PET+imaging+and+therapy+of+prostate+cancer&doi=10.1002%2Fpros.22784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer</span></div><div class="casAuthors">Eder, Matthias; Schaefer, Martin; Bauder-Wuest, Ulrike; Haberkorn, Uwe; Eisenhut, Michael; Kopka, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">659-668</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: It has recently been reported that metastases of prostate cancer usually show highly heterogeneous or partly lost prostate-specific membrane antigen (PSMA) expression.  In order to image and treat both PSMA pos. and neg. tissues PSMA targeting probes need to be extended by a further specificity.  Since prostate cancer cells usually express both PSMA and gastrin-releasing peptide receptor (GRPR) a bispecific low-mol. heterodimeric mol., addressing both targets at the same time, may significantly improve prostate cancer imaging and therapy.  Methods: The nonapeptide BZH3 representing the GRPR binding part was combined with the urea-based PSMA inhibitor Glu-urea-Lys(Ahx)-HBED-CC.  The syntheses of the compds. were performed according to std. Fmoc-solid phase peptide synthesis.  The binding properties were analyzed by competitive cell binding and internalization expts.  The in vivo targeting properties were investigated by means of biodistribution studies.  Results: Cell binding expts. revealed high binding affinities to both GRPR and PSMA expressing cell lines.  The heterodimer bound with IC50-values essentially matching the IC50 values of the resp. monomers (25.0 ± 5.4 nM for PSMA and 9.0 ± 1.8 nM for GRPR, resp.).  In vivo, the heterodimer showed dual targeting of PSMA (5.4%ID/g for PSMA-pos. tumors) and GRPR receptors (3.3% ID/g for GRPR-pos. tumors) while exhibiting fast pharmacokinetic properties.  The clearance from background was comparable to the monomeric PSMA-targeting ref.  Conclusions: The heterodimeric mol. is a promising agent for PET imaging of primary and recurrent prostate cancer covering two receptor entities which might lead to an improved diagnostic sensitivity and therapeutic efficiency.  Prostate 74:659-668, 2014. cpr 2014 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9nvRTGN-RKrVg90H21EOLACvtfcHk0lhSXNp83UL5Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVGgsb8%253D&md5=f7d819461748bc02af3ad99a4c463b87</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fpros.22784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.22784%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DM.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DM.%26aulast%3DBauder-W%25C3%25BCst%26aufirst%3DU.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DEisenhut%26aufirst%3DM.%26aulast%3DKopka%26aufirst%3DK.%26atitle%3DPreclinical%2520evaluation%2520of%2520a%2520bispecific%2520low-molecular%2520heterodimer%2520targeting%2520both%2520PSMA%2520and%2520GRPR%2520for%2520improved%2520PET%2520imaging%2520and%2520therapy%2520of%2520prostate%2520cancer%26jtitle%3DProstate%26date%3D2014%26volume%3D74%26spage%3D659%26epage%3D668%26doi%3D10.1002%2Fpros.22784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, W.</span></span> <span> </span><span class="NLM_article-title">Design and applications of bispecific heterodimers: molecular imaging and beyond</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1750</span>– <span class="NLM_lpage">1761</span>, <span class="refDoi"> DOI: 10.1021/mp500115x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500115x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtFWlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=1750-1761&author=H.+Luoauthor=H.+Hongauthor=S.+P.+Yangauthor=W.+Cai&title=Design+and+applications+of+bispecific+heterodimers%3A+molecular+imaging+and+beyond&doi=10.1021%2Fmp500115x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Applications of Bispecific Heterodimers: Molecular Imaging and beyond</span></div><div class="casAuthors">Luo, Haiming; Hong, Hao; Yang, Sarah P.; Cai, Weibo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1750-1761</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Ligand-based mol. imaging probes have been designed with high affinity and specificity for monitoring biol. process and responses.  Single-target recognition by traditional probes can limit their applicability for disease detection and therapy because synergistic action between disease mediators and different receptors is often involved in disease progression.  Consequently, probes that can recognize multiple targets should demonstrate higher targeting efficacy and specificity than their monospecific peers.  This concept has been validated by multiple bispecific heterodimer-based imaging probes that demonstrated promising results in several animal models.  This review summarizes the design strategies for bispecific peptide- and antibody-based heterodimers and their applications in mol. targeting and imaging.  The design and application of bispecific heterodimer-conjugated nanomaterials are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3DP6EHtoAuLVg90H21EOLACvtfcHk0lhtH-awe4oTIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtFWlu7o%253D&md5=126043335b195f421558bac683c38c33</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fmp500115x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500115x%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DHong%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DS.%2BP.%26aulast%3DCai%26aufirst%3DW.%26atitle%3DDesign%2520and%2520applications%2520of%2520bispecific%2520heterodimers%253A%2520molecular%2520imaging%2520and%2520beyond%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26spage%3D1750%26epage%3D1761%26doi%3D10.1021%2Fmp500115x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, J. R.</span></span> <span> </span><span class="NLM_article-title">Engineered proteins pull double duty</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">17ps5</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3000276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1126%2Fscitranslmed.3000276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=20371477" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=17ps5&author=J.+R.+Cochran&title=Engineered+proteins+pull+double+duty&doi=10.1126%2Fscitranslmed.3000276"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000276%26sid%3Dliteratum%253Aachs%26aulast%3DCochran%26aufirst%3DJ.%2BR.%26atitle%3DEngineered%2520proteins%2520pull%2520double%2520duty%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D17ps5%26doi%3D10.1126%2Fscitranslmed.3000276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig, S. A.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to drugs targeting receptor tyrosine kinases</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">1041</span>– <span class="NLM_lpage">1048</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2011.12.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1016%2Fj.bcp.2011.12.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2012&pages=1041-1048&author=S.+A.+Rosenzweig&title=Acquired+resistance+to+drugs+targeting+receptor+tyrosine+kinases&doi=10.1016%2Fj.bcp.2011.12.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2011.12.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2011.12.025%26sid%3Dliteratum%253Aachs%26aulast%3DRosenzweig%26aufirst%3DS.%2BA.%26atitle%3DAcquired%2520resistance%2520to%2520drugs%2520targeting%2520receptor%2520tyrosine%2520kinases%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D83%26spage%3D1041%26epage%3D1048%26doi%3D10.1016%2Fj.bcp.2011.12.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handl, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mash, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span> <span> </span><span class="NLM_article-title">Heterobivalent ligands crosslink multiple cell-surface receptors: The human melanocortin-4 and δ-opioid receptors</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1685</span>– <span class="NLM_lpage">1688</span>, <span class="refDoi"> DOI: 10.1002/anie.200702770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1002%2Fanie.200702770" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=1685-1688&author=J.+Vagnerauthor=L.+Xuauthor=H.+L.+Handlauthor=J.+S.+Josanauthor=D.+L.+Morseauthor=E.+A.+Mashauthor=R.+J.+Gilliesauthor=V.+J.+Hruby&title=Heterobivalent+ligands+crosslink+multiple+cell-surface+receptors%3A+The+human+melanocortin-4+and+%CE%B4-opioid+receptors&doi=10.1002%2Fanie.200702770"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fanie.200702770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200702770%26sid%3Dliteratum%253Aachs%26aulast%3DVagner%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DHandl%26aufirst%3DH.%2BL.%26aulast%3DJosan%26aufirst%3DJ.%2BS.%26aulast%3DMorse%26aufirst%3DD.%2BL.%26aulast%3DMash%26aufirst%3DE.%2BA.%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26atitle%3DHeterobivalent%2520ligands%2520crosslink%2520multiple%2520cell-surface%2520receptors%253A%2520The%2520human%2520melanocortin-4%2520and%2520%25CE%25B4-opioid%2520receptors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2008%26volume%3D47%26spage%3D1685%26epage%3D1688%26doi%3D10.1002%2Fanie.200702770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mash, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, R. J.</span></span> <span> </span><span class="NLM_article-title">Enhanced targeting with heterobivalent ligands</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2356</span>– <span class="NLM_lpage">2365</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-1183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1158%2F1535-7163.MCT-08-1183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=19671749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFCmsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2356-2365&author=L.+Xuauthor=J.+Vagnerauthor=J.+Josanauthor=R.+M.+Lynchauthor=D.+L.+Morseauthor=B.+Baggettauthor=H.+Hanauthor=E.+A.+Mashauthor=V.+J.+Hrubyauthor=R.+J.+Gillies&title=Enhanced+targeting+with+heterobivalent+ligands&doi=10.1158%2F1535-7163.MCT-08-1183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced targeting with heterobivalent ligands</span></div><div class="casAuthors">Xu, Liping; Vagner, Josef; Josan, Jatinder; Lynch, Ronald M.; Morse, David L.; Baggett, Brenda; Han, Haiyong; Mash, Eugene A.; Hruby, Victor J.; Gillies, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2356-2365</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A novel approach to specifically target tumor cells for detection and treatment is the proposed use of heteromultivalent ligands, which are designed to interact with, and noncovalently crosslink, multiple different cell surface receptors.  Although enhanced binding has been shown for synthetic homomultivalent ligands, proof of crosslinking requires the use of ligands with two or more different binding moieties.  As proof-of-concept, we have examd. the binding of synthetic heterobivalent ligands to cell lines that were engineered to coexpress two different G-protein-coupled human receptors, i.e., the human melanocortin 4 receptor (MC4R) expressed in combination with either the human δ-opioid receptor (δOR) or the human cholecystokinin-2 receptor (CCK2R).  Expression levels of these receptors were characterized by time-resolved fluorescence satn. binding assays using Europium-labeled ligands; Eu-DPLCE, Eu-NDP-α-MSH, and Eu-CCK8 for the δOR, MC4R, and CCK2R, resp.  Heterobivalent ligands were synthesized to contain a MC4R agonist connected via chem. linkers to either a δOR or a CCK2R agonist.  In both cell systems, the heterobivalent constructs bound with much higher affinity to cells expressing both receptors, compared with cells with single receptors or to cells where one of the receptors was competitively blocked.  These results indicate that synthetic heterobivalent ligands can noncovalently crosslink two unrelated cell surface receptors, making feasible the targeting of receptor combinations.  The in vitro cell models described herein will lead to the development of multivalent ligands for target combinations identified in human cancers. [Mol Cancer Ther 2009;8(8):2356-65].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkQo44KF9nTrVg90H21EOLACvtfcHk0lhtH-awe4oTIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFCmsrc%253D&md5=10c62f74f213f9661eeb2bed436622a2</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-1183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-1183%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DL.%26aulast%3DVagner%26aufirst%3DJ.%26aulast%3DJosan%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DR.%2BM.%26aulast%3DMorse%26aufirst%3DD.%2BL.%26aulast%3DBaggett%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DMash%26aufirst%3DE.%2BA.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26atitle%3DEnhanced%2520targeting%2520with%2520heterobivalent%2520ligands%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2356%26epage%3D2365%26doi%3D10.1158%2F1535-7163.MCT-08-1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Josan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handl, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankaranarayanan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mash, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, R. J.</span></span> <span> </span><span class="NLM_article-title">Cell-specific targeting by heterobivalent ligands</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1270</span>– <span class="NLM_lpage">1278</span>, <span class="refDoi"> DOI: 10.1021/bc1004284</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc1004284" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFSqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=1270-1278&author=J.+S.+Josanauthor=H.+L.+Handlauthor=R.+Sankaranarayananauthor=L.+Xuauthor=R.+M.+Lynchauthor=J.+Vagnerauthor=E.+A.+Mashauthor=V.+J.+Hrubyauthor=R.+J.+Gillies&title=Cell-specific+targeting+by+heterobivalent+ligands&doi=10.1021%2Fbc1004284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-Specific Targeting by Heterobivalent Ligands</span></div><div class="casAuthors">Josan, Jatinder S.; Handl, Heather L.; Sankaranarayanan, Rajesh; Xu, Liping; Lynch, Ronald M.; Vagner, Josef; Mash, Eugene A.; Hruby, Victor J.; Gillies, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1270-1278</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Current cancer therapies exploit either differential metab. or targeting to specific individual gene products that are overexpressed in aberrant cells.  The work described herein proposes an alternative approach-to specifically target combinations of cell-surface receptors using heteromultivalent ligands ("receptor combination approach").  As a proof-of-concept that functionally unrelated receptors can be noncovalently cross-linked with high avidity and specificity, a series of heterobivalent ligands (htBVLs) were constructed from analogs of the melanocortin peptide ligand ([Nle4, D-Phe7]-α-MSH) and the cholecystokinin peptide ligand (CCK-8).  Binding of these ligands to cells expressing the human melanocortin-4 receptor and the cholecystokinin-2 receptor was analyzed.  The MSH(7) and CCK(6) were tethered with linkers of varying rigidity and length, constructed from natural and/or synthetic building blocks.  Modeling data suggest that a linker length of 20-50 Å is needed to simultaneously bind these two different G-protein coupled receptors (GPCRs).  These ligands exhibited up to 24-fold enhancement in binding affinity to cells that expressed both (bivalent binding), compared to cells with only one (monovalent binding) of the cognate receptors.  The htBVLs had up to 50-fold higher affinity than that of a monomeric CCK ligand, i.e., Ac-CCK(6)-NH2.  Cell-surface targeting of these two cell types with labeled heteromultivalent ligand demonstrated high avidity and specificity, thereby validating the receptor combination approach.  This ability to noncovalently cross-link heterologous receptors and target individual cells using a receptor combination approach opens up new possibilities for specific cell targeting in vivo for therapy or imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9JSNzA-4QhrVg90H21EOLACvtfcHk0lhU-JThCm2jIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFSqs7g%253D&md5=c0d5a49a887aaf2258b1f0e9314e195d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fbc1004284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc1004284%26sid%3Dliteratum%253Aachs%26aulast%3DJosan%26aufirst%3DJ.%2BS.%26aulast%3DHandl%26aufirst%3DH.%2BL.%26aulast%3DSankaranarayanan%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DR.%2BM.%26aulast%3DVagner%26aufirst%3DJ.%26aulast%3DMash%26aufirst%3DE.%2BA.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26atitle%3DCell-specific%2520targeting%2520by%2520heterobivalent%2520ligands%26jtitle%3DBioconjugate%2520Chem.%26date%3D2011%26volume%3D22%26spage%3D1270%26epage%3D1278%26doi%3D10.1021%2Fbc1004284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caplan, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mash, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, R. J.</span></span> <span> </span><span class="NLM_article-title">Heterobivalent ligands target cell-surface receptor combinations in vivo</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">21295</span>– <span class="NLM_lpage">21300</span>, <span class="refDoi"> DOI: 10.1073/pnas.1211762109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1073%2Fpnas.1211762109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=23236171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslSgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=21295-21300&author=L.+Xuauthor=J.+S.+Josanauthor=J.+Vagnerauthor=M.+R.+Caplanauthor=V.+J.+Hrubyauthor=E.+A.+Mashauthor=R.+M.+Lynchauthor=D.+L.+Morseauthor=R.+J.+Gillies&title=Heterobivalent+ligands+target+cell-surface+receptor+combinations+in+vivo&doi=10.1073%2Fpnas.1211762109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Heterobivalent ligands target cell-surface receptor combinations in vivo</span></div><div class="casAuthors">Xu, Liping; Josan, Jatinder S.; Vagner, Josef; Caplan, Michael R.; Hruby, Victor J.; Mash, Eugene A.; Lynch, Ronald M.; Morse, David L.; Gillies, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">21295-21300, S21295/1-S21295/14</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A challenge in tumor targeting is to deliver payloads to cancers while sparing normal tissues.  A limited no. of antibodies appear to meet this challenge as therapeutics themselves or as drug-antibody conjugates.  However, antibodies suffer from their large size, which can lead to unfavorable pharmacokinetics for some therapeutic payloads, and that they are targeted against only a single epitope, which can reduce their selectivity and specificity.  Here, we propose an alternative targeting approach based on patterns of cell surface proteins to rationally develop small, synthetic heteromultivalent ligands (htMVLs) that target multiple receptors simultaneously.  To gain insight into the multivalent ligand strategy in vivo, we have generated synthetic htMVLs that contain melanocortin (MSH) and cholecystokinin (CCK) pharmacophores that are connected via a fluorescent labeled, rationally designed synthetic linker.  These ligands were tested in an exptl. animal model contg. tumors that expressed only one (control) or both (target) MSH and CCK receptors.  After systemic injection of the htMVL in tumor-bearing mice, label was highly retained in tumors that expressed both, compared with one, target receptors.  Selectivity was quantified by using ex vivo measurement of Europium-labeled htMVL, which had up to 12-fold higher specificity for dual compared with single receptor expressing cells.  This proof-of-principle study provides in vivo evidence that small, rationally designed bivalent htMVLs can be used to selectively target cells that express both, compared with single complimentary cell surface targets.  These data open the possibility that specific combinations of targets on tumors can be identified and selectively targeted using htMVLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5JhGq_H5GILVg90H21EOLACvtfcHk0lhU-JThCm2jIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslSgsw%253D%253D&md5=ec09130d0da0d380cd91cea77bbeca72</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1211762109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1211762109%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DL.%26aulast%3DJosan%26aufirst%3DJ.%2BS.%26aulast%3DVagner%26aufirst%3DJ.%26aulast%3DCaplan%26aufirst%3DM.%2BR.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26aulast%3DMash%26aufirst%3DE.%2BA.%26aulast%3DLynch%26aufirst%3DR.%2BM.%26aulast%3DMorse%26aufirst%3DD.%2BL.%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26atitle%3DHeterobivalent%2520ligands%2520target%2520cell-surface%2520receptor%2520combinations%2520in%2520vivo%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D21295%26epage%3D21300%26doi%3D10.1073%2Fpnas.1211762109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1021/jm801285t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801285t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Kg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=425-432&author=Z.+Liuauthor=Y.+Yanauthor=F.+T.+Chinauthor=F.+Wangauthor=X.+Chen&title=Dual+integrin+and+gastrin-releasing+peptide+receptor+targeted+tumor+imaging+using+18F-labeled+PEGylated+RGD-bombesin+heterodimer+18F-FB-PEG3-Glu-RGD-BBN&doi=10.1021%2Fjm801285t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Integrin and Gastrin-Releasing Peptide Receptor Targeted Tumor Imaging Using 18F-labeled PEGylated RGD-Bombesin Heterodimer 18F-FB-PEG3-Glu-RGD-BBN</span></div><div class="casAuthors">Liu, Zhaofei; Yan, Yongjun; Chin, Frederic T.; Wang, Fan; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">425-432</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Radiolabeled RGD and bombesin peptides have been extensively investigated for tumor integrin αvβ3 and GRPR imaging, resp.  Due to the fact that many tumors are both integrin and GRPR pos., we designed and synthesized a heterodimeric peptide Glu-RGD-BBN, which is expected to be advantageous over the monomeric peptides for dual-receptor targeting.  A PEG3 spacer was attached to the glutamate α-amino group of Glu-RGD-BBN to enhance the 18F labeling yield and to improve the in vivo kinetics. PEG3-Glu-RGD-BBN possesses the comparable GRPR and integrin αvβ3 receptor-binding affinities as the corresponding monomers, resp.  The dual-receptor targeting properties of 18F-FB-PEG3-Glu-RGD-BBN were obsd. in PC-3 tumor model. 18F-FB-PEG3-Glu-RGD-BBN with high tumor contrast and favorable pharmacokinetics is a promising PET tracer for dual integrin and GRPR pos. tumor imaging.  This heterodimer strategy may also be an applicable method to develop other mols. with improved in vitro and in vivo characterizations for tumor diagnosis and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2SA_rxlFb7bVg90H21EOLACvtfcHk0lhU-JThCm2jIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Kg&md5=74337ada6620f3948a43119d529c83f4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm801285t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801285t%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DChin%26aufirst%3DF.%2BT.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DDual%2520integrin%2520and%2520gastrin-releasing%2520peptide%2520receptor%2520targeted%2520tumor%2520imaging%2520using%252018F-labeled%2520PEGylated%2520RGD-bombesin%2520heterodimer%252018F-FB-PEG3-Glu-RGD-BBN%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D425%26epage%3D432%26doi%3D10.1021%2Fjm801285t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">18F-labeled BBN-RGD heterodimer for prostate cancer imaging</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.2967/jnumed.107.048009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.2967%2Fjnumed.107.048009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=18287274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlOns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=453-461&author=Z.-B.+Liauthor=Z.+Wuauthor=K.+Chenauthor=E.+K.+Ryuauthor=X.+Chen&title=18F-labeled+BBN-RGD+heterodimer+for+prostate+cancer+imaging&doi=10.2967%2Fjnumed.107.048009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">18F-labeled BBN-RGD heterodimer for prostate cancer imaging</span></div><div class="casAuthors">Li, Zi-Bo; Wu, Zhanghong; Chen, Kai; Ryu, Eun Kyoung; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">453-461</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine</span>)
        </div><div class="casAbstract">Both bombesin (BBN) analogs and cyclic RGD peptides have been suitably radiolabeled for prostate cancer imaging.  However, the limited expression of gastrin-releasing peptide receptor (GRPR) and integrin αvβ3 as well as unfavorable in vivo kinetics limited further applications of these imaging agents.  We hypothesize that a peptide ligand recognizing both GRPR and integrin will be advantageous because of its dual-receptor-targeting ability.  Methods: A BBN-RGD heterodimer was synthesized from bombesin(7-14) and c(RGDyK) through a glutamate linker and then labeled with 18F via the N-succinimidyl-4-18F-fluorobenzoate (18F-SFB) prosthetic group.  The receptor-binding characteristics and tumor-targeting efficacy of 18F-FB-BBN-RGD were tested in vitro and in vivo.  Results: FB-BBN-RGD had comparable integrin αvβ3-binding affinity with c(RGDyK) and comparable GRPR-binding affinity with BBN(7-14).  18F-FB-BBN-RGD had significantly higher tumor uptake compared with monomeric RGD and monomeric BBN peptide tracer analogs at all time points examd.  The PC-3 tumor uptake of 18F-FB-BBN-RGD was inhibited only partially in the presence of an excess amt. of unlabeled BBN(7-14) or c(RGDyK) but was blocked completely in the presence of both BBN(7-14) and c(RGDyK).  Compared with 18F-FB-BBN and 18F-FB-RGD, 18F-FB-BBN-RGD also had improved pharmacokinetics, resulting in a significantly higher imaging quality.  Conclusion: Dual integrin αvβ3 and GRPR recognition showed significantly improved tumor-targeting efficacy and pharmacokinetics compared with 18F-labeled RGD and BBN analogs.  The same heterodimeric ligand design may also be applicable to other receptor system combinations and other imaging modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo53fuaN_K7s7Vg90H21EOLACvtfcHk0lgUiwULYytVVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlOns7o%253D&md5=2f3945deb587757802d92faded69575e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.107.048009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.107.048009%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.-B.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DRyu%26aufirst%3DE.%2BK.%26aulast%3DChen%26aufirst%3DX.%26atitle%3D18F-labeled%2520BBN-RGD%2520heterodimer%2520for%2520prostate%2520cancer%2520imaging%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2008%26volume%3D49%26spage%3D453%26epage%3D461%26doi%3D10.2967%2Fjnumed.107.048009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">A new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging</span>. <i>Amino Acids</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1007/s00726-010-0762-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1007%2Fs00726-010-0762-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=439-447&author=Y.+Yanauthor=K.+Chenauthor=M.+Yangauthor=X.+Sunauthor=S.+Liuauthor=X.+Chen&title=A+new+18F-labeled+BBN-RGD+peptide+heterodimer+with+a+symmetric+linker+for+prostate+cancer+imaging&doi=10.1007%2Fs00726-010-0762-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs00726-010-0762-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00726-010-0762-5%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DA%2520new%252018F-labeled%2520BBN-RGD%2520peptide%2520heterodimer%2520with%2520a%2520symmetric%2520linker%2520for%2520prostate%2520cancer%2520imaging%26jtitle%3DAmino%2520Acids%26date%3D2011%26volume%3D41%26spage%3D439%26epage%3D447%26doi%3D10.1007%2Fs00726-010-0762-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Clinical translation of a dual integrin αvβ3– and gastrin-releasing peptide receptor–targeting PET radiotracer, 68Ga-BBN-RGD</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.2967/jnumed.116.177048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.2967%2Fjnumed.116.177048" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=228-234&author=J.+Zhangauthor=G.+Niuauthor=L.+Langauthor=F.+Liauthor=X.+Fanauthor=X.+Yanauthor=S.+Yaoauthor=W.+Yanauthor=L.+Huoauthor=L.+Chenauthor=Z.+Liauthor=Z.+Zhuauthor=X.+Chen&title=Clinical+translation+of+a+dual+integrin+%CE%B1v%CE%B23%E2%80%93+and+gastrin-releasing+peptide+receptor%E2%80%93targeting+PET+radiotracer%2C+68Ga-BBN-RGD&doi=10.2967%2Fjnumed.116.177048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.116.177048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.116.177048%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DG.%26aulast%3DLang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DS.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DHuo%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DClinical%2520translation%2520of%2520a%2520dual%2520integrin%2520%25CE%25B1v%25CE%25B23%25E2%2580%2593%2520and%2520gastrin-releasing%2520peptide%2520receptor%25E2%2580%2593targeting%2520PET%2520radiotracer%252C%252068Ga-BBN-RGD%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2017%26volume%3D58%26spage%3D228%26epage%3D234%26doi%3D10.2967%2Fjnumed.116.177048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Razumienko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dryden, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scollard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, R. M.</span></span> <span> </span><span class="NLM_article-title">MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using 111In-labeled bispecific radioimmunoconjugates</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1007/s10549-013-2490-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1007%2Fs10549-013-2490-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=23525982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFektbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2013&pages=709-718&author=E.+Razumienkoauthor=L.+Drydenauthor=D.+Scollardauthor=R.+M.+Reilly&title=MicroSPECT%2FCT+imaging+of+co-expressed+HER2+and+EGFR+on+subcutaneous+human+tumor+xenografts+in+athymic+mice+using+111In-labeled+bispecific+radioimmunoconjugates&doi=10.1007%2Fs10549-013-2490-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using 111In-labeled bispecific radioimmunoconjugates</span></div><div class="casAuthors">Razumienko, Eva; Dryden, Lindsay; Scollard, Deborah; Reilly, Raymond M.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">709-718</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Epidermal growth factor receptors (EGFR) form heterodimers with HER2 in breast cancer, and increased EGFR expression has been found in HER2-pos. tumors resistant to trastuzumab (Herceptin).  Our objective was to synthesize bispecific radioimmunoconjugates (bsRICs) that recognize HER2 and EGFR and evaluate their ability to image tumors in athymic mice that express one or both receptors by microSPECT/CT.  Bispecific radioimmunoconjugates were constructed by conjugating maleimide-derivatized trastuzumab Fab fragments that bind HER2 to a thiolated form of EGF with an intervening 24 mer polyethylene glycol (PEG24) spacer.  Bispecific radioimmunoconjugates were derivatized with diethylenetriaminepentaacetic acid for labeling with 111In.  The ability of 111In-bsRICs to bind HER2 or EGFR was detd. in competition assays using cells expressing one or both receptors.  Tumor and normal tissue uptake were examd. in CD1 athymic mice bearing s.c. tumor xenografts that expressed HER2, EGFR, or both receptors, with or without pre-administration of Fab or EGF to det. specificity.  HER2 and EGFR binding and displacement of binding by competitors were found for 111In-bsICs.  The highest uptake of 111In-bsRICs [7.3 ± 3.5 %ID/g] in 231-H2N human breast cancer xenografts (HER2+/EGFR+) occurred at 48 h post-injection.  Pre-administration of trastuzumab Fab decreased uptake in SK-OV-3 (HER2+/EGFR-) human ovarian cancer xenografts from 7.1 ± 1.2 to 2.4 ± 1.5 %ID/g.  Pre-administration of excess EGF decreased uptake in MDA-MB-231 (HER2-/EGFR+) human breast cancer xenografts from 5.9 ± 0.5 to 2.0 ± 0.1 %ID/g.  All tumors were imaged by microSPECT/CT.  We conclude that 111In-bsRICs composed of trastuzumab Fab and EGF exhibited specific binding in vitro to tumor cells displaying HER2 or EGFR, and were taken up specifically in vivo in tumors expressing one or both receptors, permitting tumor visualization by microSPECT/CT.  These agents may ultimately be useful for imaging heterodimerized HER2-EGFR complexes since their bivalent properties permit more avid binding to these complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTL0vbo0n4trVg90H21EOLACvtfcHk0lgUiwULYytVVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFektbc%253D&md5=0bb9facb59bb1edef1ff660065b214fb</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10549-013-2490-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-013-2490-5%26sid%3Dliteratum%253Aachs%26aulast%3DRazumienko%26aufirst%3DE.%26aulast%3DDryden%26aufirst%3DL.%26aulast%3DScollard%26aufirst%3DD.%26aulast%3DReilly%26aufirst%3DR.%2BM.%26atitle%3DMicroSPECT%252FCT%2520imaging%2520of%2520co-expressed%2520HER2%2520and%2520EGFR%2520on%2520subcutaneous%2520human%2520tumor%2520xenografts%2520in%2520athymic%2520mice%2520using%2520111In-labeled%2520bispecific%2520radioimmunoconjugates%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2013%26volume%3D138%26spage%3D709%26epage%3D718%26doi%3D10.1007%2Fs10549-013-2490-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Arming antibodies: prospects and challenges for immunoconjugates</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1137</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1038/nbt1141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1038%2Fnbt1141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=16151407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1137-1146&author=A.+M.+Wuauthor=P.+D.+Senter&title=Arming+antibodies%3A+prospects+and+challenges+for+immunoconjugates&doi=10.1038%2Fnbt1141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Arming antibodies: prospects and challenges for immunoconjugates</span></div><div class="casAuthors">Wu, Anna M.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1137-1146</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immunoconjugates-monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs (ineffective when administered systemically alone)-are becoming a significant component of anticancer treatments.  By combining the exquisite targeting specificity of mAbs with the enhanced tumor-killing power of toxic effector mols., immunoconjugates permit sensitive discrimination between target and normal tissue, resulting in fewer toxic side effects than most conventional chemotherapeutic drugs.  Two radioimmunoconjugates, ibritumomab tiuxetan (Zevalin) and tositumomab-131I (Bexxar), and one drug conjugate, gemtuzumab ozogamicin (Mylotarg), are now on the market.  For the next generation of immunoconjugates, advances in protein engineering will permit greater control of mAb targeting, clearance and pharmacokinetics, resulting in significantly improved delivery to tumors of radioisotopes and potent anticancer drugs.  Pretargeting strategies, which sep. the two functions of antibody-based localization and delivery or generation of the toxic agent into two steps, also promise to afford superior tumor targeting and therapeutic efficacy.  Several challenges in optimizing immunoconjugates remain, however, including poor intratumoral mAb uptake, normal tissue conjugate exposure and issues surrounding drug potency and conditional release from mAb carriers.  Nonetheless, highly promising results from preclin. models will continue to drive the clin. development of this therapeutic class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQIsb1wtkWs7Vg90H21EOLACvtfcHk0liuX_hIqlCT8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D&md5=6c2d10cdcffad09d516386607d2223a9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnbt1141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1141%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DA.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DArming%2520antibodies%253A%2520prospects%2520and%2520challenges%2520for%2520immunoconjugates%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D1137%26epage%3D1146%26doi%3D10.1038%2Fnbt1141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lum, L. G.</span></span> <span> </span><span class="NLM_article-title">Cancer therapy with bispecific antibodies: clinical experience</span>. <i>Curr. Opin. Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">340</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=20521223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlaktLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=340&author=A.+Thakurauthor=L.+G.+Lum&title=Cancer+therapy+with+bispecific+antibodies%3A+clinical+experience"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer therapy with bispecific antibodies: clinical experience</span></div><div class="casAuthors">Thakur, Archana; Lum, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Molecular Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">340-349</span>CODEN:
                <span class="NLM_cas:coden">CUOTFO</span>;
        ISSN:<span class="NLM_cas:issn">2040-3445</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  The binding of at least two mol. targets simultaneously with a single bispecific antibody is an attractive concept.  The use of bispecific antibodies as possible therapeutic agents for cancer treatment was proposed in the mid-1980s.  The design and prodn. of bispecific antibodies using antibody- and/or receptor-based platform technol. has improved significantly with advances in the knowledge of mol. manipulations, protein engineering techniques, and the expression of antigens and receptors on healthy and malignant cells.  The common strategy for making bispecific antibodies involves combining the variable domains of the desired mAbs into a single bispecific structure.  Many different formats of bispecific antibodies have been generated within the research field of bispecific immunotherapeutics, including the chem. heteroconjugation of two complete mols. or fragments of mAbs, quadromas, F(ab')2, diabodies, tandem diabodies and single-chain antibodies.  This review describes key modifications in the development of bispecific antibodies that can improve their efficacy and stability, and provides a clin. perspective on the application of bispecific antibodies for the treatment of solid and liq. tumors, including the promises and research limitations of this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6cbdL39k_WbVg90H21EOLACvtfcHk0liuX_hIqlCT8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlaktLvL&md5=c66886b31efe2f7168a6489d922ebdbf</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThakur%26aufirst%3DA.%26aulast%3DLum%26aufirst%3DL.%2BG.%26atitle%3DCancer%2520therapy%2520with%2520bispecific%2520antibodies%253A%2520clinical%2520experience%26jtitle%3DCurr.%2520Opin.%2520Mol.%2520Ther.%26date%3D2010%26volume%3D12%26spage%3D340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. D.</span></span> <span> </span><span class="NLM_article-title">EGFR overexpressed in colonic neoplasia can be detected on wide-field endoscopic imaging</span>. <i>Clin. Transl. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e101</span> <span class="refDoi"> DOI: 10.1038/ctg.2015.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1038%2Fctg.2015.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=26181290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WrtLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&author=J.+Zhouauthor=B.+P.+Joshiauthor=X.+Duanauthor=A.+Pantauthor=Z.+Qiuauthor=R.+Kuickauthor=S.+R.+Owensauthor=T.+D.+Wang&title=EGFR+overexpressed+in+colonic+neoplasia+can+be+detected+on+wide-field+endoscopic+imaging&doi=10.1038%2Fctg.2015.28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Overexpressed in Colonic Neoplasia Can be Detected on Wide-Field Endoscopic Imaging</span></div><div class="casAuthors">Zhou, Juan; Joshi, Bishnu P.; Duan, Xiyu; Pant, Asha; Qiu, Zhen; Kuick, Rork; Owens, Scott R.; Wang, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Gastroenterology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e101</span>CODEN:
                <span class="NLM_cas:coden">CTGLAG</span>;
        ISSN:<span class="NLM_cas:issn">2155-384X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Objectives: Colorectal cancer initially lies dormant as dysplasia, a premalignant state that provides an opportunity for early cancer detection.  Dysplasia can be flat in morphol., focal in size, and patchy in distribution, and thus it appears "invisible" on conventional wide-field endoscopy.  Aims: We aim to develop and validate a peptide that is specific for epidermal growth factor receptor (EGFR), a cell surface target that is overexpressed in colonic adenomas and is readily accessible for imaging.  Methods: We expressed and purified the extracellular domain of EGFR for use with phage display to identify a peptide QRHKPRE that binds to domain 2 of this target.  A near-IR fluorescence endoscope was used to perform in vivo imaging to validate specific peptide binding to spontaneous colonic adenomas in a mouse model with topical administration.  We also validated specific peptide binding to human colonic adenomas on immunohistochem. and immunofluorescence.  Results: After labeling with Cy5.5, we validated specific peptide binding to EGFR on knockdown and competition studies.  Peptide binding to cells occurred within 2.46 min and had an affinity of 50 nM.  No downstream signaling was obsd.  We measured a target-to-background ratio of 4.0±1.7 and 2.7±0.7, for polyps and flat lesions, resp.  On immunofluorescence of human colonic specimens, greater intensity from peptide binding to dysplasia than normal was found with a 19.4-fold difference.  Conclusions: We have selected and validated a peptide that can be used as a specific contrast agent to identify colonic adenomas that overexpress EGFR in vivo on fluorescence endoscopy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbPT3gBw7OlbVg90H21EOLACvtfcHk0liuX_hIqlCT8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WrtLbP&md5=c657a8b2eefd5ac4b39df370b70a90ef</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fctg.2015.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fctg.2015.28%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DJoshi%26aufirst%3DB.%2BP.%26aulast%3DDuan%26aufirst%3DX.%26aulast%3DPant%26aufirst%3DA.%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DKuick%26aufirst%3DR.%26aulast%3DOwens%26aufirst%3DS.%2BR.%26aulast%3DWang%26aufirst%3DT.%2BD.%26atitle%3DEGFR%2520overexpressed%2520in%2520colonic%2520neoplasia%2520can%2520be%2520detected%2520on%2520wide-field%2520endoscopic%2520imaging%26jtitle%3DClin.%2520Transl.%2520Gastroenterol.%26date%3D2015%26volume%3D6%26doi%3D10.1038%2Fctg.2015.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. D.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of near-infrared peptide for in vivo molecular imaging of HER2</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">494</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.5b00565</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.5b00565" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=481-494&author=B.+P.+Joshiauthor=J.+Zhouauthor=A.+Pantauthor=X.+Duanauthor=Q.+Zhouauthor=R.+Kuickauthor=S.+R.+Owensauthor=H.+Appelmanauthor=T.+D.+Wang&title=Design+and+synthesis+of+near-infrared+peptide+for+in+vivo+molecular+imaging+of+HER2&doi=10.1021%2Facs.bioconjchem.5b00565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Near-Infrared Peptide for in Vivo Molecular Imaging of HER2</span></div><div class="casAuthors">Joshi, Bishnu P.; Zhou, Juan; Pant, Asha; Duan, Xiyu; Zhou, Quan; Kuick, Rork; Owens, Scott R.; Appelman, Henry; Wang, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">481-494</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report the development, characterization, and validation of a peptide specific for the extracellular domain of HER2.  This probe chem. was developed for mol. imaging by using a structural model to select an optimal combination of amino acids that maximize the likelihood for unique hydrophobic and hydrophilic interactions with HER2 domain 3.  The sequence KSPNPRF was identified and conjugated with either FITC or Cy5.5 via a GGGSK linker using Fmoc-mediated solid-phase synthesis to demonstrate flexibility for this chem. structure to be labeled with different fluorophores.  A scrambled sequence was developed for control by altering the conformationally rigid spacer and moving both hydrophobic and hydrophilic amino acids on the C-terminus.  The authors validated peptide specificity for HER2 in knockdown and competition expts. using human colorectal cancer cells in vitro, and measured a binding affinity of kd = 21 nM and time const. of k = 0.14 min-1 (7.14 min).  The authors used this peptide with either topical or i.v. administration in a preclin. model of colorectal cancer to demonstrate specific uptake in spontaneous adenomas and to show feasibility for real time in vivo imaging with near-IR fluorescence.  The authors used this peptide in immunofluorescence studies of human proximal colon specimens to evaluate specificity for sessile serrated and sporadic adenomas.  Improved visualization can be used endoscopically to guide tissue biopsy and detect premalignant lesions that would otherwise be missed.  The authors' peptide design for specificity to HER2 is promising for clin. translation in mol. imaging methods for early cancer detection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKCVSE6nA0SLVg90H21EOLACvtfcHk0lhyfELC3BF_OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCksro%253D&md5=4a54754652f14c5d665f352d025dd236</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.5b00565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.5b00565%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DB.%2BP.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DPant%26aufirst%3DA.%26aulast%3DDuan%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DKuick%26aufirst%3DR.%26aulast%3DOwens%26aufirst%3DS.%2BR.%26aulast%3DAppelman%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DT.%2BD.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520near-infrared%2520peptide%2520for%2520in%2520vivo%2520molecular%2520imaging%2520of%2520HER2%26jtitle%3DBioconjugate%2520Chem.%26date%3D2016%26volume%3D27%26spage%3D481%26epage%3D494%26doi%3D10.1021%2Facs.bioconjchem.5b00565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, C.</span></span> <span> </span><span class="NLM_article-title">A review of NIR dyes in cancer targeting and imaging</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">7127</span>– <span class="NLM_lpage">7138</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2011.06.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1016%2Fj.biomaterials.2011.06.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=21724249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFWhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=7127-7138&author=S.+Luoauthor=E.+Zhangauthor=Y.+Suauthor=T.+Chengauthor=C.+Shi&title=A+review+of+NIR+dyes+in+cancer+targeting+and+imaging&doi=10.1016%2Fj.biomaterials.2011.06.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A review of NIR dyes in cancer targeting and imaging</span></div><div class="casAuthors">Luo, Shenglin; Zhang, Erlong; Su, Yongping; Cheng, Tianmin; Shi, Chunmeng</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">7127-7138</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of multifunctional agents for simultaneous tumor targeting and near IR (NIR) fluorescence imaging is expected to have significant impact on future personalized oncol. owing to the very low tissue autofluorescence and high tissue penetration depth in the NIR spectrum window.  Cancer NIR mol. imaging relies greatly on the development of stable, highly specific and sensitive mol. probes.  Org. dyes have shown promising clin. implications as non-targeting agents for optical imaging in which indocyanine green has long been implemented in clin. use.  Recently, significant progress has been made on the development of unique NIR dyes with tumor targeting properties.  Current ongoing design strategies have overcome some of the limitations of conventional NIR org. dyes, such as poor hydrophilicity and photostability, low quantum yield, insufficient stability in biol. system, low detection sensitivity, etc.  This potential is further realized with the use of these NIR dyes or NIR dye-encapsulated nanoparticles by conjugation with tumor specific ligands (such as small mols., peptides, proteins and antibodies) for tumor targeted imaging.  Very recently, natively multifunctional NIR dyes that can preferentially accumulate in tumor cells without the need of chem. conjugation to tumor targeting ligands have been developed and these dyes have shown unique optical and pharmaceutical properties for biomedical imaging with superior signal-to-background contrast index.  The main focus of this article is to provide a concise overview of newly developed NIR dyes and their potential applications in cancer targeting and imaging.  The development of future multifunctional agents by combining targeting, imaging and even therapeutic routes will also be discussed.  We believe these newly developed multifunctional NIR dyes will broaden current concept of tumor targeted imaging and hold promise to make an important contribution to the diagnosis and therapeutics for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJJQph7DjLr7Vg90H21EOLACvtfcHk0lhyfELC3BF_OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFWhtbs%253D&md5=733be27dd9858f9a6ca73f70fabd77c1</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2011.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2011.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DC.%26atitle%3DA%2520review%2520of%2520NIR%2520dyes%2520in%2520cancer%2520targeting%2520and%2520imaging%26jtitle%3DBiomaterials%26date%3D2011%26volume%3D32%26spage%3D7127%26epage%3D7138%26doi%3D10.1016%2Fj.biomaterials.2011.06.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Björkelund, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmqvist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, K.</span></span> <span> </span><span class="NLM_article-title">Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with 125I-EGF</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e24739</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0024739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1371%2Fjournal.pone.0024739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=21931838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A280%3ADC%252BC3MfkvFajsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&author=H.+Bj%C3%B6rkelundauthor=L.+Geddaauthor=P.+Bartaauthor=M.+Malmqvistauthor=K.+Andersson&title=Gefitinib+induces+epidermal+growth+factor+receptor+dimers+which+alters+the+interaction+characteristics+with+125I-EGF&doi=10.1371%2Fjournal.pone.0024739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with 125I-EGF</span></div><div class="casAuthors">Bjorkelund Hanna; Gedda Lars; Barta Pavel; Malmqvist Magnus; Andersson Karl</div><div class="citationInfo"><span class="NLM_cas:title">PloS one</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e24739</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The tyrosine kinase inhibitor gefitinib inhibits growth in some tumor types by targeting the epidermal growth factor receptor (EGFR).  Previous studies show that the affinity of the EGF-EGFR interaction varies between hosting cell line, and that gefitinib increases the affinity for some cell lines.  In this paper, we investigate possible mechanisms behind these observations.  Real-time interaction analysis in LigandTracer® Grey revealed that the HER2 dimerization preventing antibody pertuzumab clearly modified the binding of 125I-EGF to EGFR on HER2 overexpressing SKOV3 cells in the presence of gefitinib.  Pertuzumab did not affect the binding on A431 cells, which express low levels of HER2.  Cross-linking measurements showed that gefitinib increased the amount of EGFR dimers 3.0-3.8 times in A431 cells in the absence of EGF.  In EGF stimulated SKOV3 cells the amount of EGFR dimers increased 1.8-2.2 times by gefitinib, but this effect was cancelled by pertuzumab.  Gefitinib treatment did not alter the number of EGFR or HER2 expressed in tumor cell lines A431, U343, SKOV3 and SKBR3.  Real-time binding traces were further analyzed in a novel tool, Interaction Map, which deciphered the different components of the measured interaction and supports EGF binding to multiple binding sites.  EGFR and HER2 expression affect the levels of EGFR monomers, homodimers and heterodimers and EGF binds to the various monomeric/dimeric forms of EGFR with unique binding properties.  Taken together, we conclude that dimerization explains the varying affinity of EGF-EGFR in different cells, and we propose that gefitinib induces EGFR dimmers, which alters the interaction characteristics with 125I-EGF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmKCzaldFZyMyail4HZd-ifW6udTcc2eax3GJlHXiSi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfkvFajsQ%253D%253D&md5=c2bfe5fe03d421cf313e4c2cac0a23b2</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0024739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0024739%26sid%3Dliteratum%253Aachs%26aulast%3DBj%25C3%25B6rkelund%26aufirst%3DH.%26aulast%3DGedda%26aufirst%3DL.%26aulast%3DBarta%26aufirst%3DP.%26aulast%3DMalmqvist%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DK.%26atitle%3DGefitinib%2520induces%2520epidermal%2520growth%2520factor%2520receptor%2520dimers%2520which%2520alters%2520the%2520interaction%2520characteristics%2520with%2520125I-EGF%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26doi%3D10.1371%2Fjournal.pone.0024739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Peptide heterodimers for molecular imaging</span>. <i>Amino Acids</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1081</span>– <span class="NLM_lpage">1092</span>, <span class="refDoi"> DOI: 10.1007/s00726-010-0546-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1007%2Fs00726-010-0546-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=20232091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyqtbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=1081-1092&author=Y.+Yanauthor=X.+Chen&title=Peptide+heterodimers+for+molecular+imaging&doi=10.1007%2Fs00726-010-0546-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide heterodimers for molecular imaging</span></div><div class="casAuthors">Yan, Yongjun; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Amino Acids</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1081-1092</span>CODEN:
                <span class="NLM_cas:coden">AACIE6</span>;
        ISSN:<span class="NLM_cas:issn">0939-4451</span>.
    
            (<span class="NLM_cas:orgname">SpringerWienNewYork</span>)
        </div><div class="casAbstract">A review.  One main issue with peptide-based mol. imaging probes is their relatively low tumor affinity and short retention time.  To improve peptide binding affinity, multivalency approach has been introduced.  Traditionally, this approach involves the use of peptide homodimers or homomultimers in which peptide ligands of the same type are constructed with suitable linkers.  Recently, a new approach using peptide heterodimers has emerged as a promising method for targeting multi-receptor over-expressed tumor cells.  Significant affinity enhancements have been obsd. with peptide heterodimers compared with their parent peptide monomers.  In a peptide heterodimer, two different peptide ligands capable of targeting two different receptors are covalently linked.  The binding modes of peptide heterodimers can be monovalent or bivalent depending on whether simultaneous binding of two ligands can be achieved.  Increased local ligand concn. and improved binding kinetics contribute to enhanced binding in both monovalent- and bivalent binding modes, while multivalency effect also plays an important role in bivalent binding mode.  As many tumors overexpress multiple receptors, more peptide heterodimer-based mol. imaging probes are expected to be developed in future.  This review article will discuss the peptide homodimers and heterodimers for mol. imaging with special emphasis on peptide heterodimers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocHwT9jt2idLVg90H21EOLACvtfcHk0lhQYyFhQoVihA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyqtbnE&md5=cca77484bd29bb7d26570f9c6d37d5e8</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs00726-010-0546-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00726-010-0546-y%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DPeptide%2520heterodimers%2520for%2520molecular%2520imaging%26jtitle%3DAmino%2520Acids%26date%3D2011%26volume%3D41%26spage%3D1081%26epage%3D1092%26doi%3D10.1007%2Fs00726-010-0546-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessenius, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukowski, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semmler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiedenmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grötzinger, C.</span></span> <span> </span><span class="NLM_article-title">Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1038/86707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1038%2F86707" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=327-331&author=A.+Beckerauthor=C.+Hesseniusauthor=K.+Lichaauthor=B.+Ebertauthor=U.+Sukowskiauthor=W.+Semmlerauthor=B.+Wiedenmannauthor=C.+Gr%C3%B6tzinger&title=Receptor-targeted+optical+imaging+of+tumors+with+near-infrared+fluorescent+ligands&doi=10.1038%2F86707"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2F86707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F86707%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DA.%26aulast%3DHessenius%26aufirst%3DC.%26aulast%3DLicha%26aufirst%3DK.%26aulast%3DEbert%26aufirst%3DB.%26aulast%3DSukowski%26aufirst%3DU.%26aulast%3DSemmler%26aufirst%3DW.%26aulast%3DWiedenmann%26aufirst%3DB.%26aulast%3DGr%25C3%25B6tzinger%26aufirst%3DC.%26atitle%3DReceptor-targeted%2520optical%2520imaging%2520of%2520tumors%2520with%2520near-infrared%2520fluorescent%2520ligands%26jtitle%3DNat.%2520Biotechnol.%26date%3D2001%26volume%3D19%26spage%3D327%26epage%3D331%26doi%3D10.1038%2F86707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Peptides and peptide hormones for molecular imaging and disease diagnosis</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">3087</span>– <span class="NLM_lpage">3111</span>, <span class="refDoi"> DOI: 10.1021/cr900361p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr900361p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFOqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2010&pages=3087-3111&author=S.+Leeauthor=J.+Xieauthor=X.+Chen&title=Peptides+and+peptide+hormones+for+molecular+imaging+and+disease+diagnosis&doi=10.1021%2Fcr900361p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Peptides and Peptide Hormones for Molecular Imaging and Disease Diagnosis</span></div><div class="casAuthors">Lee, Seulki; Xie, Jin; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3087-3111</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA_xN6jlx4-LVg90H21EOLACvtfcHk0lhQYyFhQoVihA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFOqs78%253D&md5=b9cc74399e83cf1fe3fa5f02157520d9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fcr900361p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr900361p%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DPeptides%2520and%2520peptide%2520hormones%2520for%2520molecular%2520imaging%2520and%2520disease%2520diagnosis%26jtitle%3DChem.%2520Rev.%26date%3D2010%26volume%3D110%26spage%3D3087%26epage%3D3111%26doi%3D10.1021%2Fcr900361p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tangri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LiCalsi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sette, A.</span></span> <span> </span><span class="NLM_article-title">Rationally engineered proteins or antibodies with absent or reduced immunogenicity</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2191</span>– <span class="NLM_lpage">2199</span>, <span class="refDoi"> DOI: 10.2174/0929867023368647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.2174%2F0929867023368647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=12470241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD38XovV2qsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=2191-2199&author=S.+Tangriauthor=C.+LiCalsiauthor=J.+Sidneyauthor=A.+Sette&title=Rationally+engineered+proteins+or+antibodies+with+absent+or+reduced+immunogenicity&doi=10.2174%2F0929867023368647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally engineered proteins or antibodies with absent or reduced immunogenicity</span></div><div class="casAuthors">Tangri, S.; LiCalsi, C.; Sidney, J.; Sette, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2191-2199</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  One challenge assocd. with the clin. use of protein therapeutics destined for chronic administration is the potential for the development of unwanted anti-drug immune reactions.  The mol. basis for this reactivity is the binding of peptide fragments (epitopes) derived from the breakdown of the protein drug to the HLA receptors expressed by the patient's immune cells.  If these epitopes are recognized as "foreign" by the immune system, specific helper T lymphocytes (HTL), are activated, which initiate and direct the formation of antibodies against the protein drug.  These antibodies can bind and neutralize the protein drug, resulting in either decreased efficacy or total ineffectiveness of the drug.  Moreover, various safety concerns, such as allergic reactions and other adverse events, are also frequently assocd. with the formation of anti-drug antibodies.  Herein, the describe the development of "ImmunoStealth", an integrated bioinformatics, biochem. and cellular immunol. approach that specifically addresses the issue of unwanted immune responses against protein therapeutics.  Unwanted HTL epitopes are identified using in silico sequence anal. methods and high throughput in vitro biochem. evaluations and thereafter confirmed using cellular immunogenicity assays.  The "offending" epitopes within the drug are then rationally modified to alter their HLA binding capacity, and thus render them non-recognizable by the immune system.  This technol. will ultimately facilitate the design of safer, more potent and more economical drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqGbiCmilHQLVg90H21EOLACvtfcHk0liFAMFQ3TswMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovV2qsb4%253D&md5=66a58493a82e0d287f4c6866a2920152</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2174%2F0929867023368647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867023368647%26sid%3Dliteratum%253Aachs%26aulast%3DTangri%26aufirst%3DS.%26aulast%3DLiCalsi%26aufirst%3DC.%26aulast%3DSidney%26aufirst%3DJ.%26aulast%3DSette%26aufirst%3DA.%26atitle%3DRationally%2520engineered%2520proteins%2520or%2520antibodies%2520with%2520absent%2520or%2520reduced%2520immunogenicity%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2002%26volume%3D9%26spage%3D2191%26epage%3D2199%26doi%3D10.2174%2F0929867023368647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bray, B. L.</span></span> <span> </span><span class="NLM_article-title">Large-scale manufacture of peptide therapeutics by chemical synthesis</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">593</span>, <span class="refDoi"> DOI: 10.1038/nrd1133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1038%2Fnrd1133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=12815383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD3sXks1Oqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=587-593&author=B.+L.+Bray&title=Large-scale+manufacture+of+peptide+therapeutics+by+chemical+synthesis&doi=10.1038%2Fnrd1133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Innovation: Large-scale manufacture of peptide therapeutics by chemical synthesis</span></div><div class="casAuthors">Bray, Brian L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">587-593</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The large-scale com. prodn. of a 36-amino-acid peptide by chem. synthesis has been demonstrated in the development of enfuvirtide (T-20 or Fuzeon), a first-in-class membrane fusion inhibitor for the treatment of HIV.  The rationale behind route selection and the scale-up of the process used to manuf. enfuvirtide are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq23FtVAsqBerVg90H21EOLACvtfcHk0liFAMFQ3TswMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXks1Oqsr4%253D&md5=cd8a087455cf8058855d84076bc75927</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrd1133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1133%26sid%3Dliteratum%253Aachs%26aulast%3DBray%26aufirst%3DB.%2BL.%26atitle%3DLarge-scale%2520manufacture%2520of%2520peptide%2520therapeutics%2520by%2520chemical%2520synthesis%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D587%26epage%3D593%26doi%3D10.1038%2Fnrd1133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiaowen Ma, Xiaoyu Kang, Lei He, Jiming Zhou, Juan Zhou, Matthew B. Sturm, David G. Beer, Rork Kuick, Derek J. Nancarrow, Henry D. Appelman, Zhijun Pang, Weina Li, Cun Zhang, Wei Zhang, Yingqi Zhang, Thomas D. Wang, <span class="NLM_string-name hlFld-ContribAuthor">Meng Li</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Tumor Specific Peptide as EpCAM Ligand and Its Potential Diagnostic and Therapeutic Clinical Application. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2019,</strong> <em>16 </em>
                                    (5)
                                     , 2199-2213. <a href="https://doi.org/10.1021/acs.molpharmaceut.9b00185" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.9b00185</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.9b00185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.9b00185%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DIdentification%252Bof%252BTumor%252BSpecific%252BPeptide%252Bas%252BEpCAM%252BLigand%252Band%252BIts%252BPotential%252BDiagnostic%252Band%252BTherapeutic%252BClinical%252BApplication%26aulast%3DMa%26aufirst%3DXiaowen%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D12022019%26date%3D11042019%26date%3D18032019%26date%3D18042019%26date%3D11042019%26volume%3D16%26issue%3D5%26spage%3D2199%26epage%3D2213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyu  Kang</span>, <span class="hlFld-ContribAuthor ">Meng  Li</span>, <span class="hlFld-ContribAuthor ">Lei  liu</span>, <span class="hlFld-ContribAuthor ">Shaopeng  Liu</span>, <span class="hlFld-ContribAuthor ">Hao  Hu</span>, <span class="hlFld-ContribAuthor ">Rui  Zhang</span>, <span class="hlFld-ContribAuthor ">Siming  Ning</span>, <span class="hlFld-ContribAuthor ">Zuhong  Tian</span>, <span class="hlFld-ContribAuthor ">Yanglin  Pan</span>, <span class="hlFld-ContribAuthor ">Xuegang  Guo</span>, <span class="hlFld-ContribAuthor ">Kaichun  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted imaging of esophageal adenocarcinoma with a near-infrared fluorescent peptide. </span><span class="cited-content_cbyCitation_journal-name">BMC Gastroenterology</span><span> <strong>2021,</strong> <em>21 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12876-021-01840-3" title="DOI URL">https://doi.org/10.1186/s12876-021-01840-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12876-021-01840-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12876-021-01840-3%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Gastroenterology%26atitle%3DTargeted%252Bimaging%252Bof%252Besophageal%252Badenocarcinoma%252Bwith%252Ba%252Bnear-infrared%252Bfluorescent%252Bpeptide%26aulast%3DKang%26aufirst%3DXiaoyu%26date%3D2021%26date%3D2021%26volume%3D21%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Renfa  Liu</span>, <span class="hlFld-ContribAuthor ">Yunxue  Xu</span>, <span class="hlFld-ContribAuthor ">Kun  Xu</span>, <span class="hlFld-ContribAuthor ">Zhifei  Dai</span>. </span><span class="cited-content_cbyCitation_article-title">Current trends and key considerations in the clinical translation of targeted fluorescent probes for intraoperative navigation. </span><span class="cited-content_cbyCitation_journal-name">Aggregate</span><span> <strong>2021,</strong> <em>2 </em>
                                    (3)
                                     <a href="https://doi.org/10.1002/agt2.23" title="DOI URL">https://doi.org/10.1002/agt2.23</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/agt2.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fagt2.23%26sid%3Dliteratum%253Aachs%26jtitle%3DAggregate%26atitle%3DCurrent%252Btrends%252Band%252Bkey%252Bconsiderations%252Bin%252Bthe%252Bclinical%252Btranslation%252Bof%252Btargeted%252Bfluorescent%252Bprobes%252Bfor%252Bintraoperative%252Bnavigation%26aulast%3DLiu%26aufirst%3DRenfa%26date%3D2021%26date%3D2021%26volume%3D2%26issue%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Chen</span>, <span class="hlFld-ContribAuthor ">Tse-Shao  Chang</span>, <span class="hlFld-ContribAuthor ">Joel H.  Rubenstein</span>, <span class="hlFld-ContribAuthor ">Richard S.  Kwon</span>, <span class="hlFld-ContribAuthor ">Erik J.  Wamsteker</span>, <span class="hlFld-ContribAuthor ">Anoop  Prabhu</span>, <span class="hlFld-ContribAuthor ">Henry D.  Appelman</span>, <span class="hlFld-ContribAuthor ">Scott R.  Owens</span>, <span class="hlFld-ContribAuthor ">David G.  Beer</span>, <span class="hlFld-ContribAuthor ">D. Kim  Turgeon</span>, <span class="hlFld-ContribAuthor ">Eric J.  Seibel</span>, <span class="hlFld-ContribAuthor ">Thomas D.  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Detection of Barrett's Neoplasia with Near-Infrared Fluorescent Heterodimeric Peptide: Feasibility Results from a Phase 1 Study. </span><span class="cited-content_cbyCitation_journal-name">SSRN Electronic Journal</span><span> <strong>2021,</strong> <em>136 </em><a href="https://doi.org/10.2139/ssrn.3798559" title="DOI URL">https://doi.org/10.2139/ssrn.3798559</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2139/ssrn.3798559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2139%2Fssrn.3798559%26sid%3Dliteratum%253Aachs%26jtitle%3DSSRN%2520Electronic%2520Journal%26atitle%3DDetection%252Bof%252BBarrett%252527s%252BNeoplasia%252Bwith%252BNear-Infrared%252BFluorescent%252BHeterodimeric%252BPeptide%25253A%252BFeasibility%252BResults%252Bfrom%252Ba%252BPhase%252B1%252BStudy%26aulast%3DChen%26aufirst%3DJing%26date%3D2021%26volume%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gaoming  Li</span>, <span class="hlFld-ContribAuthor ">Xiyu  Duan</span>, <span class="hlFld-ContribAuthor ">Miki  Lee</span>, <span class="hlFld-ContribAuthor ">Mayur  Birla</span>, <span class="hlFld-ContribAuthor ">Jing  Chen</span>, <span class="hlFld-ContribAuthor ">Kenn R.  Oldham</span>, <span class="hlFld-ContribAuthor ">Thomas D.  Wang</span>, <span class="hlFld-ContribAuthor ">Haijun  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Ultra-Compact Microsystems-Based Confocal Endomicroscope. </span><span class="cited-content_cbyCitation_journal-name">IEEE Transactions on Medical Imaging</span><span> <strong>2020,</strong> <em>39 </em>
                                    (7)
                                     , 2406-2414. <a href="https://doi.org/10.1109/TMI.2020.2971476" title="DOI URL">https://doi.org/10.1109/TMI.2020.2971476</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1109/TMI.2020.2971476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1109%2FTMI.2020.2971476%26sid%3Dliteratum%253Aachs%26jtitle%3DIEEE%2520Transactions%2520on%2520Medical%2520Imaging%26atitle%3DUltra-Compact%252BMicrosystems-Based%252BConfocal%252BEndomicroscope%26aulast%3DLi%26aufirst%3DGaoming%26date%3D2020%26volume%3D39%26issue%3D7%26spage%3D2406%26epage%3D2414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fa  Wang</span>, <span class="hlFld-ContribAuthor ">Xiyu  Duan</span>, <span class="hlFld-ContribAuthor ">Jing  Chen</span>, <span class="hlFld-ContribAuthor ">Zhenghong  Gao</span>, <span class="hlFld-ContribAuthor ">Juan  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaoli  Wu</span>, <span class="hlFld-ContribAuthor ">Tse-Shao  Chang</span>, <span class="hlFld-ContribAuthor ">Miki  Lee</span>, <span class="hlFld-ContribAuthor ">Gaoming  Li</span>, <span class="hlFld-ContribAuthor ">Asma  Nusrat</span>, <span class="hlFld-ContribAuthor ">Rork  Kuick</span>, <span class="hlFld-ContribAuthor ">Henry D.  Appelman</span>, <span class="hlFld-ContribAuthor ">Thomas D.  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Integrated Imaging Methodology Detects Claudin-1 Expression in Premalignant Nonpolypoid and Polypoid Colonic Epithelium in Mice. </span><span class="cited-content_cbyCitation_journal-name">Clinical and Translational Gastroenterology</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     , e00089. <a href="https://doi.org/10.14309/ctg.0000000000000089" title="DOI URL">https://doi.org/10.14309/ctg.0000000000000089</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.14309/ctg.0000000000000089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.14309%2Fctg.0000000000000089%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520and%2520Translational%2520Gastroenterology%26atitle%3DIntegrated%252BImaging%252BMethodology%252BDetects%252BClaudin-1%252BExpression%252Bin%252BPremalignant%252BNonpolypoid%252Band%252BPolypoid%252BColonic%252BEpithelium%252Bin%252BMice%26aulast%3DWang%26aufirst%3DFa%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D1%26spage%3De00089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Chen</span>, <span class="hlFld-ContribAuthor ">Zhenghong  Gao</span>, <span class="hlFld-ContribAuthor ">Gaoming  Li</span>, <span class="hlFld-ContribAuthor ">Thomas D.  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-modal
              in vivo
              fluorescence and photoacoustic imaging using a heterodimeric peptide. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2018,</strong> <em>54 </em>
                                    (94)
                                     , 13196-13199. <a href="https://doi.org/10.1039/C8CC06774K" title="DOI URL">https://doi.org/10.1039/C8CC06774K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8CC06774K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8CC06774K%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DDual-modal%252Bin%252Bvivo%252Bfluorescence%252Band%252Bphotoacoustic%252Bimaging%252Busing%252Ba%252Bheterodimeric%252Bpeptide%26aulast%3DChen%26aufirst%3DJing%26date%3D2018%26date%3D2018%26volume%3D54%26issue%3D94%26spage%3D13196%26epage%3D13199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of the peptide heterodimer. Chemical structures for heptapeptide monomers QRHKPRE (QRH*) and KSPNPRF (KSP*) are shown along with the arrangement of heterodimer configuration with the variable-length linkers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Optimization of the peptide heterodimer. (A–E) Confocal-microscopy images of fluorescence from the binding of the candidate heterodimers with linkers (A) E2, (B) Hex, (C) E3, (D) E6, and (E) E10 to the surfaces of SKBr3 cells (arrows). (F) Quantified results showing that the E3 linker provides the highest mean fluorescence intensity. <i>P</i>-values were determined using unpaired <i>t</i> tests. Measurements are an average of 10 randomly chosen cells from 4 images collected independently. (G) Western blot showing EGFR and ErbB2 expression in SKBr3 and QhTERT cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Characterization of the peptide heterodimer. (A–D) siRNA knockdown experiments of QRH*–KSP*–E3–Cy5.5 (red) showing significantly greater binding to the surfaces (arrows) of (A) siCL (control) SkBr3 cells than to (B) siEGFR (knockdown) cells and significantly greater binding to the surfaces of (C) siCL cells than to (D) siErbB2 (knockdown) cells. (E) Quantified results showing significantly greater intensity for siCL-cell binding versus siEGFR-cell binding and significantly greater intensity for siCL-cell binding versus siErbB2-cell binding (<i>P</i> = 3.6 × 10<sup>–4</sup> and <i>P</i> = 7.8 × 10<sup>–3</sup>, respectively, by unpaired <i>t</i> tests). The mean values were calculated from five cells chosen randomly from three images collected independently. (F) Western blots showing EGFR and ErbB2 expression in the control and knockdown cells. (G) Apparent dissociation constant (binding affinity) of QRH*–KSP*–E3–Cy5.5, <i>k</i><sub>d</sub> = 23 nM, versus those of QRH*–Cy5.5 and KSP*–Cy5.5, <i>k</i><sub>d</sub> = 98 and 54 nM, respectively. (H) Apparent association-time constant of QRH*–KSP*–E3–Cy5.5, <i>k</i> = 0.22 min<sup>–1</sup> (4.5 min), versus those of QRH*–Cy5.5 and KSP*–Cy5.5, <i>k</i> = 0.21 min<sup>–1</sup> (4.8 min) and 0.35 min<sup>–1</sup> (2.9 min), respectively. Results for each measurement are representative of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. No effect of the peptide heterodimer on cell signaling. We evaluated the effects of QRH*–KSP*–E3–Cy5.5 binding on downstream cell signaling in SKBr3 cells. In the Western blot, we observed no changes in phosphorylation of EGFR (p-EGFR), ErbB2 (p-ErbB2), or of downstream AKT (p-AKT) and ERK (p-ERK) when the cells were incubated with the heterodimer at 1, 5, and 20 μM. By comparison, the addition of EGF, an endogenous ligand for EGFR, showed increased expression of p-AKT and p-ERK. The addition of 100 nM lapatinib, a tyrosine-kinase inhibitor known to interrupt EGFR and ErbB2 signaling in solid tumors, resulted in reduced expression of p-EGFR, p-ErbB2, and p-AKT. Cells treated with 1% DMSO and untreated cells showed no suppression of EGFR- and ErbB2-mediated signaling. β-tubulin was used as a loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pharmacokinetics of the peptide heterodimer. (A) Representative whole-body NIR-fluorescence images showing uptake of the targeted peptide heterodimer QRH*–KSP*–E3–Cy5.5 in a xenograft tumor (arrow) over time. (B) Representative whole-body NIR-fluorescence images with (GGGAGGG)<sub>2</sub>KK–Cy5.5, the control. (C) Quantitative analysis showing peak mean signal from <i>n</i> = 6 tumors at 2 h following iv injection. Mean (±SD) T/B ratios of 2.39 ± 0.52 and 1.43 ± 0.28 were measured at the tumors for the targeted (<i>n</i> = 6) and control (<i>n</i> = 6) peptides, respectively. The signal returns to baseline by ∼24 h. (D) Mean fluorescence intensities from individual tumors at 2 h with the targeted and control peptides, <i>P</i> = 2.9 × 10<sup>–3</sup> by an unpaired <i>t</i> test. (E) Representative whole-body NIR-fluorescence images with unlabeled QRH*, KSP*, and both (QRH* and KSP*) monomer peptides iv-injected prior to the heterodimer for blocking. (F) Quantified results showing significant reduction in mean intensity from the tumor (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Biodistribution of the peptide heterodimer. (A,B) Representative fluorescence images from excised mouse organs at ∼2 h postinjection of (A) targeted peptide heterodimer QRH*–KSP*–E3–Cy5.5 and (B) control peptide (GGGAGGG)<sub>2</sub>KK–Cy5.5. (C) Fluorescent signals quantified from individual organs (<i>n</i> = 6) for each peptide. The mean fluorescence intensity for the targeted one was significantly greater than that for the control (5.28 ± 1.14 versus 2.24 ± 0.82, <i>P</i> = 5.5 × 10<sup>–4</sup> by an unpaired <i>t</i> test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Specific binding of the peptide heterodimer to Barrett’s neoplasia: representative confocal-microscopy images of human esophageal specimens ex vivo with minimal QRH*–KSP*–E3–Cy5.5 (red) staining in (A) squamous (SQ) and (B) Barrett’s esophagus (BE) cells and increased intensity in (C) high-grade dysplasia (HGD) and (D) esophageal adenocarcinoma (EAC) cells. Similar results were found with the AF568-labeled anti-EGFR antibody (yellow) and the AF488-labeled anti-ErbB2 antibody (green). Merged images show colocalization of peptide and antibody binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/medium/jm-2018-00405p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Colocalization of the peptide heterodimer and antibody binding to Barrett’s neoplasia. (A) Confocal-microscopy images of serial sections of HGD in human esophageal specimens following staining with QRH*–KSP*–E3–Cy5.5 (red), anti-EGFR antibody labeled with AF568 (yellow), and anti-ErbB2 antibody labeled with AF488 (green). Fluorescence intensity was quantified from the mean of a set of three boxes with dimensions of 20 × 20 μm<sup>2</sup> placed over random crypts. Colocalization of binding can be appreciated on the merged image. (B) High-magnification images from the dashed boxes. On the merged image, Pearson’s correlation coefficients of ρ = 0.60 and 0.75 were measured for EGFR and ErbB2, respectively. (C) Significantly greater mean QRH*–KSP*–E3–Cy5.5-fluorescence intensities from HGD and EAC cells compared with those from BE and SQ cells, from <i>n</i> = 31, 8, 23, and 12 SQ, BE, HGD, and EAC specimens, respectively. The <i>P</i>-value for the differences are calculated by Tukey’s multiple comparisons. Similar results were found for anti-EGFR-AF568 and anti-ErbB2-AF488. (D) ROC curve showing 88% sensitivity, 87% specificity, and an AUC of 0.95 with QRH*–KSP*–E3–Cy5.5; 74% sensitivity, 69% specificity, and an AUC of 0.79 with anti-EGRF-AF568; and 85% sensitivity, 79% specificity, and an AUC of 0.91 with anti-ErbB2-AF488.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-12/acs.jmedchem.8b00405/20180622/images/large/jm-2018-00405p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00405&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i37">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00880" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00880" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 40 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torre, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Global cancer incidence and mortality rates and trends—an update</span>. <i>Cancer Epidemiol., Biomarkers Prev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1158/1055-9965.EPI-15-0578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1158%2F1055-9965.EPI-15-0578" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=16-27&author=L.+A.+Torreauthor=R.+L.+Siegelauthor=E.+M.+Wardauthor=A.+Jemal&title=Global+cancer+incidence+and+mortality+rates+and+trends%E2%80%94an+update&doi=10.1158%2F1055-9965.EPI-15-0578"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1158%2F1055-9965.EPI-15-0578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1055-9965.EPI-15-0578%26sid%3Dliteratum%253Aachs%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DWard%26aufirst%3DE.%2BM.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520cancer%2520incidence%2520and%2520mortality%2520rates%2520and%2520trends%25E2%2580%2594an%2520update%26jtitle%3DCancer%2520Epidemiol.%252C%2520Biomarkers%2520Prev.%26date%3D2016%26volume%3D25%26spage%3D16%26epage%3D27%26doi%3D10.1158%2F1055-9965.EPI-15-0578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spechler, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, R. F.</span></span> <span> </span><span class="NLM_article-title">Barrett’s esophagus</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">836</span>– <span class="NLM_lpage">845</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1314704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1056%2FNEJMra1314704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=25162890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12jtLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=836-845&author=S.+J.+Spechlerauthor=R.+F.+Souza&title=Barrett%E2%80%99s+esophagus&doi=10.1056%2FNEJMra1314704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Barrett's esophagus</span></div><div class="casAuthors">Spechler, Stuart J.; Souza, Rhonda F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">836-845, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGronTSVJJPJlbVg90H21EOLACvtfcHk0lgK0JzJVWkJKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12jtLbN&md5=124a4595410a69ef7c81fcf27ce7b193</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1314704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1314704%26sid%3Dliteratum%253Aachs%26aulast%3DSpechler%26aufirst%3DS.%2BJ.%26aulast%3DSouza%26aufirst%3DR.%2BF.%26atitle%3DBarrett%25E2%2580%2599s%2520esophagus%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D836%26epage%3D845%26doi%3D10.1056%2FNEJMra1314704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levine, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggitt, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blount, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, B. J.</span></span> <span> </span><span class="NLM_article-title">An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’s esophagus</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/0016-5085(93)90008-Z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1016%2F0016-5085%2893%2990008-Z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=1993&pages=40-50&author=D.+S.+Levineauthor=R.+C.+Haggittauthor=P.+L.+Blountauthor=P.+S.+Rabinovitchauthor=V.+W.+Ruschauthor=B.+J.+Reid&title=An+endoscopic+biopsy+protocol+can+differentiate+high-grade+dysplasia+from+early+adenocarcinoma+in+Barrett%E2%80%99s+esophagus&doi=10.1016%2F0016-5085%2893%2990008-Z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2F0016-5085%2893%2990008-Z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0016-5085%252893%252990008-Z%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DD.%2BS.%26aulast%3DHaggitt%26aufirst%3DR.%2BC.%26aulast%3DBlount%26aufirst%3DP.%2BL.%26aulast%3DRabinovitch%26aufirst%3DP.%2BS.%26aulast%3DRusch%26aufirst%3DV.%2BW.%26aulast%3DReid%26aufirst%3DB.%2BJ.%26atitle%3DAn%2520endoscopic%2520biopsy%2520protocol%2520can%2520differentiate%2520high-grade%2520dysplasia%2520from%2520early%2520adenocarcinoma%2520in%2520Barrett%25E2%2580%2599s%2520esophagus%26jtitle%3DGastroenterology%26date%3D1993%26volume%3D105%26spage%3D40%26epage%3D50%26doi%3D10.1016%2F0016-5085%2893%2990008-Z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lekakos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karidis, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitroulis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsigris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouraklis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiteas, N.</span></span> <span> </span><span class="NLM_article-title">Barrett’s esophagus with high-grade dysplasia: focus on current treatment options</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">4174</span>, <span class="refDoi"> DOI: 10.3748/wjg.v17.i37.4174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.3748%2Fwjg.v17.i37.4174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=22072848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A280%3ADC%252BC3MbotlOltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=4174&author=L.+Lekakosauthor=N.+P.+Karidisauthor=D.+Dimitroulisauthor=C.+Tsigrisauthor=G.+Kouraklisauthor=N.+Nikiteas&title=Barrett%E2%80%99s+esophagus+with+high-grade+dysplasia%3A+focus+on+current+treatment+options&doi=10.3748%2Fwjg.v17.i37.4174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Barrett's esophagus with high-grade dysplasia: focus on current treatment options</span></div><div class="casAuthors">Lekakos Leonidas; Karidis Nikolaos P; Dimitroulis Dimitrios; Tsigris Christos; Kouraklis Gregory; Nikiteas Nikolaos</div><div class="citationInfo"><span class="NLM_cas:title">World journal of gastroenterology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">4174-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">High-grade dysplasia (HGD) in Barrett's esophagus (BE) is the critical step before invasive esophageal adenocarcinoma.  Although its natural history remains unclear, an aggressive therapeutic approach is usually indicated.  Esophagectomy represents the only treatment able to reliably eradicate the neoplastic epithelium.  In healthy patients with reasonable life expectancy, vagal-sparing esophagectomy, with associated low mortality and low early and late postoperative morbidity, is considered the treatment of choice for BE with HGD.  Patients unfit for surgery should be managed in a less aggressive manner, using endoscopic ablation or endoscopic mucosal resection of the entire BE segment, followed by lifelong surveillance.  Patients eligible for surgery who present with a long BE segment, multifocal dysplastic lesions, severe reflux symptoms, a large fixed hiatal hernia or dysphagia comprise a challenging group with regard to the appropriate treatment, either surgical or endoscopic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNbjar9RT4pDMsgLhIoICsfW6udTcc2ebdqGjPblEQObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbotlOltA%253D%253D&md5=cf552aa08a496f6c2c91cd8dd25795c8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v17.i37.4174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v17.i37.4174%26sid%3Dliteratum%253Aachs%26aulast%3DLekakos%26aufirst%3DL.%26aulast%3DKaridis%26aufirst%3DN.%2BP.%26aulast%3DDimitroulis%26aufirst%3DD.%26aulast%3DTsigris%26aufirst%3DC.%26aulast%3DKouraklis%26aufirst%3DG.%26aulast%3DNikiteas%26aufirst%3DN.%26atitle%3DBarrett%25E2%2580%2599s%2520esophagus%2520with%2520high-grade%2520dysplasia%253A%2520focus%2520on%2520current%2520treatment%2520options%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2011%26volume%3D17%26spage%3D4174%26doi%3D10.3748%2Fwjg.v17.i37.4174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaheen, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerson, L. B.</span></span> <span> </span><span class="NLM_article-title">ACG clinical guideline: diagnosis and management of Barrett’s esophagus</span>. <i>Am. J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/ajg.2015.322</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1038%2Fajg.2015.322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=26526079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Cmt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=30-50&author=N.+J.+Shaheenauthor=G.+W.+Falkauthor=P.+G.+Iyerauthor=L.+B.+Gerson&title=ACG+clinical+guideline%3A+diagnosis+and+management+of+Barrett%E2%80%99s+esophagus&doi=10.1038%2Fajg.2015.322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus</span></div><div class="casAuthors">Shaheen, Nicholas J.; Falk, Gary W.; Iyer, Prasad G.; Gerson, Lauren B.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-50</span>CODEN:
                <span class="NLM_cas:coden">AJGAAR</span>;
        ISSN:<span class="NLM_cas:issn">0002-9270</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Barrett's esophagus (BE) is among the most common conditions encountered by the gastroenterologist.  In this document, the American College of Gastroenterol. updates its guidance for the best practices in caring for these patients.  These guidelines continue to endorse screening of high-risk patients for BE; however, routine screening is limited to men with reflux symptoms and multiple other risk factors.  Acknowledging recent data on the low risk of malignant progression in patients with nondysplastic BE, endoscopic surveillance intervals are attenuated in this population; patients with nondysplastic BE should undergo endoscopic surveillance no more frequently than every 3-5 years.  Neither routine use of biomarker panels nor advanced endoscopic imaging techniques (beyond high-definition endoscopy) is recommended at this time.  Endoscopic ablative therapy is recommended for patients with BE and high-grade dysplasia, as well as T1a esophageal adenocarcinoma.  Based on recent level 1 evidence, endoscopic ablative therapy is also recommended for patients with BE and low-grade dysplasia, although endoscopic surveillance continues to be an acceptable alternative.  Given the relatively common recurrence of BE after ablation, we suggest postablation endoscopic surveillance intervals.  Although many of the recommendations provided are based on weak evidence or expert opinion, this document provides a pragmatic framework for the care of the patient with BE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTxL2_G9NEVrVg90H21EOLACvtfcHk0lgK0JzJVWkJKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Cmt7Y%253D&md5=e3117fc652ebd9988d8c5a64b36c2424</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fajg.2015.322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fajg.2015.322%26sid%3Dliteratum%253Aachs%26aulast%3DShaheen%26aufirst%3DN.%2BJ.%26aulast%3DFalk%26aufirst%3DG.%2BW.%26aulast%3DIyer%26aufirst%3DP.%2BG.%26aulast%3DGerson%26aufirst%3DL.%2BB.%26atitle%3DACG%2520clinical%2520guideline%253A%2520diagnosis%2520and%2520management%2520of%2520Barrett%25E2%2580%2599s%2520esophagus%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2016%26volume%3D111%26spage%3D30%26epage%3D50%26doi%3D10.1038%2Fajg.2015.322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, J. A.</span></span> <span> </span><span class="NLM_article-title">Chemoprevention of esophageal adenocarcinoma</span>. <i>Ther. Adv. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1177/1756283X08093568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1177%2F1756283X08093568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=21180511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FmvVOnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2008&pages=7-18&author=J.+A.+Abrams&title=Chemoprevention+of+esophageal+adenocarcinoma&doi=10.1177%2F1756283X08093568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoprevention of esophageal adenocarcinoma</span></div><div class="casAuthors">Abrams Julian A</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic advances in gastroenterology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-18</span>
        ISSN:<span class="NLM_cas:issn">1756-283X</span>.
    </div><div class="casAbstract">The incidence of esophageal adenocarcinoma (EAC) is rising rapidly in Western countries, and effective chemoprevention for this malignancy is lacking.  Endoscopic surveillance of patients with Barrett's esophagus is currently employed to diagnose EAC at earlier stages, but this strategy has several limitations.  Non-steroidal anti-inflammatory drugs and proton pump inhibitors are the most promising agents for prevention of EAC, and a randomized controlled trial of aspirin and esomeprazole is ongoing.  Other agents under investigation include green tea, berries, and antioxidants.  Cost-effectiveness analyses have shown that chemopreventive agents need to be highly effective at preventing EAC in order to have benefit beyond endoscopic surveillance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4gQmIkMU1A-2mnZh2OgS0fW6udTcc2ebDEt7w0okMrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FmvVOnsA%253D%253D&md5=cbb911f99ec887331baf8477256efcca</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1177%2F1756283X08093568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1756283X08093568%26sid%3Dliteratum%253Aachs%26aulast%3DAbrams%26aufirst%3DJ.%2BA.%26atitle%3DChemoprevention%2520of%2520esophageal%2520adenocarcinoma%26jtitle%3DTher.%2520Adv.%2520Gastroenterol.%26date%3D2008%26volume%3D1%26spage%3D7%26epage%3D18%26doi%3D10.1177%2F1756283X08093568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dulak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lieshout, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saksena, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baca, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">4383</span>– <span class="NLM_lpage">4393</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1158%2F0008-5472.CAN-11-3893" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=4383-4393&author=A.+M.+Dulakauthor=S.+E.+Schumacherauthor=J.+van+Lieshoutauthor=Y.+Imamuraauthor=C.+Foxauthor=B.+Shimauthor=A.+H.+Ramosauthor=G.+Saksenaauthor=S.+C.+Bacaauthor=J.+Baselga&title=Gastrointestinal+adenocarcinomas+of+the+esophagus%2C+stomach%2C+and+colon+exhibit+distinct+patterns+of+genome+instability+and+oncogenesis&doi=10.1158%2F0008-5472.CAN-11-3893"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3893%26sid%3Dliteratum%253Aachs%26aulast%3DDulak%26aufirst%3DA.%2BM.%26aulast%3DSchumacher%26aufirst%3DS.%2BE.%26aulast%3Dvan%2BLieshout%26aufirst%3DJ.%26aulast%3DImamura%26aufirst%3DY.%26aulast%3DFox%26aufirst%3DC.%26aulast%3DShim%26aufirst%3DB.%26aulast%3DRamos%26aufirst%3DA.%2BH.%26aulast%3DSaksena%26aufirst%3DG.%26aulast%3DBaca%26aufirst%3DS.%2BC.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DGastrointestinal%2520adenocarcinomas%2520of%2520the%2520esophagus%252C%2520stomach%252C%2520and%2520colon%2520exhibit%2520distinct%2520patterns%2520of%2520genome%2520instability%2520and%2520oncogenesis%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D4383%26epage%3D4393%26doi%3D10.1158%2F0008-5472.CAN-11-3893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAdam, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danikas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tselepis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, G.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett’s esophagus (BE)</span>. <i>Am. J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1038/ajg.2010.433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1038%2Fajg.2010.433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=21157443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVKitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2011&pages=46-56&author=J.+Croninauthor=E.+McAdamauthor=A.+Danikasauthor=C.+Tselepisauthor=P.+Griffithsauthor=J.+Baxterauthor=L.+Thomasauthor=J.+Mansonauthor=G.+Jenkins&title=Epidermal+growth+factor+receptor+%28EGFR%29+is+overexpressed+in+high-grade+dysplasia+and+adenocarcinoma+of+the+esophagus+and+may+represent+a+biomarker+of+histological+progression+in+Barrett%E2%80%99s+esophagus+%28BE%29&doi=10.1038%2Fajg.2010.433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in High-Grade Dysplasia and Adenocarcinoma of the Esophagus and May Represent a Biomarker of Histological Progression in Barrett's Esophagus (BE)</span></div><div class="casAuthors">Cronin, James; McAdam, Elizabeth; Danikas, Antonios; Tselepis, Chris; Griffiths, Paul; Baxter, John; Thomas, Linzi; Manson, James; Jenkins, Gareth</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-56</span>CODEN:
                <span class="NLM_cas:coden">AJGAAR</span>;
        ISSN:<span class="NLM_cas:issn">0002-9270</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Objectives: The assessment of cancer risk in patients with Barrett's esophagus (BE) is currently fraught with difficulty.  The current gold std. method of assessing cancer risk is histol. assessment, with the appearance of high-grade dysplasia (HGD) as the key event monitored.  Sampling error during endoscopy limits the usefulness of this approach, and there has been much recent interest in supplementing histol. assessment with mol. markers, which may aid in patient stratification.  Methods: No mol. marker has been yet validated to accurately correlate with esophageal histol. progression.  Here, we assessed the suitability of several membranous proteins as biomarkers by correlating their abundance with histol. progression.  In all, 107 patient samples, from 100 patients, were arranged on a tissue microarray (TMA) and represented the various stages of histol. progression in BE.  This TMA was probed with antibodies for eight receptor proteins (mostly membranous).  Results: Epidermal growth factor receptor (EGFR) staining was found to be the most promising biomarker identified with clear increases in staining accompanying histol. progression.  Further, immunohistochem. was performed using the full-tissue sections from BE, HGD, and adenocarcinoma tissues, which confirmed the stepwise increase in EGFR abundance.  Using a robust H-score anal., EGFR abundance was shown to increase 13-fold in the adenocarcinoma tissues compared to the BE tissues.  EGFR was "overexpressed" in 35% of HGD specimens and 80% of adenocarcinoma specimens when using the H-score of the BE patients (plus 3 s.d.) as the threshold to define overexpression.  EGFR staining was also noted to be higher in BE tissues adjacent to HGD/adenocarcinoma.  Western blotting, although showing more EGFR protein in the adenocarcinomas compared to the BE tissue, was highly variable.  EGFR overexpression was accompanied by aneuploidy (gain) of chromosome 7, plus amplification of the EGFR locus.  Finally, the bile acid deoxycholic acid (DCA) (at neutral and acidic pH) and acid alone was capable of upregulating EGFR mRNA in vitro, and in the case of neutral pH DCA, this was NF-κB dependent.  Conclusions: EGFR is overexpressed during the histol. progression in BE tissues and hence may be useful as a biomarker of histol. progression.  Furthermore, as EGFR is a membranous protein expressed on the luminal surface of the esophageal mucosa, it may also be a useful target for biopsy guidance during endoscopy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1ixl-JgkXuLVg90H21EOLACvtfcHk0lgcqrYn6TxcEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVKitQ%253D%253D&md5=0b11a2f2b16a57005f64dc04736915f7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fajg.2010.433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fajg.2010.433%26sid%3Dliteratum%253Aachs%26aulast%3DCronin%26aufirst%3DJ.%26aulast%3DMcAdam%26aufirst%3DE.%26aulast%3DDanikas%26aufirst%3DA.%26aulast%3DTselepis%26aufirst%3DC.%26aulast%3DGriffiths%26aufirst%3DP.%26aulast%3DBaxter%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3DManson%26aufirst%3DJ.%26aulast%3DJenkins%26aufirst%3DG.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520is%2520overexpressed%2520in%2520high-grade%2520dysplasia%2520and%2520adenocarcinoma%2520of%2520the%2520esophagus%2520and%2520may%2520represent%2520a%2520biomarker%2520of%2520histological%2520progression%2520in%2520Barrett%25E2%2580%2599s%2520esophagus%2520%2528BE%2529%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2011%26volume%3D106%26spage%3D46%26epage%3D56%26doi%3D10.1038%2Fajg.2010.433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratzke, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddaus, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrin, L. J.</span></span> <span> </span><span class="NLM_article-title">ERBB2 amplifications in esophageal adenocarcinoma</span>. <i>Ann. Thorac. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1790</span>– <span class="NLM_lpage">1800</span>, <span class="refDoi"> DOI: 10.1016/j.athoracsur.2004.05.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1016%2Fj.athoracsur.2004.05.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=15511476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A280%3ADC%252BD2crks1Sitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=1790-1800&author=P.+S.+Dahlbergauthor=B.+A.+Jacobsonauthor=G.+Dahalauthor=J.+M.+Finkauthor=R.+A.+Kratzkeauthor=M.+A.+Maddausauthor=L.+J.+Ferrin&title=ERBB2+amplifications+in+esophageal+adenocarcinoma&doi=10.1016%2Fj.athoracsur.2004.05.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB2 amplifications in esophageal adenocarcinoma</span></div><div class="casAuthors">Dahlberg Peter S; Jacobson Blake A; Dahal Ganesh; Fink James M; Kratzke Robert A; Maddaus Michael A; Ferrin Lance J</div><div class="citationInfo"><span class="NLM_cas:title">The Annals of thoracic surgery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1790-800</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, Her-2-neu) gene amplification and overexpression has been reported in several types of cancer.  The purpose of this study was to (1) determine the frequency of ERBB2 amplification (in comparison to other proto-oncogenes) in tumors from patients with esophageal adenocarcinoma, (2) characterize structural details of an ERBB2 amplicon in the esophageal adenocarcinoma cell line OE19 (contains a 100-fold ERBB2 amplification), and (3) test whether growth of the OE19 cell line is sensitive to the ERBB2 inhibitor trastuzumab (Herceptin; Genetech, Inc, San Francisco, CA).  METHODS:  First, we determined the frequency, by Southern blotting techniques, of amplification of ERBB2 and 13 other proto-oncogenes in a panel of 25 esophageal adenocarcinoma tumors.  Then, in a second panel of 10 tumor specimens, expression levels of the ERBB2 gene and of several other genes that flank ERBB2 on chromosome 17 were determined by microarray analysis.  Next we characterized the ERBB2 amplicon in the esophageal adenocarcinoma cell line OE19 using cytogenetic methods and a Rec-A protein assisted restriction endonuclease mapping technique.  Finally, an in vitro growth inhibition assay was used to measure the sensitivity of OE19 and OE33 cells to treatment with trastuzumab (humanized antibody to ERBB2).  RESULTS:  ERBB2 was the most frequently amplified proto-oncogene among 25 esophageal adenocarcinoma tumors tested (greater than 10-fold amplification in 3 of 25 (12%) tumors tested).  The OE19 cell line contains a 100-fold amplification of the ERBB2 gene, and highly expresses its messenger ribonucleic acid.  Transcripts from genes that flank ERBB2 including GRB7, a protein linked to metastasis in esophageal cancer, also showed high levels of expression.  In OE19 cells, the ERBB2 amplicon was localized to a homogeneously staining region of chromosome 14.  Southern blots from the Rec-A protein assisted restriction endonuclease cleavage mapping experiments in OE19 showed a strong band of 210 kilobases in size, demonstrating that the main amplicon was a tandem repeat.  In the in vitro growth inhibition assay, trastuzumab inhibited the OE19 and OE33 cells growth by 49% and 20%, respectively, at a saturating concentration of 20 microg/mL.  CONCLUSIONS:  ERBB2 is the most frequently amplified proto-oncogene in esophageal adenocarcinoma among the genes that we tested.  In the OE19 esophageal adenocarcinoma cell line, the ERBB2 amplicon is translocated onto chromosome 14, is amplified 100-fold at the deoxyribonucleic acid level, and is highly overexpressed at the messenger ribonucleic acid level.  Finally, the growth of this cell line was inhibited by incubation with trastuzumab.  These results demonstrate that a substantial number of esophageal adenocarcinomas have amplified copies of the ERBB2 gene, and that they may be responsive to ERBB2 targeted therapies such as trastuzumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfmkLzcsXZvdyzdcP07UmufW6udTcc2ebDEt7w0okMrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crks1Sitg%253D%253D&md5=32fb182bab6d577d127691f1de55e868</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.athoracsur.2004.05.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.athoracsur.2004.05.037%26sid%3Dliteratum%253Aachs%26aulast%3DDahlberg%26aufirst%3DP.%2BS.%26aulast%3DJacobson%26aufirst%3DB.%2BA.%26aulast%3DDahal%26aufirst%3DG.%26aulast%3DFink%26aufirst%3DJ.%2BM.%26aulast%3DKratzke%26aufirst%3DR.%2BA.%26aulast%3DMaddaus%26aufirst%3DM.%2BA.%26aulast%3DFerrin%26aufirst%3DL.%2BJ.%26atitle%3DERBB2%2520amplifications%2520in%2520esophageal%2520adenocarcinoma%26jtitle%3DAnn.%2520Thorac.%2520Surg.%26date%3D2004%26volume%3D78%26spage%3D1790%26epage%3D1800%26doi%3D10.1016%2Fj.athoracsur.2004.05.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Citri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span> <span> </span><span class="NLM_article-title">EGF–ERBB signalling: towards the systems level</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1038/nrm1962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1038%2Fnrm1962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=16829981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1OhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=505-516&author=A.+Citriauthor=Y.+Yarden&title=EGF%E2%80%93ERBB+signalling%3A+towards+the+systems+level&doi=10.1038%2Fnrm1962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">EGF-ERBB signaling: towards the systems level</span></div><div class="casAuthors">Citri, Ami; Yarden, Yosef</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">505-516</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Signaling through the ErbB/HER receptors is intricately involved in human cancer and already serves as a target for several cancer drugs.  Because of its inherent complexity, it is useful to envision ErbB signaling as a bow-tie-configured, evolvable network, which shares modularity, redundancy, and control circuits with robust biol. and engineered systems.  Because network fragility is an inevitable trade-off of robustness, systems-level understanding is expected to generate therapeutic opportunities to intercept aberrant network activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSSvt-HLGFXLVg90H21EOLACvtfcHk0lj5eGIi0rwvMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1OhsLc%253D&md5=0d41fd52d0498765a16b422d66398037</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrm1962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1962%26sid%3Dliteratum%253Aachs%26aulast%3DCitri%26aufirst%3DA.%26aulast%3DYarden%26aufirst%3DY.%26atitle%3DEGF%25E2%2580%2593ERBB%2520signalling%253A%2520towards%2520the%2520systems%2520level%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2006%26volume%3D7%26spage%3D505%26epage%3D516%26doi%3D10.1038%2Fnrm1962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, A.
L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’donovan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provenzano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McManus, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovat, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, R. C.</span></span> <span> </span><span class="NLM_article-title">Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>230</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1002/path.4044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1002%2Fpath.4044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=22733579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVektb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=230&publication_year=2013&pages=118-128&author=A.%0AL.+Patersonauthor=M.+O%E2%80%99donovanauthor=E.+Provenzanoauthor=L.+J.+Murrayauthor=H.+G.+Colemanauthor=B.+T.+Johnsonauthor=D.+T.+McManusauthor=M.+Novelliauthor=L.+B.+Lovatauthor=R.+C.+Fitzgerald&title=Characterization+of+the+timing+and+prevalence+of+receptor+tyrosine+kinase+expression+changes+in+oesophageal+carcinogenesis&doi=10.1002%2Fpath.4044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis</span></div><div class="casAuthors">Paterson, Anna L.; O'Donovan, Maria; Provenzano, Elena; Murray, Liam J.; Coleman, Helen G.; Johnson, Brian T.; McManus, Damian T.; Novelli, Marco; Lovat, Laurence B.; Fitzgerald, Rebecca C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">230</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">118-128</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Despite being common in epithelial malignancies, the timing of receptor tyrosine kinase (RTK) up-regulation is poorly understood and therefore hampers the identification of the receptor to target for effective treatment.  We aimed to det. if RTK expression changes were early events in carcinogenesis.  Oesophageal adenocarcinoma and its pre-invasive lesion, Barrett's esophagus, were used for immunohistochem. anal. of the RTK panel, EGFR, ErbB2, ErbB3, Met, and FGFR2, by utilizing a cohort of patients with invasive disease (n = 367) and two cohorts with pre-invasive disease, one cross-sectional (n = 110) and one longitudinal in time (n = 91).  The results demonstrated that 51% of esophageal adenocarcinomas overexpressed at least one of the RTK panel, with 21% of these overexpressing multiple receptors.  Up-regulation of RTK expression was an early event corresponding with low-grade dysplasia development (25% in areas without dysplasia vs. 63% in low-grade dysplasia, p < 0.001).  There was a trend for an increase in the prevalence of concomitant overexpression of multiple receptors as intestinal metaplasia progressed to low-grade dysplasia, 7% vs. 10%; and from low-grade dysplasia to high-grade dysplasia, 10% vs. 19% (p = 0.06 and 0.24, resp.).  The timing of receptor up-regulation varied; FGFR, ErbB2, and Met overexpression occurred as dysplasia first developed, while EGFR overexpression was predominately seen in invasive disease and ErbB3 overexpression was uniformly rare.  We provide evidence for a frequent and early role for multiple different RTKs in esophageal carcinogenesis.  Given the early timing of receptor deregulation, inhibiting RTKs in pre-invasive disease may also represent a novel and effective chemopreventive strategy.  Copyright © 2012 Pathol. Society of Great Britain and Ireland.  Published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7OUn3UOb2ubVg90H21EOLACvtfcHk0lj5eGIi0rwvMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVektb8%253D&md5=c8f98db6cc760c49eae45eb546462c3f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fpath.4044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.4044%26sid%3Dliteratum%253Aachs%26aulast%3DPaterson%26aufirst%3DA.%2BL.%26aulast%3DO%25E2%2580%2599donovan%26aufirst%3DM.%26aulast%3DProvenzano%26aufirst%3DE.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26aulast%3DColeman%26aufirst%3DH.%2BG.%26aulast%3DJohnson%26aufirst%3DB.%2BT.%26aulast%3DMcManus%26aufirst%3DD.%2BT.%26aulast%3DNovelli%26aufirst%3DM.%26aulast%3DLovat%26aufirst%3DL.%2BB.%26aulast%3DFitzgerald%26aufirst%3DR.%2BC.%26atitle%3DCharacterization%2520of%2520the%2520timing%2520and%2520prevalence%2520of%2520receptor%2520tyrosine%2520kinase%2520expression%2520changes%2520in%2520oesophageal%2520carcinogenesis%26jtitle%3DJ.%2520Pathol.%26date%3D2013%26volume%3D230%26spage%3D118%26epage%3D128%26doi%3D10.1002%2Fpath.4044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schipper, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normolle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannettoni, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orringer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, D. G.</span></span> <span> </span><span class="NLM_article-title">Gene amplification in esophageal adenocarcinomas and Barrett’s with high-grade dysplasia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4819</span>– <span class="NLM_lpage">4825</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=14581353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVGjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=4819-4825&author=C.+T.+Millerauthor=J.+R.+Moyauthor=L.+Linauthor=M.+Schipperauthor=D.+Normolleauthor=D.+E.+Brennerauthor=M.+D.+Iannettoniauthor=M.+B.+Orringerauthor=D.+G.+Beer&title=Gene+amplification+in+esophageal+adenocarcinomas+and+Barrett%E2%80%99s+with+high-grade+dysplasia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Gene Amplification in Esophageal Adenocarcinomas and Barrett's with High-Grade Dysplasia</span></div><div class="casAuthors">Miller, Charles T.; Moy, Justin R.; Lin, Lin; Schipper, Matthew; Normolle, Daniel; Brenner, Dean E.; Iannettoni, Mark D.; Orringer, Mark B.; Beer, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4819-4825</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The purpose of this study was to det. the frequency and overall contribution of specific gene amplification events in the formation of Barrett's adenocarcinomas.  The relationship of gene amplification to clin.-pathol. variables and its potential usefulness as a marker for early cancer detection were also examd.  The authors used quant. PCR and Southern blot anal. to screen 87 cases of Barrett's adenocarcinoma for the presence or absence of 13 distinct gene amplification events.  Gene amplification was then examd. for correlation with other amplification events and clin. variables (survival, stage, nodal involvement, tumor invasion, smoking history, and gender).  Addnl., 22 specimens of Barrett's with high-grade dysplasia (HGD) were examd. for the presence of gene amplification.  One or more amplification events were present in 50 of 87 (57%) adenocarcinomas.  The ERBB2 gene was amplified in 19 of 87 (21.8%), CCNE1 in 11 of 87 (12.6%), GATA4 in 9 of 87 (10.3%), KRAS in 9 of 87 (10.3%), EGFR in 7 of 87 (8.0%), CCND1 in 6 of 87 (6.8%), HNF3α in 5 of 87 (5.7%), PIK3CA in 5 of 87 (5.7%), C-MYC in 4 of 87 (4.6%), DYRK2 in 2 of 87 (2.3%), and AIB1, AKT1, and IGF1R were amplified in 0 of 87 (0%) of the tumors.  CCND1 amplification was found to correlate neg. with survival (P < 0.05).  In addn., the ERBB2 amplicon pos. correlated (P < 0.05) with GATA4 amplification.  Increased copy no. of the ERBB2 (1 of 22), GATA4 (1 of 22), KRAS (2 of 22), C-MYC (1 of 22), CCNE1 (2 of 22), and CCND1 (2 of 22) genes was also obsd. in one or more Barrett's adenocarcinomas with HGD.  The high frequency of gene amplification in esophageal adenocarcinomas and HGD indicates the important role of these events in esophageal adenocarcinoma development.  Addnl., these results underscore the possible usefulness of early detection approaches and chemotherapeutic strategies (ErbB2 and cyclin D1) targeted against amplified gene products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLaCLtPpj7_bVg90H21EOLACvtfcHk0lj5eGIi0rwvMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVGjtr0%253D&md5=1490e308399c9bbb6b2e047d188d2a51</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DC.%2BT.%26aulast%3DMoy%26aufirst%3DJ.%2BR.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DSchipper%26aufirst%3DM.%26aulast%3DNormolle%26aufirst%3DD.%26aulast%3DBrenner%26aufirst%3DD.%2BE.%26aulast%3DIannettoni%26aufirst%3DM.%2BD.%26aulast%3DOrringer%26aufirst%3DM.%2BB.%26aulast%3DBeer%26aufirst%3DD.%2BG.%26atitle%3DGene%2520amplification%2520in%2520esophageal%2520adenocarcinomas%2520and%2520Barrett%25E2%2580%2599s%2520with%2520high-grade%2520dysplasia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D4819%26epage%3D4825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesides, G. M.</span></span> <span> </span><span class="NLM_article-title">A trivalent system from vancomycin·d-Ala-d-Ala with higher affinity than avidin biotin</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">711</span>, <span class="refDoi"> DOI: 10.1126/science.280.5364.708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1126%2Fscience.280.5364.708" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=1998&pages=708-711&author=J.+Raoauthor=J.+Lahiriauthor=L.+Isaacsauthor=R.+M.+Weisauthor=G.+M.+Whitesides&title=A+trivalent+system+from+vancomycin%C2%B7d-Ala-d-Ala+with+higher+affinity+than+avidin+biotin&doi=10.1126%2Fscience.280.5364.708"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.280.5364.708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.280.5364.708%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DJ.%26aulast%3DLahiri%26aufirst%3DJ.%26aulast%3DIsaacs%26aufirst%3DL.%26aulast%3DWeis%26aufirst%3DR.%2BM.%26aulast%3DWhitesides%26aufirst%3DG.%2BM.%26atitle%3DA%2520trivalent%2520system%2520from%2520vancomycin%25C2%25B7d-Ala-d-Ala%2520with%2520higher%2520affinity%2520than%2520avidin%2520biotin%26jtitle%3DScience%26date%3D1998%26volume%3D280%26spage%3D708%26epage%3D711%26doi%3D10.1126%2Fscience.280.5364.708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Handl, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mash, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, R. J.</span></span> <span> </span><span class="NLM_article-title">Hitting multiple targets with multimeric ligands</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1517/14728222.8.6.565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1517%2F14728222.8.6.565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=15584863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1eisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2004&pages=565-586&author=H.+L.+Handlauthor=J.+Vagnerauthor=H.+Hanauthor=E.+Mashauthor=V.+J.+Hrubyauthor=R.+J.+Gillies&title=Hitting+multiple+targets+with+multimeric+ligands&doi=10.1517%2F14728222.8.6.565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Hitting multiple targets with multimeric ligands</span></div><div class="casAuthors">Handl, Heather L.; Vagner, Josef; Han, Haiyong; Mash, Eugene; Hruby, Victor J.; Gillies, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">565-586</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Multimeric ligands consist of multiple monomeric ligands attached to a single backbone mol., creating a multimer that can bind to multiple receptors or targets simultaneously.  Numerous examples of multimeric binding exist within nature.  Due to the multiple and simultaneous binding events, multimeric ligands bind with an increased affinity compared to their corresponding monomers.  Multimeric ligands may provide opportunities in the field of drug discovery by providing enhanced selectivity and affinity of binding interactions, thus providing mol.-based targeted therapies.  However, gaps in our knowledge currently exist regarding the quant. measures for important design characteristics, such as flexibility, length and orientation of the inter-ligand linkers, receptor d. and ligand sequence.  In this review, multimeric ligand binding in two sep. phases is examd.  The prerecruitment phase describes the binding of one ligand of a multimer to its corresponding receptor, an event similar to monomeric ligand binding.  This results in transient increases in the local concn. of the other ligands, leading to apparent cooperativity.  The postrecruitment phase only occurs once all receptors have been aligned and bound by their corresponding ligand.  This phase is analogous to DNA-DNA interactions in that the stability of the complex is derived from phys. orientation.  Multiple factors influence the kinetics and thermodn. of multimeric binding, and these are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7NOkX9Q-NcLVg90H21EOLACvtfcHk0ljMDndzVgtWuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1eisg%253D%253D&md5=8aad8ea5debf2373eb5d59f5bab63dc5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1517%2F14728222.8.6.565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.8.6.565%26sid%3Dliteratum%253Aachs%26aulast%3DHandl%26aufirst%3DH.%2BL.%26aulast%3DVagner%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DMash%26aufirst%3DE.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26atitle%3DHitting%2520multiple%2520targets%2520with%2520multimeric%2520ligands%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2004%26volume%3D8%26spage%3D565%26epage%3D586%26doi%3D10.1517%2F14728222.8.6.565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Landers, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebay, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purdie, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scells, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samaratunga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavin, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, R. A.</span></span> <span> </span><span class="NLM_article-title">Use of multiple biomarkers for a molecular diagnosis of prostate cancer</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">950</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1002/ijc.20760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1002%2Fijc.20760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=15609297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsFWjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2005&pages=950-956&author=K.+A.+Landersauthor=M.+J.+Burgerauthor=M.+A.+Tebayauthor=D.+M.+Purdieauthor=B.+Scellsauthor=H.+Samaratungaauthor=M.+F.+Lavinauthor=R.+A.+Gardiner&title=Use+of+multiple+biomarkers+for+a+molecular+diagnosis+of+prostate+cancer&doi=10.1002%2Fijc.20760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Use of multiple biomarkers for a molecular diagnosis of prostate cancer</span></div><div class="casAuthors">Landers, Kelly A.; Burger, Michelle J.; Tebay, Michelle A.; Purdie, David M.; Scells, Betty; Samaratunga, Hemamali; Lavin, Martin F.; Gardiner, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">950-956</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The identification of biomarkers capable of providing a reliable mol. diagnostic test for prostate cancer (PCa) is highly desirable clin.  The authors describe here 4 biomarkers, UDP-N-Acetyl-α-D-galactosamine transferase (GalNAc-T3; not previously assocd. with PCa), PSMA, Hepsin and DD3/PCA3, which, in combination, distinguish prostate cancer from benign prostate hyperplasia (BPH).  GalNAc-T3 was identified as overexpressed in PCa tissues by microarray anal., confirmed by quant. real-time PCR and shown immunohistochem. to be localized to prostate epithelial cells with higher expression in malignant cells.  Real-time quant. PCR anal. across 21 PCa and 34 BPH tissues showed 4.6-fold overexpression of GalNAc-T3.  The noncoding mRNA (DD3/PCA3) was overexpressed 140-fold in the cancer samples compared to BPH tissues.  Hepsin was overexpressed 21-fold, whereas the overexpression for PSMA was 66-fold.  When the gene expression data for these 4 biomarkers was combined in a logistic regression model, a predictive index was obtained that distinguished 100% of the PCa samples from all of the BPH samples.  Therefore, combining these genes in a real-time PCR assay represents a powerful new approach to diagnosing PCa by mol. profiling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocvyIEXQFnHLVg90H21EOLACvtfcHk0ljMDndzVgtWuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsFWjsrg%253D&md5=57d7dcc04c857bfdbecd6755b7165586</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fijc.20760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.20760%26sid%3Dliteratum%253Aachs%26aulast%3DLanders%26aufirst%3DK.%2BA.%26aulast%3DBurger%26aufirst%3DM.%2BJ.%26aulast%3DTebay%26aufirst%3DM.%2BA.%26aulast%3DPurdie%26aufirst%3DD.%2BM.%26aulast%3DScells%26aufirst%3DB.%26aulast%3DSamaratunga%26aufirst%3DH.%26aulast%3DLavin%26aufirst%3DM.%2BF.%26aulast%3DGardiner%26aufirst%3DR.%2BA.%26atitle%3DUse%2520of%2520multiple%2520biomarkers%2520for%2520a%2520molecular%2520diagnosis%2520of%2520prostate%2520cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2005%26volume%3D114%26spage%3D950%26epage%3D956%26doi%3D10.1002%2Fijc.20760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shallal, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minn, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisok, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mease, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomper, M. G.</span></span> <span> </span><span class="NLM_article-title">Heterobivalent agents targeting PSMA and integrin-αvβ3</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.1021/bc4005377</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc4005377" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsVSguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=393-405&author=H.+M.+Shallalauthor=I.+Minnauthor=S.+R.+Banerjeeauthor=A.+Lisokauthor=R.+C.+Measeauthor=M.+G.+Pomper&title=Heterobivalent+agents+targeting+PSMA+and+integrin-%CE%B1v%CE%B23&doi=10.1021%2Fbc4005377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Heterobivalent Agents Targeting PSMA and Integrin-αvβ3</span></div><div class="casAuthors">Shallal, Hassan M.; Minn, Il; Banerjee, Sangeeta R.; Lisok, Ala; Mease, Ronnie C.; Pomper, Martin G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">393-405</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Differential expression of surface proteins on normal vs malignant cells provides the rationale for the development of receptor-, antigen-, and transporter-based, cancer-selective imaging and therapeutic agents.  However, tumors are heterogeneous, and do not always express what can be considered reliable, tumor-selective markers.  That suggests development of more flexible targeting platforms that incorporate multiple moieties enabling concurrent targeting to a variety of putative markers.  We report the synthesis, biochem., in vitro, and preliminary in vivo evaluation of a new heterobivalent (HtBv) imaging agent targeting both the prostate-specific membrane antigen (PSMA) and integrin-αvβ3 surface markers, each of which can be overexpressed in certain tumor epithelium and/or neovasculature.  The HtBv agent was functionalized with either 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) or the com. available IRDye800CW.  DOTA-conjugated HtBv probe 9 bound to PSMA or αvβ3 with affinities similar to those of monovalent (Mnv) compds. designed to bind to their targets independently.  In situ energy minimization expts. support a model describing the conformations adapted by 9 that enable it to bind both targets.  IRDye800-conjugated HtBv probe 10 demonstrated target-specific binding to either PSMA or integrin-αvβ3 overexpressing xenografts.  HtBv agents 9 and 10 may enable dual-targeted imaging of malignant cells and tissues in an effort to address heterogeneity that confounds many cancer-targeted imaging agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFuI-0LWEK6rVg90H21EOLACvtfcHk0lhWogfbVQBXrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsVSguw%253D%253D&md5=8102ca98c2564749c6c3cd356a1d1ebf</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fbc4005377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc4005377%26sid%3Dliteratum%253Aachs%26aulast%3DShallal%26aufirst%3DH.%2BM.%26aulast%3DMinn%26aufirst%3DI.%26aulast%3DBanerjee%26aufirst%3DS.%2BR.%26aulast%3DLisok%26aufirst%3DA.%26aulast%3DMease%26aufirst%3DR.%2BC.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26atitle%3DHeterobivalent%2520agents%2520targeting%2520PSMA%2520and%2520integrin-%25CE%25B1v%25CE%25B23%26jtitle%3DBioconjugate%2520Chem.%26date%3D2014%26volume%3D25%26spage%3D393%26epage%3D405%26doi%3D10.1021%2Fbc4005377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauder-Wüst, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhut, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">659</span>– <span class="NLM_lpage">668</span>, <span class="refDoi"> DOI: 10.1002/pros.22784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1002%2Fpros.22784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=24464532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVGgsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=659-668&author=M.+Ederauthor=M.+Sch%C3%A4ferauthor=U.+Bauder-W%C3%BCstauthor=U.+Haberkornauthor=M.+Eisenhutauthor=K.+Kopka&title=Preclinical+evaluation+of+a+bispecific+low-molecular+heterodimer+targeting+both+PSMA+and+GRPR+for+improved+PET+imaging+and+therapy+of+prostate+cancer&doi=10.1002%2Fpros.22784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer</span></div><div class="casAuthors">Eder, Matthias; Schaefer, Martin; Bauder-Wuest, Ulrike; Haberkorn, Uwe; Eisenhut, Michael; Kopka, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">659-668</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: It has recently been reported that metastases of prostate cancer usually show highly heterogeneous or partly lost prostate-specific membrane antigen (PSMA) expression.  In order to image and treat both PSMA pos. and neg. tissues PSMA targeting probes need to be extended by a further specificity.  Since prostate cancer cells usually express both PSMA and gastrin-releasing peptide receptor (GRPR) a bispecific low-mol. heterodimeric mol., addressing both targets at the same time, may significantly improve prostate cancer imaging and therapy.  Methods: The nonapeptide BZH3 representing the GRPR binding part was combined with the urea-based PSMA inhibitor Glu-urea-Lys(Ahx)-HBED-CC.  The syntheses of the compds. were performed according to std. Fmoc-solid phase peptide synthesis.  The binding properties were analyzed by competitive cell binding and internalization expts.  The in vivo targeting properties were investigated by means of biodistribution studies.  Results: Cell binding expts. revealed high binding affinities to both GRPR and PSMA expressing cell lines.  The heterodimer bound with IC50-values essentially matching the IC50 values of the resp. monomers (25.0 ± 5.4 nM for PSMA and 9.0 ± 1.8 nM for GRPR, resp.).  In vivo, the heterodimer showed dual targeting of PSMA (5.4%ID/g for PSMA-pos. tumors) and GRPR receptors (3.3% ID/g for GRPR-pos. tumors) while exhibiting fast pharmacokinetic properties.  The clearance from background was comparable to the monomeric PSMA-targeting ref.  Conclusions: The heterodimeric mol. is a promising agent for PET imaging of primary and recurrent prostate cancer covering two receptor entities which might lead to an improved diagnostic sensitivity and therapeutic efficiency.  Prostate 74:659-668, 2014. cpr 2014 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9nvRTGN-RKrVg90H21EOLACvtfcHk0lhWogfbVQBXrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVGgsb8%253D&md5=f7d819461748bc02af3ad99a4c463b87</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fpros.22784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.22784%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DM.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DM.%26aulast%3DBauder-W%25C3%25BCst%26aufirst%3DU.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DEisenhut%26aufirst%3DM.%26aulast%3DKopka%26aufirst%3DK.%26atitle%3DPreclinical%2520evaluation%2520of%2520a%2520bispecific%2520low-molecular%2520heterodimer%2520targeting%2520both%2520PSMA%2520and%2520GRPR%2520for%2520improved%2520PET%2520imaging%2520and%2520therapy%2520of%2520prostate%2520cancer%26jtitle%3DProstate%26date%3D2014%26volume%3D74%26spage%3D659%26epage%3D668%26doi%3D10.1002%2Fpros.22784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, W.</span></span> <span> </span><span class="NLM_article-title">Design and applications of bispecific heterodimers: molecular imaging and beyond</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1750</span>– <span class="NLM_lpage">1761</span>, <span class="refDoi"> DOI: 10.1021/mp500115x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500115x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtFWlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=1750-1761&author=H.+Luoauthor=H.+Hongauthor=S.+P.+Yangauthor=W.+Cai&title=Design+and+applications+of+bispecific+heterodimers%3A+molecular+imaging+and+beyond&doi=10.1021%2Fmp500115x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Applications of Bispecific Heterodimers: Molecular Imaging and beyond</span></div><div class="casAuthors">Luo, Haiming; Hong, Hao; Yang, Sarah P.; Cai, Weibo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1750-1761</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Ligand-based mol. imaging probes have been designed with high affinity and specificity for monitoring biol. process and responses.  Single-target recognition by traditional probes can limit their applicability for disease detection and therapy because synergistic action between disease mediators and different receptors is often involved in disease progression.  Consequently, probes that can recognize multiple targets should demonstrate higher targeting efficacy and specificity than their monospecific peers.  This concept has been validated by multiple bispecific heterodimer-based imaging probes that demonstrated promising results in several animal models.  This review summarizes the design strategies for bispecific peptide- and antibody-based heterodimers and their applications in mol. targeting and imaging.  The design and application of bispecific heterodimer-conjugated nanomaterials are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3DP6EHtoAuLVg90H21EOLACvtfcHk0lhWogfbVQBXrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtFWlu7o%253D&md5=126043335b195f421558bac683c38c33</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fmp500115x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500115x%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DHong%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DS.%2BP.%26aulast%3DCai%26aufirst%3DW.%26atitle%3DDesign%2520and%2520applications%2520of%2520bispecific%2520heterodimers%253A%2520molecular%2520imaging%2520and%2520beyond%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26spage%3D1750%26epage%3D1761%26doi%3D10.1021%2Fmp500115x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, J. R.</span></span> <span> </span><span class="NLM_article-title">Engineered proteins pull double duty</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">17ps5</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3000276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1126%2Fscitranslmed.3000276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=20371477" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=17ps5&author=J.+R.+Cochran&title=Engineered+proteins+pull+double+duty&doi=10.1126%2Fscitranslmed.3000276"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000276%26sid%3Dliteratum%253Aachs%26aulast%3DCochran%26aufirst%3DJ.%2BR.%26atitle%3DEngineered%2520proteins%2520pull%2520double%2520duty%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D17ps5%26doi%3D10.1126%2Fscitranslmed.3000276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig, S. A.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to drugs targeting receptor tyrosine kinases</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">1041</span>– <span class="NLM_lpage">1048</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2011.12.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1016%2Fj.bcp.2011.12.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2012&pages=1041-1048&author=S.+A.+Rosenzweig&title=Acquired+resistance+to+drugs+targeting+receptor+tyrosine+kinases&doi=10.1016%2Fj.bcp.2011.12.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2011.12.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2011.12.025%26sid%3Dliteratum%253Aachs%26aulast%3DRosenzweig%26aufirst%3DS.%2BA.%26atitle%3DAcquired%2520resistance%2520to%2520drugs%2520targeting%2520receptor%2520tyrosine%2520kinases%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D83%26spage%3D1041%26epage%3D1048%26doi%3D10.1016%2Fj.bcp.2011.12.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handl, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mash, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span> <span> </span><span class="NLM_article-title">Heterobivalent ligands crosslink multiple cell-surface receptors: The human melanocortin-4 and δ-opioid receptors</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1685</span>– <span class="NLM_lpage">1688</span>, <span class="refDoi"> DOI: 10.1002/anie.200702770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1002%2Fanie.200702770" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=1685-1688&author=J.+Vagnerauthor=L.+Xuauthor=H.+L.+Handlauthor=J.+S.+Josanauthor=D.+L.+Morseauthor=E.+A.+Mashauthor=R.+J.+Gilliesauthor=V.+J.+Hruby&title=Heterobivalent+ligands+crosslink+multiple+cell-surface+receptors%3A+The+human+melanocortin-4+and+%CE%B4-opioid+receptors&doi=10.1002%2Fanie.200702770"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fanie.200702770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200702770%26sid%3Dliteratum%253Aachs%26aulast%3DVagner%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DHandl%26aufirst%3DH.%2BL.%26aulast%3DJosan%26aufirst%3DJ.%2BS.%26aulast%3DMorse%26aufirst%3DD.%2BL.%26aulast%3DMash%26aufirst%3DE.%2BA.%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26atitle%3DHeterobivalent%2520ligands%2520crosslink%2520multiple%2520cell-surface%2520receptors%253A%2520The%2520human%2520melanocortin-4%2520and%2520%25CE%25B4-opioid%2520receptors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2008%26volume%3D47%26spage%3D1685%26epage%3D1688%26doi%3D10.1002%2Fanie.200702770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mash, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, R. J.</span></span> <span> </span><span class="NLM_article-title">Enhanced targeting with heterobivalent ligands</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2356</span>– <span class="NLM_lpage">2365</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-1183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1158%2F1535-7163.MCT-08-1183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=19671749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFCmsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2356-2365&author=L.+Xuauthor=J.+Vagnerauthor=J.+Josanauthor=R.+M.+Lynchauthor=D.+L.+Morseauthor=B.+Baggettauthor=H.+Hanauthor=E.+A.+Mashauthor=V.+J.+Hrubyauthor=R.+J.+Gillies&title=Enhanced+targeting+with+heterobivalent+ligands&doi=10.1158%2F1535-7163.MCT-08-1183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced targeting with heterobivalent ligands</span></div><div class="casAuthors">Xu, Liping; Vagner, Josef; Josan, Jatinder; Lynch, Ronald M.; Morse, David L.; Baggett, Brenda; Han, Haiyong; Mash, Eugene A.; Hruby, Victor J.; Gillies, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2356-2365</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A novel approach to specifically target tumor cells for detection and treatment is the proposed use of heteromultivalent ligands, which are designed to interact with, and noncovalently crosslink, multiple different cell surface receptors.  Although enhanced binding has been shown for synthetic homomultivalent ligands, proof of crosslinking requires the use of ligands with two or more different binding moieties.  As proof-of-concept, we have examd. the binding of synthetic heterobivalent ligands to cell lines that were engineered to coexpress two different G-protein-coupled human receptors, i.e., the human melanocortin 4 receptor (MC4R) expressed in combination with either the human δ-opioid receptor (δOR) or the human cholecystokinin-2 receptor (CCK2R).  Expression levels of these receptors were characterized by time-resolved fluorescence satn. binding assays using Europium-labeled ligands; Eu-DPLCE, Eu-NDP-α-MSH, and Eu-CCK8 for the δOR, MC4R, and CCK2R, resp.  Heterobivalent ligands were synthesized to contain a MC4R agonist connected via chem. linkers to either a δOR or a CCK2R agonist.  In both cell systems, the heterobivalent constructs bound with much higher affinity to cells expressing both receptors, compared with cells with single receptors or to cells where one of the receptors was competitively blocked.  These results indicate that synthetic heterobivalent ligands can noncovalently crosslink two unrelated cell surface receptors, making feasible the targeting of receptor combinations.  The in vitro cell models described herein will lead to the development of multivalent ligands for target combinations identified in human cancers. [Mol Cancer Ther 2009;8(8):2356-65].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkQo44KF9nTrVg90H21EOLACvtfcHk0lj_yJsURSw3Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFCmsrc%253D&md5=10c62f74f213f9661eeb2bed436622a2</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-1183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-1183%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DL.%26aulast%3DVagner%26aufirst%3DJ.%26aulast%3DJosan%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DR.%2BM.%26aulast%3DMorse%26aufirst%3DD.%2BL.%26aulast%3DBaggett%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DMash%26aufirst%3DE.%2BA.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26atitle%3DEnhanced%2520targeting%2520with%2520heterobivalent%2520ligands%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2356%26epage%3D2365%26doi%3D10.1158%2F1535-7163.MCT-08-1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Josan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handl, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankaranarayanan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mash, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, R. J.</span></span> <span> </span><span class="NLM_article-title">Cell-specific targeting by heterobivalent ligands</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1270</span>– <span class="NLM_lpage">1278</span>, <span class="refDoi"> DOI: 10.1021/bc1004284</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc1004284" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFSqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=1270-1278&author=J.+S.+Josanauthor=H.+L.+Handlauthor=R.+Sankaranarayananauthor=L.+Xuauthor=R.+M.+Lynchauthor=J.+Vagnerauthor=E.+A.+Mashauthor=V.+J.+Hrubyauthor=R.+J.+Gillies&title=Cell-specific+targeting+by+heterobivalent+ligands&doi=10.1021%2Fbc1004284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-Specific Targeting by Heterobivalent Ligands</span></div><div class="casAuthors">Josan, Jatinder S.; Handl, Heather L.; Sankaranarayanan, Rajesh; Xu, Liping; Lynch, Ronald M.; Vagner, Josef; Mash, Eugene A.; Hruby, Victor J.; Gillies, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1270-1278</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Current cancer therapies exploit either differential metab. or targeting to specific individual gene products that are overexpressed in aberrant cells.  The work described herein proposes an alternative approach-to specifically target combinations of cell-surface receptors using heteromultivalent ligands ("receptor combination approach").  As a proof-of-concept that functionally unrelated receptors can be noncovalently cross-linked with high avidity and specificity, a series of heterobivalent ligands (htBVLs) were constructed from analogs of the melanocortin peptide ligand ([Nle4, D-Phe7]-α-MSH) and the cholecystokinin peptide ligand (CCK-8).  Binding of these ligands to cells expressing the human melanocortin-4 receptor and the cholecystokinin-2 receptor was analyzed.  The MSH(7) and CCK(6) were tethered with linkers of varying rigidity and length, constructed from natural and/or synthetic building blocks.  Modeling data suggest that a linker length of 20-50 Å is needed to simultaneously bind these two different G-protein coupled receptors (GPCRs).  These ligands exhibited up to 24-fold enhancement in binding affinity to cells that expressed both (bivalent binding), compared to cells with only one (monovalent binding) of the cognate receptors.  The htBVLs had up to 50-fold higher affinity than that of a monomeric CCK ligand, i.e., Ac-CCK(6)-NH2.  Cell-surface targeting of these two cell types with labeled heteromultivalent ligand demonstrated high avidity and specificity, thereby validating the receptor combination approach.  This ability to noncovalently cross-link heterologous receptors and target individual cells using a receptor combination approach opens up new possibilities for specific cell targeting in vivo for therapy or imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9JSNzA-4QhrVg90H21EOLACvtfcHk0lj_yJsURSw3Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFSqs7g%253D&md5=c0d5a49a887aaf2258b1f0e9314e195d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fbc1004284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc1004284%26sid%3Dliteratum%253Aachs%26aulast%3DJosan%26aufirst%3DJ.%2BS.%26aulast%3DHandl%26aufirst%3DH.%2BL.%26aulast%3DSankaranarayanan%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DR.%2BM.%26aulast%3DVagner%26aufirst%3DJ.%26aulast%3DMash%26aufirst%3DE.%2BA.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26atitle%3DCell-specific%2520targeting%2520by%2520heterobivalent%2520ligands%26jtitle%3DBioconjugate%2520Chem.%26date%3D2011%26volume%3D22%26spage%3D1270%26epage%3D1278%26doi%3D10.1021%2Fbc1004284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caplan, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mash, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, R. J.</span></span> <span> </span><span class="NLM_article-title">Heterobivalent ligands target cell-surface receptor combinations in vivo</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">21295</span>– <span class="NLM_lpage">21300</span>, <span class="refDoi"> DOI: 10.1073/pnas.1211762109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1073%2Fpnas.1211762109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=23236171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslSgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=21295-21300&author=L.+Xuauthor=J.+S.+Josanauthor=J.+Vagnerauthor=M.+R.+Caplanauthor=V.+J.+Hrubyauthor=E.+A.+Mashauthor=R.+M.+Lynchauthor=D.+L.+Morseauthor=R.+J.+Gillies&title=Heterobivalent+ligands+target+cell-surface+receptor+combinations+in+vivo&doi=10.1073%2Fpnas.1211762109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Heterobivalent ligands target cell-surface receptor combinations in vivo</span></div><div class="casAuthors">Xu, Liping; Josan, Jatinder S.; Vagner, Josef; Caplan, Michael R.; Hruby, Victor J.; Mash, Eugene A.; Lynch, Ronald M.; Morse, David L.; Gillies, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">21295-21300, S21295/1-S21295/14</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A challenge in tumor targeting is to deliver payloads to cancers while sparing normal tissues.  A limited no. of antibodies appear to meet this challenge as therapeutics themselves or as drug-antibody conjugates.  However, antibodies suffer from their large size, which can lead to unfavorable pharmacokinetics for some therapeutic payloads, and that they are targeted against only a single epitope, which can reduce their selectivity and specificity.  Here, we propose an alternative targeting approach based on patterns of cell surface proteins to rationally develop small, synthetic heteromultivalent ligands (htMVLs) that target multiple receptors simultaneously.  To gain insight into the multivalent ligand strategy in vivo, we have generated synthetic htMVLs that contain melanocortin (MSH) and cholecystokinin (CCK) pharmacophores that are connected via a fluorescent labeled, rationally designed synthetic linker.  These ligands were tested in an exptl. animal model contg. tumors that expressed only one (control) or both (target) MSH and CCK receptors.  After systemic injection of the htMVL in tumor-bearing mice, label was highly retained in tumors that expressed both, compared with one, target receptors.  Selectivity was quantified by using ex vivo measurement of Europium-labeled htMVL, which had up to 12-fold higher specificity for dual compared with single receptor expressing cells.  This proof-of-principle study provides in vivo evidence that small, rationally designed bivalent htMVLs can be used to selectively target cells that express both, compared with single complimentary cell surface targets.  These data open the possibility that specific combinations of targets on tumors can be identified and selectively targeted using htMVLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5JhGq_H5GILVg90H21EOLACvtfcHk0lg4BTTzktvoXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslSgsw%253D%253D&md5=ec09130d0da0d380cd91cea77bbeca72</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1211762109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1211762109%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DL.%26aulast%3DJosan%26aufirst%3DJ.%2BS.%26aulast%3DVagner%26aufirst%3DJ.%26aulast%3DCaplan%26aufirst%3DM.%2BR.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26aulast%3DMash%26aufirst%3DE.%2BA.%26aulast%3DLynch%26aufirst%3DR.%2BM.%26aulast%3DMorse%26aufirst%3DD.%2BL.%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26atitle%3DHeterobivalent%2520ligands%2520target%2520cell-surface%2520receptor%2520combinations%2520in%2520vivo%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D21295%26epage%3D21300%26doi%3D10.1073%2Fpnas.1211762109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1021/jm801285t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801285t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Kg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=425-432&author=Z.+Liuauthor=Y.+Yanauthor=F.+T.+Chinauthor=F.+Wangauthor=X.+Chen&title=Dual+integrin+and+gastrin-releasing+peptide+receptor+targeted+tumor+imaging+using+18F-labeled+PEGylated+RGD-bombesin+heterodimer+18F-FB-PEG3-Glu-RGD-BBN&doi=10.1021%2Fjm801285t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Integrin and Gastrin-Releasing Peptide Receptor Targeted Tumor Imaging Using 18F-labeled PEGylated RGD-Bombesin Heterodimer 18F-FB-PEG3-Glu-RGD-BBN</span></div><div class="casAuthors">Liu, Zhaofei; Yan, Yongjun; Chin, Frederic T.; Wang, Fan; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">425-432</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Radiolabeled RGD and bombesin peptides have been extensively investigated for tumor integrin αvβ3 and GRPR imaging, resp.  Due to the fact that many tumors are both integrin and GRPR pos., we designed and synthesized a heterodimeric peptide Glu-RGD-BBN, which is expected to be advantageous over the monomeric peptides for dual-receptor targeting.  A PEG3 spacer was attached to the glutamate α-amino group of Glu-RGD-BBN to enhance the 18F labeling yield and to improve the in vivo kinetics. PEG3-Glu-RGD-BBN possesses the comparable GRPR and integrin αvβ3 receptor-binding affinities as the corresponding monomers, resp.  The dual-receptor targeting properties of 18F-FB-PEG3-Glu-RGD-BBN were obsd. in PC-3 tumor model. 18F-FB-PEG3-Glu-RGD-BBN with high tumor contrast and favorable pharmacokinetics is a promising PET tracer for dual integrin and GRPR pos. tumor imaging.  This heterodimer strategy may also be an applicable method to develop other mols. with improved in vitro and in vivo characterizations for tumor diagnosis and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2SA_rxlFb7bVg90H21EOLACvtfcHk0lg4BTTzktvoXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Kg&md5=74337ada6620f3948a43119d529c83f4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm801285t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801285t%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DChin%26aufirst%3DF.%2BT.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DDual%2520integrin%2520and%2520gastrin-releasing%2520peptide%2520receptor%2520targeted%2520tumor%2520imaging%2520using%252018F-labeled%2520PEGylated%2520RGD-bombesin%2520heterodimer%252018F-FB-PEG3-Glu-RGD-BBN%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D425%26epage%3D432%26doi%3D10.1021%2Fjm801285t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">18F-labeled BBN-RGD heterodimer for prostate cancer imaging</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.2967/jnumed.107.048009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.2967%2Fjnumed.107.048009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=18287274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlOns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=453-461&author=Z.-B.+Liauthor=Z.+Wuauthor=K.+Chenauthor=E.+K.+Ryuauthor=X.+Chen&title=18F-labeled+BBN-RGD+heterodimer+for+prostate+cancer+imaging&doi=10.2967%2Fjnumed.107.048009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">18F-labeled BBN-RGD heterodimer for prostate cancer imaging</span></div><div class="casAuthors">Li, Zi-Bo; Wu, Zhanghong; Chen, Kai; Ryu, Eun Kyoung; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">453-461</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine</span>)
        </div><div class="casAbstract">Both bombesin (BBN) analogs and cyclic RGD peptides have been suitably radiolabeled for prostate cancer imaging.  However, the limited expression of gastrin-releasing peptide receptor (GRPR) and integrin αvβ3 as well as unfavorable in vivo kinetics limited further applications of these imaging agents.  We hypothesize that a peptide ligand recognizing both GRPR and integrin will be advantageous because of its dual-receptor-targeting ability.  Methods: A BBN-RGD heterodimer was synthesized from bombesin(7-14) and c(RGDyK) through a glutamate linker and then labeled with 18F via the N-succinimidyl-4-18F-fluorobenzoate (18F-SFB) prosthetic group.  The receptor-binding characteristics and tumor-targeting efficacy of 18F-FB-BBN-RGD were tested in vitro and in vivo.  Results: FB-BBN-RGD had comparable integrin αvβ3-binding affinity with c(RGDyK) and comparable GRPR-binding affinity with BBN(7-14).  18F-FB-BBN-RGD had significantly higher tumor uptake compared with monomeric RGD and monomeric BBN peptide tracer analogs at all time points examd.  The PC-3 tumor uptake of 18F-FB-BBN-RGD was inhibited only partially in the presence of an excess amt. of unlabeled BBN(7-14) or c(RGDyK) but was blocked completely in the presence of both BBN(7-14) and c(RGDyK).  Compared with 18F-FB-BBN and 18F-FB-RGD, 18F-FB-BBN-RGD also had improved pharmacokinetics, resulting in a significantly higher imaging quality.  Conclusion: Dual integrin αvβ3 and GRPR recognition showed significantly improved tumor-targeting efficacy and pharmacokinetics compared with 18F-labeled RGD and BBN analogs.  The same heterodimeric ligand design may also be applicable to other receptor system combinations and other imaging modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo53fuaN_K7s7Vg90H21EOLACvtfcHk0lg4BTTzktvoXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlOns7o%253D&md5=2f3945deb587757802d92faded69575e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.107.048009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.107.048009%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.-B.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DRyu%26aufirst%3DE.%2BK.%26aulast%3DChen%26aufirst%3DX.%26atitle%3D18F-labeled%2520BBN-RGD%2520heterodimer%2520for%2520prostate%2520cancer%2520imaging%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2008%26volume%3D49%26spage%3D453%26epage%3D461%26doi%3D10.2967%2Fjnumed.107.048009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">A new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging</span>. <i>Amino Acids</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1007/s00726-010-0762-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1007%2Fs00726-010-0762-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=439-447&author=Y.+Yanauthor=K.+Chenauthor=M.+Yangauthor=X.+Sunauthor=S.+Liuauthor=X.+Chen&title=A+new+18F-labeled+BBN-RGD+peptide+heterodimer+with+a+symmetric+linker+for+prostate+cancer+imaging&doi=10.1007%2Fs00726-010-0762-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs00726-010-0762-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00726-010-0762-5%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DA%2520new%252018F-labeled%2520BBN-RGD%2520peptide%2520heterodimer%2520with%2520a%2520symmetric%2520linker%2520for%2520prostate%2520cancer%2520imaging%26jtitle%3DAmino%2520Acids%26date%3D2011%26volume%3D41%26spage%3D439%26epage%3D447%26doi%3D10.1007%2Fs00726-010-0762-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Clinical translation of a dual integrin αvβ3– and gastrin-releasing peptide receptor–targeting PET radiotracer, 68Ga-BBN-RGD</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.2967/jnumed.116.177048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.2967%2Fjnumed.116.177048" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=228-234&author=J.+Zhangauthor=G.+Niuauthor=L.+Langauthor=F.+Liauthor=X.+Fanauthor=X.+Yanauthor=S.+Yaoauthor=W.+Yanauthor=L.+Huoauthor=L.+Chenauthor=Z.+Liauthor=Z.+Zhuauthor=X.+Chen&title=Clinical+translation+of+a+dual+integrin+%CE%B1v%CE%B23%E2%80%93+and+gastrin-releasing+peptide+receptor%E2%80%93targeting+PET+radiotracer%2C+68Ga-BBN-RGD&doi=10.2967%2Fjnumed.116.177048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.116.177048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.116.177048%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DG.%26aulast%3DLang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DS.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DHuo%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DClinical%2520translation%2520of%2520a%2520dual%2520integrin%2520%25CE%25B1v%25CE%25B23%25E2%2580%2593%2520and%2520gastrin-releasing%2520peptide%2520receptor%25E2%2580%2593targeting%2520PET%2520radiotracer%252C%252068Ga-BBN-RGD%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2017%26volume%3D58%26spage%3D228%26epage%3D234%26doi%3D10.2967%2Fjnumed.116.177048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Razumienko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dryden, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scollard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, R. M.</span></span> <span> </span><span class="NLM_article-title">MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using 111In-labeled bispecific radioimmunoconjugates</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1007/s10549-013-2490-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1007%2Fs10549-013-2490-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=23525982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFektbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2013&pages=709-718&author=E.+Razumienkoauthor=L.+Drydenauthor=D.+Scollardauthor=R.+M.+Reilly&title=MicroSPECT%2FCT+imaging+of+co-expressed+HER2+and+EGFR+on+subcutaneous+human+tumor+xenografts+in+athymic+mice+using+111In-labeled+bispecific+radioimmunoconjugates&doi=10.1007%2Fs10549-013-2490-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using 111In-labeled bispecific radioimmunoconjugates</span></div><div class="casAuthors">Razumienko, Eva; Dryden, Lindsay; Scollard, Deborah; Reilly, Raymond M.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">709-718</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Epidermal growth factor receptors (EGFR) form heterodimers with HER2 in breast cancer, and increased EGFR expression has been found in HER2-pos. tumors resistant to trastuzumab (Herceptin).  Our objective was to synthesize bispecific radioimmunoconjugates (bsRICs) that recognize HER2 and EGFR and evaluate their ability to image tumors in athymic mice that express one or both receptors by microSPECT/CT.  Bispecific radioimmunoconjugates were constructed by conjugating maleimide-derivatized trastuzumab Fab fragments that bind HER2 to a thiolated form of EGF with an intervening 24 mer polyethylene glycol (PEG24) spacer.  Bispecific radioimmunoconjugates were derivatized with diethylenetriaminepentaacetic acid for labeling with 111In.  The ability of 111In-bsRICs to bind HER2 or EGFR was detd. in competition assays using cells expressing one or both receptors.  Tumor and normal tissue uptake were examd. in CD1 athymic mice bearing s.c. tumor xenografts that expressed HER2, EGFR, or both receptors, with or without pre-administration of Fab or EGF to det. specificity.  HER2 and EGFR binding and displacement of binding by competitors were found for 111In-bsICs.  The highest uptake of 111In-bsRICs [7.3 ± 3.5 %ID/g] in 231-H2N human breast cancer xenografts (HER2+/EGFR+) occurred at 48 h post-injection.  Pre-administration of trastuzumab Fab decreased uptake in SK-OV-3 (HER2+/EGFR-) human ovarian cancer xenografts from 7.1 ± 1.2 to 2.4 ± 1.5 %ID/g.  Pre-administration of excess EGF decreased uptake in MDA-MB-231 (HER2-/EGFR+) human breast cancer xenografts from 5.9 ± 0.5 to 2.0 ± 0.1 %ID/g.  All tumors were imaged by microSPECT/CT.  We conclude that 111In-bsRICs composed of trastuzumab Fab and EGF exhibited specific binding in vitro to tumor cells displaying HER2 or EGFR, and were taken up specifically in vivo in tumors expressing one or both receptors, permitting tumor visualization by microSPECT/CT.  These agents may ultimately be useful for imaging heterodimerized HER2-EGFR complexes since their bivalent properties permit more avid binding to these complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTL0vbo0n4trVg90H21EOLACvtfcHk0lgj_nm2zJBmvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFektbc%253D&md5=0bb9facb59bb1edef1ff660065b214fb</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10549-013-2490-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-013-2490-5%26sid%3Dliteratum%253Aachs%26aulast%3DRazumienko%26aufirst%3DE.%26aulast%3DDryden%26aufirst%3DL.%26aulast%3DScollard%26aufirst%3DD.%26aulast%3DReilly%26aufirst%3DR.%2BM.%26atitle%3DMicroSPECT%252FCT%2520imaging%2520of%2520co-expressed%2520HER2%2520and%2520EGFR%2520on%2520subcutaneous%2520human%2520tumor%2520xenografts%2520in%2520athymic%2520mice%2520using%2520111In-labeled%2520bispecific%2520radioimmunoconjugates%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2013%26volume%3D138%26spage%3D709%26epage%3D718%26doi%3D10.1007%2Fs10549-013-2490-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Arming antibodies: prospects and challenges for immunoconjugates</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1137</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1038/nbt1141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1038%2Fnbt1141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=16151407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1137-1146&author=A.+M.+Wuauthor=P.+D.+Senter&title=Arming+antibodies%3A+prospects+and+challenges+for+immunoconjugates&doi=10.1038%2Fnbt1141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Arming antibodies: prospects and challenges for immunoconjugates</span></div><div class="casAuthors">Wu, Anna M.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1137-1146</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immunoconjugates-monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs (ineffective when administered systemically alone)-are becoming a significant component of anticancer treatments.  By combining the exquisite targeting specificity of mAbs with the enhanced tumor-killing power of toxic effector mols., immunoconjugates permit sensitive discrimination between target and normal tissue, resulting in fewer toxic side effects than most conventional chemotherapeutic drugs.  Two radioimmunoconjugates, ibritumomab tiuxetan (Zevalin) and tositumomab-131I (Bexxar), and one drug conjugate, gemtuzumab ozogamicin (Mylotarg), are now on the market.  For the next generation of immunoconjugates, advances in protein engineering will permit greater control of mAb targeting, clearance and pharmacokinetics, resulting in significantly improved delivery to tumors of radioisotopes and potent anticancer drugs.  Pretargeting strategies, which sep. the two functions of antibody-based localization and delivery or generation of the toxic agent into two steps, also promise to afford superior tumor targeting and therapeutic efficacy.  Several challenges in optimizing immunoconjugates remain, however, including poor intratumoral mAb uptake, normal tissue conjugate exposure and issues surrounding drug potency and conditional release from mAb carriers.  Nonetheless, highly promising results from preclin. models will continue to drive the clin. development of this therapeutic class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQIsb1wtkWs7Vg90H21EOLACvtfcHk0lgj_nm2zJBmvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D&md5=6c2d10cdcffad09d516386607d2223a9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnbt1141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1141%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DA.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DArming%2520antibodies%253A%2520prospects%2520and%2520challenges%2520for%2520immunoconjugates%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D1137%26epage%3D1146%26doi%3D10.1038%2Fnbt1141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lum, L. G.</span></span> <span> </span><span class="NLM_article-title">Cancer therapy with bispecific antibodies: clinical experience</span>. <i>Curr. Opin. Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">340</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=20521223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlaktLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=340&author=A.+Thakurauthor=L.+G.+Lum&title=Cancer+therapy+with+bispecific+antibodies%3A+clinical+experience"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer therapy with bispecific antibodies: clinical experience</span></div><div class="casAuthors">Thakur, Archana; Lum, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Molecular Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">340-349</span>CODEN:
                <span class="NLM_cas:coden">CUOTFO</span>;
        ISSN:<span class="NLM_cas:issn">2040-3445</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  The binding of at least two mol. targets simultaneously with a single bispecific antibody is an attractive concept.  The use of bispecific antibodies as possible therapeutic agents for cancer treatment was proposed in the mid-1980s.  The design and prodn. of bispecific antibodies using antibody- and/or receptor-based platform technol. has improved significantly with advances in the knowledge of mol. manipulations, protein engineering techniques, and the expression of antigens and receptors on healthy and malignant cells.  The common strategy for making bispecific antibodies involves combining the variable domains of the desired mAbs into a single bispecific structure.  Many different formats of bispecific antibodies have been generated within the research field of bispecific immunotherapeutics, including the chem. heteroconjugation of two complete mols. or fragments of mAbs, quadromas, F(ab')2, diabodies, tandem diabodies and single-chain antibodies.  This review describes key modifications in the development of bispecific antibodies that can improve their efficacy and stability, and provides a clin. perspective on the application of bispecific antibodies for the treatment of solid and liq. tumors, including the promises and research limitations of this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6cbdL39k_WbVg90H21EOLACvtfcHk0lgj_nm2zJBmvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlaktLvL&md5=c66886b31efe2f7168a6489d922ebdbf</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThakur%26aufirst%3DA.%26aulast%3DLum%26aufirst%3DL.%2BG.%26atitle%3DCancer%2520therapy%2520with%2520bispecific%2520antibodies%253A%2520clinical%2520experience%26jtitle%3DCurr.%2520Opin.%2520Mol.%2520Ther.%26date%3D2010%26volume%3D12%26spage%3D340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. D.</span></span> <span> </span><span class="NLM_article-title">EGFR overexpressed in colonic neoplasia can be detected on wide-field endoscopic imaging</span>. <i>Clin. Transl. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e101</span> <span class="refDoi"> DOI: 10.1038/ctg.2015.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1038%2Fctg.2015.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=26181290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WrtLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&author=J.+Zhouauthor=B.+P.+Joshiauthor=X.+Duanauthor=A.+Pantauthor=Z.+Qiuauthor=R.+Kuickauthor=S.+R.+Owensauthor=T.+D.+Wang&title=EGFR+overexpressed+in+colonic+neoplasia+can+be+detected+on+wide-field+endoscopic+imaging&doi=10.1038%2Fctg.2015.28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Overexpressed in Colonic Neoplasia Can be Detected on Wide-Field Endoscopic Imaging</span></div><div class="casAuthors">Zhou, Juan; Joshi, Bishnu P.; Duan, Xiyu; Pant, Asha; Qiu, Zhen; Kuick, Rork; Owens, Scott R.; Wang, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Gastroenterology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e101</span>CODEN:
                <span class="NLM_cas:coden">CTGLAG</span>;
        ISSN:<span class="NLM_cas:issn">2155-384X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Objectives: Colorectal cancer initially lies dormant as dysplasia, a premalignant state that provides an opportunity for early cancer detection.  Dysplasia can be flat in morphol., focal in size, and patchy in distribution, and thus it appears "invisible" on conventional wide-field endoscopy.  Aims: We aim to develop and validate a peptide that is specific for epidermal growth factor receptor (EGFR), a cell surface target that is overexpressed in colonic adenomas and is readily accessible for imaging.  Methods: We expressed and purified the extracellular domain of EGFR for use with phage display to identify a peptide QRHKPRE that binds to domain 2 of this target.  A near-IR fluorescence endoscope was used to perform in vivo imaging to validate specific peptide binding to spontaneous colonic adenomas in a mouse model with topical administration.  We also validated specific peptide binding to human colonic adenomas on immunohistochem. and immunofluorescence.  Results: After labeling with Cy5.5, we validated specific peptide binding to EGFR on knockdown and competition studies.  Peptide binding to cells occurred within 2.46 min and had an affinity of 50 nM.  No downstream signaling was obsd.  We measured a target-to-background ratio of 4.0±1.7 and 2.7±0.7, for polyps and flat lesions, resp.  On immunofluorescence of human colonic specimens, greater intensity from peptide binding to dysplasia than normal was found with a 19.4-fold difference.  Conclusions: We have selected and validated a peptide that can be used as a specific contrast agent to identify colonic adenomas that overexpress EGFR in vivo on fluorescence endoscopy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbPT3gBw7OlbVg90H21EOLACvtfcHk0lgSHCWNCNMVpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WrtLbP&md5=c657a8b2eefd5ac4b39df370b70a90ef</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fctg.2015.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fctg.2015.28%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DJoshi%26aufirst%3DB.%2BP.%26aulast%3DDuan%26aufirst%3DX.%26aulast%3DPant%26aufirst%3DA.%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DKuick%26aufirst%3DR.%26aulast%3DOwens%26aufirst%3DS.%2BR.%26aulast%3DWang%26aufirst%3DT.%2BD.%26atitle%3DEGFR%2520overexpressed%2520in%2520colonic%2520neoplasia%2520can%2520be%2520detected%2520on%2520wide-field%2520endoscopic%2520imaging%26jtitle%3DClin.%2520Transl.%2520Gastroenterol.%26date%3D2015%26volume%3D6%26doi%3D10.1038%2Fctg.2015.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. D.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of near-infrared peptide for in vivo molecular imaging of HER2</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">494</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.5b00565</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.5b00565" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=481-494&author=B.+P.+Joshiauthor=J.+Zhouauthor=A.+Pantauthor=X.+Duanauthor=Q.+Zhouauthor=R.+Kuickauthor=S.+R.+Owensauthor=H.+Appelmanauthor=T.+D.+Wang&title=Design+and+synthesis+of+near-infrared+peptide+for+in+vivo+molecular+imaging+of+HER2&doi=10.1021%2Facs.bioconjchem.5b00565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Near-Infrared Peptide for in Vivo Molecular Imaging of HER2</span></div><div class="casAuthors">Joshi, Bishnu P.; Zhou, Juan; Pant, Asha; Duan, Xiyu; Zhou, Quan; Kuick, Rork; Owens, Scott R.; Appelman, Henry; Wang, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">481-494</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report the development, characterization, and validation of a peptide specific for the extracellular domain of HER2.  This probe chem. was developed for mol. imaging by using a structural model to select an optimal combination of amino acids that maximize the likelihood for unique hydrophobic and hydrophilic interactions with HER2 domain 3.  The sequence KSPNPRF was identified and conjugated with either FITC or Cy5.5 via a GGGSK linker using Fmoc-mediated solid-phase synthesis to demonstrate flexibility for this chem. structure to be labeled with different fluorophores.  A scrambled sequence was developed for control by altering the conformationally rigid spacer and moving both hydrophobic and hydrophilic amino acids on the C-terminus.  The authors validated peptide specificity for HER2 in knockdown and competition expts. using human colorectal cancer cells in vitro, and measured a binding affinity of kd = 21 nM and time const. of k = 0.14 min-1 (7.14 min).  The authors used this peptide with either topical or i.v. administration in a preclin. model of colorectal cancer to demonstrate specific uptake in spontaneous adenomas and to show feasibility for real time in vivo imaging with near-IR fluorescence.  The authors used this peptide in immunofluorescence studies of human proximal colon specimens to evaluate specificity for sessile serrated and sporadic adenomas.  Improved visualization can be used endoscopically to guide tissue biopsy and detect premalignant lesions that would otherwise be missed.  The authors' peptide design for specificity to HER2 is promising for clin. translation in mol. imaging methods for early cancer detection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKCVSE6nA0SLVg90H21EOLACvtfcHk0lgSHCWNCNMVpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCksro%253D&md5=4a54754652f14c5d665f352d025dd236</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.5b00565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.5b00565%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DB.%2BP.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DPant%26aufirst%3DA.%26aulast%3DDuan%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DKuick%26aufirst%3DR.%26aulast%3DOwens%26aufirst%3DS.%2BR.%26aulast%3DAppelman%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DT.%2BD.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520near-infrared%2520peptide%2520for%2520in%2520vivo%2520molecular%2520imaging%2520of%2520HER2%26jtitle%3DBioconjugate%2520Chem.%26date%3D2016%26volume%3D27%26spage%3D481%26epage%3D494%26doi%3D10.1021%2Facs.bioconjchem.5b00565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, C.</span></span> <span> </span><span class="NLM_article-title">A review of NIR dyes in cancer targeting and imaging</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">7127</span>– <span class="NLM_lpage">7138</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2011.06.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1016%2Fj.biomaterials.2011.06.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=21724249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFWhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=7127-7138&author=S.+Luoauthor=E.+Zhangauthor=Y.+Suauthor=T.+Chengauthor=C.+Shi&title=A+review+of+NIR+dyes+in+cancer+targeting+and+imaging&doi=10.1016%2Fj.biomaterials.2011.06.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A review of NIR dyes in cancer targeting and imaging</span></div><div class="casAuthors">Luo, Shenglin; Zhang, Erlong; Su, Yongping; Cheng, Tianmin; Shi, Chunmeng</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">7127-7138</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of multifunctional agents for simultaneous tumor targeting and near IR (NIR) fluorescence imaging is expected to have significant impact on future personalized oncol. owing to the very low tissue autofluorescence and high tissue penetration depth in the NIR spectrum window.  Cancer NIR mol. imaging relies greatly on the development of stable, highly specific and sensitive mol. probes.  Org. dyes have shown promising clin. implications as non-targeting agents for optical imaging in which indocyanine green has long been implemented in clin. use.  Recently, significant progress has been made on the development of unique NIR dyes with tumor targeting properties.  Current ongoing design strategies have overcome some of the limitations of conventional NIR org. dyes, such as poor hydrophilicity and photostability, low quantum yield, insufficient stability in biol. system, low detection sensitivity, etc.  This potential is further realized with the use of these NIR dyes or NIR dye-encapsulated nanoparticles by conjugation with tumor specific ligands (such as small mols., peptides, proteins and antibodies) for tumor targeted imaging.  Very recently, natively multifunctional NIR dyes that can preferentially accumulate in tumor cells without the need of chem. conjugation to tumor targeting ligands have been developed and these dyes have shown unique optical and pharmaceutical properties for biomedical imaging with superior signal-to-background contrast index.  The main focus of this article is to provide a concise overview of newly developed NIR dyes and their potential applications in cancer targeting and imaging.  The development of future multifunctional agents by combining targeting, imaging and even therapeutic routes will also be discussed.  We believe these newly developed multifunctional NIR dyes will broaden current concept of tumor targeted imaging and hold promise to make an important contribution to the diagnosis and therapeutics for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJJQph7DjLr7Vg90H21EOLACvtfcHk0lgSHCWNCNMVpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFWhtbs%253D&md5=733be27dd9858f9a6ca73f70fabd77c1</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2011.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2011.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DC.%26atitle%3DA%2520review%2520of%2520NIR%2520dyes%2520in%2520cancer%2520targeting%2520and%2520imaging%26jtitle%3DBiomaterials%26date%3D2011%26volume%3D32%26spage%3D7127%26epage%3D7138%26doi%3D10.1016%2Fj.biomaterials.2011.06.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Björkelund, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmqvist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, K.</span></span> <span> </span><span class="NLM_article-title">Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with 125I-EGF</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e24739</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0024739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1371%2Fjournal.pone.0024739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=21931838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A280%3ADC%252BC3MfkvFajsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&author=H.+Bj%C3%B6rkelundauthor=L.+Geddaauthor=P.+Bartaauthor=M.+Malmqvistauthor=K.+Andersson&title=Gefitinib+induces+epidermal+growth+factor+receptor+dimers+which+alters+the+interaction+characteristics+with+125I-EGF&doi=10.1371%2Fjournal.pone.0024739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with 125I-EGF</span></div><div class="casAuthors">Bjorkelund Hanna; Gedda Lars; Barta Pavel; Malmqvist Magnus; Andersson Karl</div><div class="citationInfo"><span class="NLM_cas:title">PloS one</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e24739</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The tyrosine kinase inhibitor gefitinib inhibits growth in some tumor types by targeting the epidermal growth factor receptor (EGFR).  Previous studies show that the affinity of the EGF-EGFR interaction varies between hosting cell line, and that gefitinib increases the affinity for some cell lines.  In this paper, we investigate possible mechanisms behind these observations.  Real-time interaction analysis in LigandTracer® Grey revealed that the HER2 dimerization preventing antibody pertuzumab clearly modified the binding of 125I-EGF to EGFR on HER2 overexpressing SKOV3 cells in the presence of gefitinib.  Pertuzumab did not affect the binding on A431 cells, which express low levels of HER2.  Cross-linking measurements showed that gefitinib increased the amount of EGFR dimers 3.0-3.8 times in A431 cells in the absence of EGF.  In EGF stimulated SKOV3 cells the amount of EGFR dimers increased 1.8-2.2 times by gefitinib, but this effect was cancelled by pertuzumab.  Gefitinib treatment did not alter the number of EGFR or HER2 expressed in tumor cell lines A431, U343, SKOV3 and SKBR3.  Real-time binding traces were further analyzed in a novel tool, Interaction Map, which deciphered the different components of the measured interaction and supports EGF binding to multiple binding sites.  EGFR and HER2 expression affect the levels of EGFR monomers, homodimers and heterodimers and EGF binds to the various monomeric/dimeric forms of EGFR with unique binding properties.  Taken together, we conclude that dimerization explains the varying affinity of EGF-EGFR in different cells, and we propose that gefitinib induces EGFR dimmers, which alters the interaction characteristics with 125I-EGF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmKCzaldFZyMyail4HZd-ifW6udTcc2eaSkhw6XsO387ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfkvFajsQ%253D%253D&md5=c2bfe5fe03d421cf313e4c2cac0a23b2</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0024739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0024739%26sid%3Dliteratum%253Aachs%26aulast%3DBj%25C3%25B6rkelund%26aufirst%3DH.%26aulast%3DGedda%26aufirst%3DL.%26aulast%3DBarta%26aufirst%3DP.%26aulast%3DMalmqvist%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DK.%26atitle%3DGefitinib%2520induces%2520epidermal%2520growth%2520factor%2520receptor%2520dimers%2520which%2520alters%2520the%2520interaction%2520characteristics%2520with%2520125I-EGF%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26doi%3D10.1371%2Fjournal.pone.0024739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Peptide heterodimers for molecular imaging</span>. <i>Amino Acids</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1081</span>– <span class="NLM_lpage">1092</span>, <span class="refDoi"> DOI: 10.1007/s00726-010-0546-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1007%2Fs00726-010-0546-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=20232091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyqtbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=1081-1092&author=Y.+Yanauthor=X.+Chen&title=Peptide+heterodimers+for+molecular+imaging&doi=10.1007%2Fs00726-010-0546-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide heterodimers for molecular imaging</span></div><div class="casAuthors">Yan, Yongjun; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Amino Acids</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1081-1092</span>CODEN:
                <span class="NLM_cas:coden">AACIE6</span>;
        ISSN:<span class="NLM_cas:issn">0939-4451</span>.
    
            (<span class="NLM_cas:orgname">SpringerWienNewYork</span>)
        </div><div class="casAbstract">A review.  One main issue with peptide-based mol. imaging probes is their relatively low tumor affinity and short retention time.  To improve peptide binding affinity, multivalency approach has been introduced.  Traditionally, this approach involves the use of peptide homodimers or homomultimers in which peptide ligands of the same type are constructed with suitable linkers.  Recently, a new approach using peptide heterodimers has emerged as a promising method for targeting multi-receptor over-expressed tumor cells.  Significant affinity enhancements have been obsd. with peptide heterodimers compared with their parent peptide monomers.  In a peptide heterodimer, two different peptide ligands capable of targeting two different receptors are covalently linked.  The binding modes of peptide heterodimers can be monovalent or bivalent depending on whether simultaneous binding of two ligands can be achieved.  Increased local ligand concn. and improved binding kinetics contribute to enhanced binding in both monovalent- and bivalent binding modes, while multivalency effect also plays an important role in bivalent binding mode.  As many tumors overexpress multiple receptors, more peptide heterodimer-based mol. imaging probes are expected to be developed in future.  This review article will discuss the peptide homodimers and heterodimers for mol. imaging with special emphasis on peptide heterodimers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocHwT9jt2idLVg90H21EOLACvtfcHk0lhudzmFRzuXOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyqtbnE&md5=cca77484bd29bb7d26570f9c6d37d5e8</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs00726-010-0546-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00726-010-0546-y%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DPeptide%2520heterodimers%2520for%2520molecular%2520imaging%26jtitle%3DAmino%2520Acids%26date%3D2011%26volume%3D41%26spage%3D1081%26epage%3D1092%26doi%3D10.1007%2Fs00726-010-0546-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessenius, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukowski, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semmler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiedenmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grötzinger, C.</span></span> <span> </span><span class="NLM_article-title">Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1038/86707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1038%2F86707" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=327-331&author=A.+Beckerauthor=C.+Hesseniusauthor=K.+Lichaauthor=B.+Ebertauthor=U.+Sukowskiauthor=W.+Semmlerauthor=B.+Wiedenmannauthor=C.+Gr%C3%B6tzinger&title=Receptor-targeted+optical+imaging+of+tumors+with+near-infrared+fluorescent+ligands&doi=10.1038%2F86707"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2F86707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F86707%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DA.%26aulast%3DHessenius%26aufirst%3DC.%26aulast%3DLicha%26aufirst%3DK.%26aulast%3DEbert%26aufirst%3DB.%26aulast%3DSukowski%26aufirst%3DU.%26aulast%3DSemmler%26aufirst%3DW.%26aulast%3DWiedenmann%26aufirst%3DB.%26aulast%3DGr%25C3%25B6tzinger%26aufirst%3DC.%26atitle%3DReceptor-targeted%2520optical%2520imaging%2520of%2520tumors%2520with%2520near-infrared%2520fluorescent%2520ligands%26jtitle%3DNat.%2520Biotechnol.%26date%3D2001%26volume%3D19%26spage%3D327%26epage%3D331%26doi%3D10.1038%2F86707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Peptides and peptide hormones for molecular imaging and disease diagnosis</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">3087</span>– <span class="NLM_lpage">3111</span>, <span class="refDoi"> DOI: 10.1021/cr900361p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr900361p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFOqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2010&pages=3087-3111&author=S.+Leeauthor=J.+Xieauthor=X.+Chen&title=Peptides+and+peptide+hormones+for+molecular+imaging+and+disease+diagnosis&doi=10.1021%2Fcr900361p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Peptides and Peptide Hormones for Molecular Imaging and Disease Diagnosis</span></div><div class="casAuthors">Lee, Seulki; Xie, Jin; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3087-3111</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA_xN6jlx4-LVg90H21EOLACvtfcHk0lhudzmFRzuXOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFOqs78%253D&md5=b9cc74399e83cf1fe3fa5f02157520d9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fcr900361p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr900361p%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DPeptides%2520and%2520peptide%2520hormones%2520for%2520molecular%2520imaging%2520and%2520disease%2520diagnosis%26jtitle%3DChem.%2520Rev.%26date%3D2010%26volume%3D110%26spage%3D3087%26epage%3D3111%26doi%3D10.1021%2Fcr900361p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tangri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LiCalsi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sette, A.</span></span> <span> </span><span class="NLM_article-title">Rationally engineered proteins or antibodies with absent or reduced immunogenicity</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2191</span>– <span class="NLM_lpage">2199</span>, <span class="refDoi"> DOI: 10.2174/0929867023368647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.2174%2F0929867023368647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=12470241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD38XovV2qsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=2191-2199&author=S.+Tangriauthor=C.+LiCalsiauthor=J.+Sidneyauthor=A.+Sette&title=Rationally+engineered+proteins+or+antibodies+with+absent+or+reduced+immunogenicity&doi=10.2174%2F0929867023368647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally engineered proteins or antibodies with absent or reduced immunogenicity</span></div><div class="casAuthors">Tangri, S.; LiCalsi, C.; Sidney, J.; Sette, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2191-2199</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  One challenge assocd. with the clin. use of protein therapeutics destined for chronic administration is the potential for the development of unwanted anti-drug immune reactions.  The mol. basis for this reactivity is the binding of peptide fragments (epitopes) derived from the breakdown of the protein drug to the HLA receptors expressed by the patient's immune cells.  If these epitopes are recognized as "foreign" by the immune system, specific helper T lymphocytes (HTL), are activated, which initiate and direct the formation of antibodies against the protein drug.  These antibodies can bind and neutralize the protein drug, resulting in either decreased efficacy or total ineffectiveness of the drug.  Moreover, various safety concerns, such as allergic reactions and other adverse events, are also frequently assocd. with the formation of anti-drug antibodies.  Herein, the describe the development of "ImmunoStealth", an integrated bioinformatics, biochem. and cellular immunol. approach that specifically addresses the issue of unwanted immune responses against protein therapeutics.  Unwanted HTL epitopes are identified using in silico sequence anal. methods and high throughput in vitro biochem. evaluations and thereafter confirmed using cellular immunogenicity assays.  The "offending" epitopes within the drug are then rationally modified to alter their HLA binding capacity, and thus render them non-recognizable by the immune system.  This technol. will ultimately facilitate the design of safer, more potent and more economical drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqGbiCmilHQLVg90H21EOLACvtfcHk0libjPqHdEWepw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovV2qsb4%253D&md5=66a58493a82e0d287f4c6866a2920152</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2174%2F0929867023368647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867023368647%26sid%3Dliteratum%253Aachs%26aulast%3DTangri%26aufirst%3DS.%26aulast%3DLiCalsi%26aufirst%3DC.%26aulast%3DSidney%26aufirst%3DJ.%26aulast%3DSette%26aufirst%3DA.%26atitle%3DRationally%2520engineered%2520proteins%2520or%2520antibodies%2520with%2520absent%2520or%2520reduced%2520immunogenicity%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2002%26volume%3D9%26spage%3D2191%26epage%3D2199%26doi%3D10.2174%2F0929867023368647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bray, B. L.</span></span> <span> </span><span class="NLM_article-title">Large-scale manufacture of peptide therapeutics by chemical synthesis</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">593</span>, <span class="refDoi"> DOI: 10.1038/nrd1133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=10.1038%2Fnrd1133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=12815383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;key=1%3ACAS%3A528%3ADC%252BD3sXks1Oqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=587-593&author=B.+L.+Bray&title=Large-scale+manufacture+of+peptide+therapeutics+by+chemical+synthesis&doi=10.1038%2Fnrd1133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Innovation: Large-scale manufacture of peptide therapeutics by chemical synthesis</span></div><div class="casAuthors">Bray, Brian L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">587-593</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The large-scale com. prodn. of a 36-amino-acid peptide by chem. synthesis has been demonstrated in the development of enfuvirtide (T-20 or Fuzeon), a first-in-class membrane fusion inhibitor for the treatment of HIV.  The rationale behind route selection and the scale-up of the process used to manuf. enfuvirtide are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq23FtVAsqBerVg90H21EOLACvtfcHk0libjPqHdEWepw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXks1Oqsr4%253D&md5=cd8a087455cf8058855d84076bc75927</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrd1133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1133%26sid%3Dliteratum%253Aachs%26aulast%3DBray%26aufirst%3DB.%2BL.%26atitle%3DLarge-scale%2520manufacture%2520of%2520peptide%2520therapeutics%2520by%2520chemical%2520synthesis%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D587%26epage%3D593%26doi%3D10.1038%2Fnrd1133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i33"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00405">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_25308"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00405">10.1021/acs.jmedchem.8b00405</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Mass spectrometry analysis, spectral properties, peptide binding on structural models, heterodimer stability, comparison of binding between heterodimer and monomers, colocalization of peptide and antibody binding, heterodimer internalization, immunohistochemistry (IHC), histology (H&E), HPLC spectra, and chemical properties of peptide monomers and heterodimers (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00405/suppl_file/jm8b00405_si_001.pdf">jm8b00405_si_001.pdf (3.18 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00405&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-12%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00405%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00405" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67996d735c6b3ca6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
